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Abstract 
Chronic obstructive pulmonary disease (COPD) is a debilitating respiratory 
condition, whose major risk factor is cigarette smoking. Exacerbations are the 
primary cause of hospitalisation of COPD patients, of these approximately 50% 
are caused by bacterial infections. Normally, alveolar macrophages 
phagocytose inhaled particles and micro-organ isms, and maintain sterility in the 
airways. Therefore, the hypothesis examined in this thesis stated that 
macrophages from COPD subjects are defective in their ability to phagocytose. 
To investigate this hypothesis, engulfment by COPD macrophages was 
compared to that of cells from controls (smokers without COPID and non- 
smokers). Phagocytosis of polystyrene beads by monocyte-derived- 
macrophages (MDM) was comparable to that of alveolar macrophages, thus 
validating the MDM model. There was no difference in uptake of beads by any 
subject group, however, COPD MDM phagocytosed significantly less Ecoli, H. 
influenzae and S. pneumoniae than cells from controls. This was not due to 
current medications as commonly prescribed therapies did not reduce 
phagocytosis of these bacteria. 
To identify the mechanism of this defect, cytoskeletal rearrangement wars 
investigated. Actin polymerisation was not altered by disease, but COPD MDM 
had a greater susceptibility to microtubule disruptors and reduced levels of 
acetylated tubulin compared to control cells. Increasing microtubule acetylation 
enhanced uptake of H. influenzae, suggesting that this may be a novel 
mechanism for improving phagocytosis. Other mechanisms investigated 
included sphingosine-1 -phosphate (S1P) signalling, as production of this 
molecule was increased by COPD MDM and inhibition of the S113 signalling 
cascade increased uptake of H. influenzae. Microarray analysis demonstrated 
that following exposure to H. influenzae, COPD MDM expressed significantly 
more inflammatory genes than control cells, suggesting that these 
macrophages respond differently to bacteria. 
These findings suggest that COPD macrophages have a reduced phagocytic 
ability, which may result in bacterial colonisation, inflammation and 
exacerbations. Improving this macrophage function would offer therapeutic 
potential in this disease. 
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FCS Fetal calf serum 
FEVi Forced expiratory volume in 1 second 
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FITC Fluorescein isothiocyanate 
FSC Forward scatter 
FVC Forced vital capacity 
GM-CSF Granulocyte macrophage-colony stimulating factor 
GOLD Global initiative for chronic obstructive lung diseases 
HBSS Hanks balanced salt solution 
HDAC Histone deactylase 
HLA-DR Human Leukocyte Antigen DR-1 
HRP Horseradish peroxidase 
IFNy Interferon-y 
Ig Immunoglobulin 
IL Interleukin 
LB Lennox broth 
L-Glu L-Glutamine 
LPS Lip opolysacch and e 
MAPK Mitogen activated protein kinase 
MDM Monocyte-derived macrophage 
MHC Major histocompatability complex 
MMP Matrix metalloproteinase 
MOPS 3-(N-morpholino) propane sulphonic acid 
mRNA Messenger ribonucleic acid 
NAD+ Nicotinamide adenine dinucleotide+ 
NF-KB Nuclear factor KB 
NHS National Health Service 
NS Non-smoker 
NTPs Nucleotide triphosphates 
OD Optical density 
PAB PBS supplemented with BSA and azide 
PBMC Peripheral blood mononuclear cell 
PBS Phosphate buffered saline 
PE Phycoerythrin 
P13K Phosphatidyl inositol-3 kinase 
PMN Polymorphonucleocyte/neutrophil 
18 
PS Phosphatidyl serine 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
RPE R-Phycoerythrin 
RPMI Roswell Park Memorial Institute 
RT Room temperature 
RT-PCR Real time polymerase chain reaction 
sip Sphingosine-1 -phosphate 
S1 PR Sphingosine-1 -phosphate receptor 
S Smoker 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEM Standard error of the mean 
SIRT Sirtuin 
SPHK Sphingosine kinase 
SPHKI Sphingosine kinase inhibitor 
SSC Side scatter 
TEM Transmitting electron microscopy 
TGFP Transforming growth factor 
TLR Toll-like receptor 
TNFa Tumour necrosis factor a 
Tris Trizma base 
Tris-HCL Tris hydrochloride 
VIV By volume 
W/V Weight by volume 
'k Wavelength 
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Chapter 1 
Introduction 
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1.1 Chronic Obstructive Pulmonary Disease 
1.1.1. Definition of chronic obstructive pulmonary disease 
Chronic obstructive pulmonary disease (COPD) is a major and increasing global 
health problem, which is predicted to become the third most common cause of 
death and the fifth commonest cause of disability in the world by 2020 (Lopez & 
Murray, 1998). The Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) define COPD as a disease state "characterised by airflow limitation that 
is not fully reversible. The airflow limitation is usually both progressive and 
associated with an abnormal inflammatory response of the lungs to noxious 
particles or gases" (GOLD, 2007). 
The most common reason for the initial diagnosis of the disease is an increase 
in dyspnoea (Friedlander et aL, 2007). Other common symptoms include 
chronic cough, frequent pulmonary infections, cachexia and depression 
(Balasubramanian & Varkey, 2006). The disease is diagnosed by spirometry, 
which measures respiration parameters and compares them to predicted 
values, to detect abnormal lung function. These tests include forced expiratory 
volume in one second (FEVI), which measures the amount of air the lungs are 
capable of expelling in one second, and the forced expiratory vital capacity 
(FVC) which refers to the total amount of air exhaled. COPD results in a 
decrease of each of these values when compared to healthy individuals (Celli, 
2000; Crapo et aL, 1981). Spirometry values have been studied in order to 
characterise the progression of the disease. Fletcher and Peto (1977) 
measured the FEVI of males aged 30-59 years over a period of 8 years. They 
found that in a proportion of their study population who smoked ("susceptible 
smokers", now termed COPD) lung function declines continuously, whereas 
non-smokers and "non-susceptible" smokers demonstrated a slower reduction 
in FEVI that rarely resulted in airflow obstruction (Fig. 1.1). The decline in lung 
function of susceptible smokers could be slowed if the individuals stopped 
smoking, but otherwise would result in disability and death. 
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Reduced lung function parameters correlate with disease severity; therefore 
GOLD has stratified COPD into four stages, according to lung function values 
(GOLD, 2007). These are presented in Table 1.1. 
GOLD stage 
I 
FEV,: FVC ratio values FIEV, % predicted values 
FI (Mild) <0.70 >80% 
11 (Moderate) <0.70 50-80% 
III (Severe) <0.70 30-50% 
IV (Very severe) <0.70 <30%. 
Table 1-1. Classification of COPQ severity. 
COPD severity can be classified according to lung function values, as defined by GOLD. 
(GOLD, 2007). 
Throughout the history of COPID research, there have been conflicting 
hypotheses as to the cause of the disease. The "British hypothesis" was 
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formulated over 40 years ago and suggested that mucus hypersecretion as a 
result of frequent pulmonary infections and cigarette smoke exposure was the 
cause of COPD (Anthonisen, 2004; Fletcher, 1959). This was challenged 
shortly after its inception by the finding that lung function decline did not 
correlated with sputum production or infections; suggesting that COPD was not 
caused by these factors (Fletcher & Peto, 1977). However, airway obstruction 
was found to be related to cigarette smoking, suggesting COPD may develop 
as a result of inhaled oxidants. The 'Dutch hypothesis" suggested another 
potential cause of COPD: that underlying allergic susceptibility is responsible for 
the progression of airflow obstruction, which may explain why only a proportion 
of smokers (<20%) will develop COPD (Jindal, 2004). Furthermore, this 
hypothesis suggested that COPD and asthma were closely related (Vestbo & 
Prescott, 1998). This latter hypothesis was given further credence by the 
discovery that a genetically linked deficiency of al-antitrypsin confers an 
increased likelihood of developing COPD (as described in section 1.1.3.2). 
Subsequent research since the advent of these hypotheses have supported 
one, the other, or neither, suggesting that the true cause of COPD is likely to be 
a combination of factors of each. 
1.1.2 Pathophysiology of COPD 
The pathophysiology of COPD comprises chronic bronchitis, small airways 
disease and emphysema. All of these contribute to airflow limitation, with the 
relative importance of each varying between individual patients (Barnes et aL, 
2003). Additionally, systemic effects such as cachexia, muscle weakening, 
anxiety, depression and an increased risk of atherosclerosis have all been 
associated with the disease (Balasubramanian & Varkey, 2006). 
1.1.2.1 Chronic bronchitis 
Chronic bronchitis describes chronic cough and sputum production, and can be 
caused by inhalation of noxious particles (MacNee, 2005). This leads to an 
innate immune response and consequently inflammation of the central airways 
epithelium. In turn, mucus hypersecretion, decreased mucociliary clearance and 
disruption of the epithelial layer may occur, all of which are accompanied by an 
increase in inflammatory cell numbers in the bronchial glands (Hogg, 2004; 
Saefta et aL, 1997). In addition to the hypersecretion from glands, excessive 
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mucus is also present due to the appearance of goblet cells in the lower airways 
in response to smoking (Jeffery, 1999). This is in contrast to the lungs of non- 
smokers where there are few or no goblet cells in the lower airways (Cosio et 
aL, 1980). There is also evidence that the composition of mucus is altered in 
COPD. A study comparing the mucin composition of sputum from COPD and 
smoker subjects found that in COPD the MUC513 form predominates, whereas 
in smokers there is increased MUC5AC (Kirkham et aL, 2008). It has been 
suggested that due to its charge, MUC513 forms tighter bonds leading to denser, 
slower moving mucus, which might contribute to its accumulation in the lungs of 
COPD patients. Mucus then builds up in the airways, causing the sputum 
expectoration that characterises this condition (Wanner, 1990). Furthermore, 
this can lead to an increased susceptibility to infections, as a result of 
compromised host defence mechanisms (Jansen et aL, 1995). A diagnosis of 
chronic bronchitis is applicable following a sputum producing cough which lasts 
for three consecutive months of a year, for two consecutive years (Barnes et aL, 
2003). A relationship between mucus accumulation and reduced lung function 
suggests that chronic bronchitis contributes to the development of airflow 
obstruction, and therefore the progression of the disease (Hogg, 2008). 
1.1.2.2 Small airways disease (Bronchiolitis) 
The small airways, which are defined as being less than 2mm in diameter and 
having no cartilage or glands, have been identified as the site of airways 
obstruction in COPID (Cosio & Guerassimov, 1999). Here, airway walls are 
thickened by fibrosis (the accumulation of fibrous material) in response to 
cigarette smoke, thus reducing the diameter of the airway. This also leads to air 
being trapped in the alveoli, which causes a reduced lung function in these 
patients, when compared to those without airflow obstruction (O'Donnell & 
Laveneziana, 2007; Sturton et al., 2008). The cause of this small airway fibrosis 
has not yet been fully elucidated, but may be due to repair mechanisms that are 
instigated in response to existing inflammation (Hogg et aL, 2004). These 
airways can also become blocked by mucus and inflammatory exudates which 
further increases the obstruction. The degree of small airways disease (as 
indicated by the number of occluded airways) has been shown to correlate with 
reduced survival (Hogg et al., 2007). 
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1.1.2.3 Emphysema 
Emphysema describes the destruction of alveolar walls by proteases. This 
causes the airways space to enlarge, resulting in a reduced expiratory force 
(Janoff, 1983). The major protease involved in the degradation of the alveolar 
structure is neutrophil elastase. This is increased in the alveoli of smokers, 
which is due to neutrophil chemotaxis in response to increased release of 
CXCL8 by epithelial cells in the presence of tobacco smoke (MacNee & Selby, 
1993). Other enzymes involved include matrix meta lloproteinases (MMP), which 
are produced by the infiltrating macrophages and neutrophils and cysteine 
proteases, such as ma crop h age-derived cathepsins (Shapiro, 2002). The 
presence of CD8+ T-lymphocytes in the airways has been shown to correlate 
with the degree of damage to the epithelium, and these cells produce increased 
cytotoxic proteins (such as granzyme and perforin) than cells from non- 
smokers, suggesting that they directly contribute to the degradation of the 
airway epithelium (Finkelstein et aL, 1995; Hodge et aL, 2006b). The severity of 
emphysema also correlates, albeit weakly, with a decline in lung function (Hogg 
et aL, 1994; Retamales et aL, 2001). 
1.1.2.4 Systemic effects of COPD. 
In addition to the pulmonary inflammation observed in COPD, there is also a 
systemic component. Numbers of circulating CD8+ T-lymphocytes and 
eosinophils are increased in COPID patients, and there is evidence of functional 
alterations due to disease state (Dentener et aL, 2001; Rufino et aL, 2007). For 
example, cytochrome oxidase activity is increased in peripheral blood 
leukocytes from COPD patients when compared to controls (Sauleda et aL, 
2000). Similarly, production of reactive oxygen species (ROS) by circulating 
neutrophils is increased in COPID patients compared with controls (Noguera et 
aL, 2001). Concentrations of various proinflammatory cytokines and mediators 
are increased in serum isolated from COPD patients. These include interleukin 
(IL)-6, CXCI-8, I ipopolysacch a ride (LPS) binding protein, tumour necrosis factor 
(TNF)a and C reactive protein (CRP) (Dentener et al., 2001; Gan et al., 2004; 
Hageman et al., 2003). The latter has increasingly been used as a marker of 
systemic inflammation and disease severity, as it negatively correlates with lung 
function parameters (Shaaban et aL, 2006). 
26 
Metabolic and nutritional abnormalities have been associated with the 
development of COPD. Associations between weight loss and increased 
mortality have been identified in COPID subjects (Schols et al., 1998). 
Approximately 50% of patients with severe forms of the disease demonstrate 
significant weight loss (Agusti et aL, 2003). Causes for this include changes in 
calorie intake, increased metabolic rate, loss of fat mass and muscle wasting 
(Wouters, et al., 2002). 
Skeletal muscle dysfunction has also been associated with COPD. A study of 
moderate to severe COPD patients found that in addition to reduced respiratory 
muscle strength, peripheral muscles were also weaker than in control subjects 
(Gosselink et al., 2000). There are various hypotheses as to the cause of this 
weakness: one such theory is that the muscles are damaged by inactivity, as a 
result of the patient's dyspnoea. Alternatively the systemic inflammation that 
cigarette smoking induces (e. g. increased levels of circulating TNFa) may be 
responsible. Many patients are prescribed glucocorticoids and these may also 
contribute to muscle changes observed in COPD (Decramer et al., 2005; 
Wagner, 2006). 
1.1.3 COPD Risk Factors 
The major cause of COPID in developed countries is cigarette smoking, which 
accounts for >90% of cases (Barnes et aL, 2003). However, only approximately 
10% of smokers will develop the disease, suggesting an underlying genetic 
predisposition (Warburton et aL, 2006). Other potential contributing factors 
include pollution, occupational exposure and poor diet. 
1.1.3.1 Cigarette smoke 
Smoking of tobacco was first reported more than four centuries ago and has 
been described as the single greatest preventable cause of death (Yanbaeva et 
aL, 2007). In the UK it is estimated that 28% of adults smoke, a proportion that 
has not significantly changed in the last decade (Edwards, 2004). By the year 
2030, smoking is predicted to be responsible for >9 million deaths worldwide 
(World Health Organisation, 2002). 
Smoking has been implicated as a cause of cancer of the lung, mouth and 
pharynx, acute myocardial infarction, atherosclerosis and stroke (Bonita et aL, 
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1999; Boyle, 1997; Howard et aL, 1998; Teo et aL, 2006). After decades of 
controversy surrounding the role of cigarette smoke inhalation in the 
development of COPD, it is now generally accepted that smoking is the major 
risk factor associated with the disease (Crofton & Bjartveit, 1989). 
The mechanism by which cigarette smoke causes COPD is complex, with 
contributions by the different components of smoke. Each inhalation of a 
cigarette transfers more than 1015 molecules to the airways (Pryor & Stone, 
1993). This consists of around 5000 different compounds, including nicotine, 
hydrocarbons, phenols, dihydroxybenzenes, aromatic amines and acids 
(Hoffmann & Hoffmann, 1997). Of these, many have been shown to be 
oxidants, toxicants, carcinogens and mutagens (Lu et al., 2008). In COPD, 
these compounds can cause detrimental changes to the airway cells function, 
resulting in the influx of inflammatory cells which then induce chronic 
inflammation and degradation of the lung structure (Yanbaeva et aL, 2007). 
1.1.3.2 Genetics factors 
The observation that only a small proportion of smokers develop COPD has led 
to a number of studies investigating putative genetic factors that may contribute 
to susceptibility. The gene that was first implicated in emphysema was serpin 
peptidase inhibitor, clade A, member 1 (SERPINAl). This remains the best 
characterised and most important susceptibility gene for COPD. When 
transcribed, SERPINA1 produces al-antitrypsin and a deficiency of this protein 
has long been associated with the development of emphysema (Ericksson, 
1964). Its absence contributes to destruction of the lung connective tissue by 
the uninhibited action of neutrophil elastase and cathepsin G (Reilly & Travis, 
1980). This finding was the basis of the protease/anti-protease theory of 
emphysema, which formed part of the "Dutch hypothesis". The amount of al- 
antitrypsin produced is dictated by two alleles of the SERPINA1 gene (Shigeoka 
et aL, 1976). Polymorphisms of this gene have been associated with increased 
severity of emphysema. A high risk for developing COPD has been associated 
with possession of two defective genes, but this risk is decreased in individuals 
with a single copy (Dahl et aL, 2001). Different polymorphisms confer different 
protein defects; the S and Z alleles are the most common in patients with 
severe al-antitrypsin deficiency, and both caused by separate point mutations. 
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These mutations cause reduced activity of the protein and slower migration 
through isoelectric focusing gels (Lomas & Parfrey, 2004). 
As SERPINA1 polymorphisms are not present in all COPD patients, small 
nucleotide polymorphism (SNP) studies have been employed in recent years to 
identify other susceptibility genes. However, concerns have been raised as to 
the validity of these studies, based on their design and the disease parameters 
used (loannidis et aL, 2001). Many analyses are carried out in specific 
geographical locations, and therefore the findings may not apply to the 
populations of other areas. For example, polymorphisms in the genes which 
code for MMP9 have been associated with development of COPD in patients in 
Japan, yet a study of patients in the USA and Canada demonstrated no such 
correlation (Joos et aL, 2002; Minematsu et aL, 2001). Other susceptibility 
genes that have also been identified include: 
Serpin peptidase inhibitor, clade E, member 2 (SERPINE2) has been 
associated with an increased risk of developing COPD (13hattacharya et aL, 
2006; DeMeo et aL, 2006; Zhu et a/., 2007). Whilst a strong association 
exists between the expression of the gene and disease state, its function in 
the pathogenesis of COPD has yet to be determined. 
Polymorphisms of the TNFa gene have also been associated with 
development of COPD (Huang et aL, 1997). However, this study was carried 
out on Taiwanese subjects, whereas others carried out in Italy, USA and 
England have shown no effect of TNFa polymorphisms on the development 
of COPD (Ferrarotti et aL, 2003; Higham et aL, 2000; Patuzzo et aL, 2000). 
Therefore, the alterations to this gene may only increase susceptibility to 
development of COPID in specific ethnic groups. It is thought that aberrant 
translation of this cytokine, due to polymorphisms in the promoter region, 
leads to increased production and contributes to the excessive inflammation 
in the lungs of COPID patients (Gingo et aL, 2008). 
a Another candidate susceptibility gene for COPID is the microsomal epoxide 
hydroxylase gene, which codes for an enzyme present in the lung epithelium 
that degrades harmful epoxides present in cigarette smoke. Polymorphisms 
of this gene correlate with development of COPID in a study of COPID 
patients in Scotland (Chappell et aL, 2008). However, similar studies 
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performed in Japan and Korea failed to demonstrate any correlation 
(Takeyabu et aL, 2000; Yim et aL, 2000). 
Polymorphisms in the P2 adrenoreceptor have also been implicated in the 
development of COPID (Ho et at, 2001). This receptor is of particular 
importance as P2 adrenergic agonists are widely used as bronchodilators in 
the treatment of COPD. Studies have shown that two polymorphisms of the 
receptor confer reduced bronchodilation following inhalation of a short acting 
P2-agonist, thus reducing the efficacy of this medication (Hizawa et aL, 
2007). 
1.1.3.3 Airpollution 
In addition to cigarette smoke, another significant cause of COPD is inhalation 
of smoke produced by burning of biomass fuels such as coal, straw, animal 
dung, crop residues, and wood (Lopez & Murray, 1998). In many developing 
nations, the use of these fuels for cooking and heating in poorly ventilated 
spaces is reported to be responsible for 36% of mortalities due to lower 
respiratory diseases (Mannino & Buist, 2007). Outdoor pollution, such as that 
produced by cars, is responsible for 1% of cases of COPID in developed 
countries, although its contribution towards the prevalence of respiratory 
infections and exacerbations of COPID is likely to be considerably higher (Liu et 
al., 2008). 
Occupational exposure to dusts and noxious chemicals is also capable of 
causing COPD. One of the first studies into the causes of chronic bronchitis 
examined the disease progression in coal miners and identified that this 
population had an increased risk of developing the condition, when compared to 
subjects in other professions (Motley et at, 1949). Recently, it was reported that 
approximately 30% of people with COPD in the USA that had never smoked, 
developed the disease whilst at work (Hnizdo et aL, 2002). Furthermore, 15% of 
total COPID-related deaths were due to occupational exposure (Leigh et aL, 
2002). The mechanism by which particulates that compose pollution induce 
COPD are likely to be similar to those associated with cigarette smoke 
exposure. 
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1.1.4 Cellular mechanisms that contribute to COPD 
1.1.4.1. The role of macrophages in COPD 
COPD is characterised by chronic inflammation of the lungs, which is mediated 
by an influx of immune cells in response to the harmful components of cigarette 
smoke. Macrophages have been proposed to be the orchestrators of many 
aspects of this lung inflammation (Barnes et aL, 2003). This is due to their 
involvement in both the innate and adaptive immune systems (discussed further 
in section 1.2.2-3). Macrophage numbers are elevated in the alveolar 
compartment and parenchyma of smokers with and without COPD (Morrison et 
aL, 1999; Tomita et aL, 2002). This accumulation may be a consequence of 
increased migration of monocytes, as levels of the monocyte chemoattractants 
transforming growth factor (TGF)P and CCI-2 have been found to correlate with 
macrophage numbers in smokers with COPD, and CCI-2 and CXCL1 
concentrations are increased in sputum of patients with COPD (de Boer et al., 
1998; Traves et al., 2002). Alveolar macrophages are potent producers of 
cytokines, chemokines and inflammatory mediators in the presence of cigarette 
smoke. Increased levels of TNFa, CXCL8, CXCL6, CCI-2 and leukotriene 
(LT)B4 have been observed following cigarette smoke exposure of these cells 
(Heguy et aL, 2006; Woodruff et aL, 2005). The release of these inflammatory 
mediators may be due to activation of mitogen activated protein (MAP)-kinase 
pathways by ROS in cigarette smoke (Forman & Torres, 2002). In addition to 
the induction of inflammation, macrophages are also capable of directly 
damaging the lungs by the release of proteases. Alveolar macrophages from 
COPD patients have been shown to cause greater levels of elastolysis than 
cells isolated from healthy individuals and the release of MMP by alveolar 
macrophages is increased by cigarette smoking (Finlay et aL, 1997; Russell et 
aL, 2002; Shapiro, 1999; Woodruff et aL, 2005). 
1.1.4.2. The role of T-cells in COPD 
CD8+ T-cells numbers are increased in the parenchyma of COPID patients 
when compared to subjects without the disease, which is associated with as 
increase in numbers of activated CD4+ cells in the airway walls (Saefta et aL, 
1999; Turato et aL, 2002). It is thought that the former, cytotoxic T-cells, play 
the most significant role in the pathophysiology of COPID, as the number of 
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these cells in bronchial biopsies from patients with chronic bronchitis inversely 
correlates with FEVI measurements (O'Shaughnessy et aL, 1997). The 
mechanism by which these cells exert their effects on the lungs of COPID 
patients is not fully understood. However, it has been postulated that release of 
cytotoxic granules may be responsible for the increased apoptosis of both 
endothelial and epithelial cells in the lungs of patients with emphysema 
(Kasahara et aL, 2001; Yokohori et aL, 2004). This is supported by upregulation 
of perforin (a membrane-lytic protein) by CD8+ T-cells, in cells isolated from 
sputum from COPID patients compared to non-smoking controls (Chrysofakis et 
aL, 2004). 
1.1.4.3. The role of neutmphils in COPD 
Neutrophils numbers in the bronchoalveolar lavage (BAL) fluid and sputum of 
COPID patients are significantly greater than in controls (Lacoste et al., 1993). 
Further analysis localised neutrophils to the bronchial epithelium (Lacoste et al., 
1993; Saefta et al., 1997). The number of neutrophils in bronchial biopsies 
correlates with inflammation and disease severity, suggesting a role for these 
cells in the pathogenesis of COPID (Di Stefano et al., 1998). This is thought to 
be due to the production of serine proteases, such as neutrophil elastase, which 
contribute to the degradation of the extracellular matrix, leading to emphysema. 
In support of this is the finding that neutrophils from patients with emphysema 
demonstrate an enhanced ability to digest fibronectin, a matrix glycoprotein, and 
exhibit an increased chemotactic response compared to cells from smokers 
(Burnett eta/., 1987). 
1.1.4.4. Changes to the epithelium in COPD 
The lung epithelium consists of many different cell types, whose proportions 
change during the descent of the airways. The epithelium includes ciliated cells, 
mucus secreting cells, basal cells and Clara cells, all of which are capable of 
contributing to lung inflammation by the release of cytokines, chemokines and 
other inflammatory mediators. The release of many of these mediators is 
increased by epithelial cells from COPD patients, suggesting that they 
contribute to the pathophysiology of the disease. For example, basal release of 
CCL2, CCL3, TGFP and CXCL8 by bronchial epithelial cells from COPD 
patients is increased when compared to non-smokers, as is that of ILAP and 
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CXCL8 in the presence of cigarette smoke (Fuke et a/., 2004; Mio at al., 1997; 
Rusznak et al., 2000; Takizawa at al., 2001). Goblet cell hyperplasia is also 
increased in COPD patients, which contributes to mucus hypersecretion and, 
therefore, chronic bronchitis, and is increased further in current smokers 
compared to ex-smokers with airway obstruction (Lapperre et al., 2007; Saefta 
et al., 2000). Additionally, increased alveolar epithelial cell apoptosis has been 
identified in the lungs of COPID patients and may be one mechanism leading to 
emphysema (Segura-Valdez et aL, 2000). The destruction of these cells 
releases proinflammatory components, which can directly damage other host 
cells, and induce the accumulation of inflammatory cells such as macrophages 
and neutrophils. As described previously (in sections 1.1.4.1-3), the actions of 
these infiltrating cells can then further perpetuate the chronic inflammation. 
1.1.4.5. Proteaselantiprotease imbalance 
In the lungs of healthy individuals, the actions of proteases are counteracted by 
antiproteases, such as al-antitrypsin and secretory leukocyte protease inhibitor 
(SLPI) (Thompson & Ohlsson, 1986). However, there is evidence that this 
balance is dysregulated in COPD, such that inhibition of degradative enzymes 
is reduced. Thus, the action of proteases is increased, which can result in 
emphysema. Expression of SLPI by bronchial epithelial cells was reduced in 
rats who had inhaled LPS in order to induce a COPD-like phenotype compared 
to control animals (Luo et aL, 2008). This was thought to be due to a TGFP- 
mediated down-regulation of SLPI expression, suggesting that this mechanism 
may be responsible for the increased neutrophil elastase action present in 
human emphysematous tissue. Tissue inhibitors of matrix metal lop rotein ases 
(TIMP)1-4 are secreted in response to inflammatory stimuli. Despite the fact 
that concentrations of TIMP1 in COPD patient sputum are increased compared 
to controls, there is a greater increase in MMP concentrations, such that 
increased TIMP1 expression has little impact on the overall protease 
dominance (Culpitt et aL, 2005). TIMP2 gene polymorphisms that reduce its 
activity, have been associated with the development of COPD, further 
supporting the role of protease imbalance in this disease (Hirano et aL, 2001). 
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1.1.4.6. The role of oxidative stress in COPD 
In addition to maintaining the protease/antiprotease balance, it is also essential 
that the oxidant/antioxidant levels are tightly controlled in the lung. As well as 
the 1 015ROS present in each inhalation of cigarette smoke itself and those in 
air pollution, inflammatory cells within the airway will also produce ROS in 
response to inhaled noxious chemicals. Therefore, ROS are increased in the 
lungs of COPD subjects and smokers. Specific examples of ROS include the 
superoxide anion, peroxnitrite, hydroxyl radical and isoprostanes (MacNee, 
2000; Morrow & Roberts, 1996). Furthermore, antioxidants, such as superoxide 
dismutase (SOD), glutathione and catalase, that counteract oxidants in healthy 
lungs, may be dysfunctional in COPD. Multiple gene polymorphisms for these 
proteins have been identified in COPD patients each of which results in either 
reduced or defective expression of specific proteins. For example, a SNP in the 
SOD3 gene correlates strongly with an increased susceptibility to COPD 
(Bentley et aL, 2008; Young et aL, 2006). 
Oxidative stress can induce airway inflammation via a number of mechanisms; 
ROS activate the nuclear factor (NF)KB pathway, leading to transcription of 
many inflammatory genes (Barnes & Karin, 1997). Activation of NFKB is 
increased in bronchial biopsies from COPID patients, suggestive of a role in the 
pathophysiology of the disease (Di Stefano et aL, 2002). Alternatively, oxidative 
stress can inhibit the action of antiproteases such as al-antitrypsin and SLPI, 
thus increasing the activity of proteases (Taggart et a/., 2000). ROS have also 
been implicated in the increased recruitment of neutrophils to the lungs, as 
cigarette smoke increases their sequestration, which can be ablated by 
antioxidants (MacNee, 2000; Rahman, 2005). 
1.1.5. Exacerbations of COPD 
The most common cause of hospital admissions of patients within the NHS are 
exacerbations of COPD, comprising 16.6% of all medical admissions (Wedzicha 
& Seemungal, 2007). Exacerbations are classified as a marked worsening in 
symptoms such as cough, shortness of breath, sputum production and 
purulence, which leads patients to experience difficulty in breathing and 
performing simple tasks. 
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Exacerbations are associated with an increase in sputum and serum markers of 
lung inflammation (Bhowmik et al., 2000; Hurst et al., 2006), and also correlate 
with indicators of oxidative stress (Tkacova et al., 2007). Furthermore, 
production of inflammatory mediators such as IL-6, TNFa and CXCL8 correlate 
with an increase in exacerbation-associated dyspnoea and fall in FEV, (Pinto- 
Plata et al., 2007). Airway neutrophilia has also been demonstrated in lung 
biopsies from patients during an exacerbation (Qiu et al., 2003). It has been 
proposed that some patients may be more likely than others to exacerbate, and 
that these "frequent exacerbators" are more likely to be admitted to hospital 
(Donaldson et al., 2002). An increased frequency of exacerbations is also 
associated with an accelerated decline in lung function, suggesting a role for 
exacerbations in the worsening of the disease (Makris et aL, 2006). 
The causes of exacerbations are often unclear, but may include pollution, 
weather changes and bacteriallviral infections (Wedzicha, 2001). Viral infections 
are thought to cause approximately 44% of COPD exacerbations, with the most 
common species being rhinoviruses (Greenberg et aL, 2000). Co-infections of 
virus and bacteria have been identified in approximately 25% of COPID patients 
during exacerbations (Papi et aL, 2006). A correlation between concentrations 
of sputum IL-6 and the number of virions suggests that viral infections result in 
an increased severity of exacerbation (Seemungal et al., 2000). The 
mechanisms by which viruses cause exacerbations has not been fully 
elucidated, but viral particles may adhere to airway epithelial cells and induce 
an upregulation of the adhesion molecule, ICAM1, via activation of NF-KB (Papi 
& Johnston, 1999). This then perpetuates the existing inflammation of the 
airways, leading to the increased sputum production and reduced lung function 
which characterise COPD exacerbations. 
1.1.5.1. Bacterial infections as causes of COPD exacerbations 
The role of bacterial infections in exacerbations of COPD has been indicated by 
protected brush bronchoscopic sampling studies which found bacterial isolates 
in approximately 50% of patients during an exacerbation, but only in 25-30% of 
stable COPD subjects (Monso et aL, 1995). However, whether the bacterial 
colonisation is the cause of the exacerbation, or vice versa, is an area of 
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controversy. The arguments for a causative role for bacteria in exacerbations 
include: 
Increased bacterial isolates from protected brush samples from 
exacerbating, when compared to stable, COPID subjects (Monso et aL, 
1995). 
Correlation between the presence of bacteria in sputum and exacerbation 
frequency (Patel et aL, 2002). 
Correlation between the presence of bacteria and airway inflammation, such 
as increased levels of CXCI-8, neutrophil elastase and TNFa in sputum, and 
CXCL8 in BAL. In addition, Haemophilus influenzae membrane protein P6 
induces CXCI-8 and TNFa secretion by macrophages (Berenson et al., 
2005; Sethi et al., 2000; Tumkaya et al., 2007). 
9 The acquisition of new strains of bacteria increases the likelihood of 
developing an exacerbation, and correlates with an increase in neutrophil 
elastase and TNFa in sputum (Sethi et aL, 2008; Sethi et aL, 2002). 
However there is also evidence against a causative role of bacteria in 
exacerbations, including: 
Only 50% protected brush samples from patients during exacerbations 
contain bacteria, yet they are also present in many non-exacerbating COPID 
subjects. 
Antibody titres to pneumococci and H. influenzae do not increase during 
exacerbations (despite bacteria being present in sputum samples) (Bogaert 
et aL, 2004; Morgan & Wood, 1965). 
The cellular profiles in bronchial biopsies from patients during exacerbations 
do not correlate with those that are generally associated with infection, e. g. 
neutrophilia. Instead neutrophil and lymphocyte numbers are only slightly 
increased, whereas eosinophils were greatly increased when compared to 
baseline values (Saetta et aL, 1994). 
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Large scale, placebo controlled trials of antibiotic use in COPD 
exacerbations have demonstrated either little or no effect, although this may 
be due to the development of resistance and/or incorrect choices of 
antibiotics (Saint et aL, 1995; Siddiqi & Sethi, 2008). 
@ Studies into the effect of pneurnococcal vaccines on COPD patients do not 
demonstrate a reduction in exacerbation frequency (Hirschmann, 2000). 
Despite the controversy surrounding the role of bacteria in exacerbations of 
COPD, it is likely that colonisation contributes to worsening of disease and 
persistent inflammation. The mechanism by which bacteria elicit inflammatory 
responses may involve the production and release of proteins which are 
recognised by host cells (Abusriwil & Stockley, 2007). This then leads to an 
upregulation of inflammatory mediator release by these cells. For example, 
proteins expressed by Psuedomonas aeruginosa and Streptococcus 
pneumoniae cause upregulation of CXCL8 and TNFa respectively by 
respiratory epithelial cells in vitro (Blue et al., 2003; Massion et al., 1994). 
Alternatively, some bacterial virulence factors are capable of directly damaging 
the lung; for example, pneumolysin and hydrogen peroxide produced by S. 
pneumoniae can damage epithelial cells (Feldman et aL, 2002; Rubins et aL, 
1993). Bacteria may also cause tissue injury by eliciting responses by host 
cells, for example, bacterial proteinases can activate MMP, thus contributing to 
the emphysematous tissue destruction present in the lungs of many COPD 
patients (Okamoto et aL, 1997). S. pneumoniae also induces apoptosis in 
airway epithelial cells (Schmeck et aL, 2004). These potential mechanisms are 
illustrated in Fig. 1.2. 
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Figure 1.2. Mechanisms of bacterial induced inflammation. 
Potential effects of bacteria on the lung include, 1. Inactive MMP expressed by host cells (m) is 
activated by bacterial proteins (A) to give active MMP (*). 2. Bacteria expressed proteins (A) 
can directly damage epithelial cells ( 
4ýý ). 3. Bacteria ligate receptors on epithelial cells and 
induce them to produce proinflammatory mediators, cytokines and chemokines (e). 
Whether or not bacterial colonisation is the cause of the increased severity of 
symptoms during exacerbations, it is clear that it plays a role in the inflammation 
observed in COPID. This presence of bacteria in the lower airways is exclusive 
to COPID subjects, contrasting with sterile lungs of non-smokers and smokers 
with normal lung function (Sethi et al., 2006). This suggests that COPD confers 
susceptibility to pulmonary bacterial infections. 
Attempts to identify the species of bacteria present in the lung have traditionally 
involved sputum or protected brush sampling and culturing. One such study 
found that Haemophilus influenzae, Streptococcus pneumoniae, Moraxella 
catarThalis, Haemophilus parainfluenzae and Pseudomonas aeruginosa are the 
most common species present in sputum samples (the percentages of each are 
presented in Table 1.2) (Sapey & Stockley, 2006). However, studies such as 
these may underestimate the number and types of bacteria present in the lung 
because the culture methods employed may not allow for the identification of all 
bacterial species present. Therefore, polymerase chain reaction (PCR) based 
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methods for identification of bacterial species which are difficult to culture are 
currently being designed. For example, identification of Chlamydia pneumoniae 
by culturing lacks specificity and can give ambiguous results, therefore a 
molecular typing method has been developed (Petitjean et aL, 1998). 
Bacteria species % of exacerbating patients 
Haemophilus influenzae 11 
Streptococcus pneumoniae 10 
Moraxella catanhalis 10 
Haemophilus parainfluenzae 10 
Pseudomonas aeruginosa 4 
Table 1.2. 
-Prevalence of 
bacteria si)ecies isolated from swtum of COPD patients durinq 
exacerbations. (Sapey & Stockley. 2006) 
An important factor which may facilitate the survival of bacteria in the lung is 
their ability to form biofilms. These are aggregations of bacteria within a self- 
produced matrix, which bind to airway mucosa and are often resistant to the 
effects of antibiotics and innate immune defences (Costerton et aL, 1999). The 
most common bacterial species identified in the lungs of COPD patients, H. 
influenzae, S. pneumoniae and M. catarrhalis form biofilms on respiratory 
mucosa (Garcia-Castillo et aL, 2007; Murphy & Kirkham, 2002; Roveta et aL, 
2007). The formation of these aggregations is regulated by the presence of pili 
and specific membrane proteins on the bacteria (Murphy & Kirkham, 2002). It is 
thought that biofilms increase the ability of bacteria to colonise mucosa, but 
their role in the development of pulmonary infections of COPD patients has 
received little attention and is not fully understood. 
1.1.5.2. Haemophilus influenzae 
H. influenzae is the most common of the potentially pathogenic bacteria isolated 
from sputum samples from COPID patients during exacerbations (Table 1.2) 
(Sapey & Stockley, 2006). It is also the most commonly identified bacteria found 
in COPID patients during a stable phase of the disease (Eldika & Sethi, 2006). 
H. influenzae causes mucosal infections, including otitis media, conjunctivitis, 
sinusitis, bronchitis and pneumonia. It is a Gram-negative coccobacillus and 
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has an outer membrane made up of 6-8 major proteins (OMPs), which form the 
basis of typing systems (Frick et aL, 2000). There is a high degree of 
heterogeneity between OMPs from different strains of H. influenzae, which arise 
as a result of point mutations. It is unknown whether this is related to virulence 
but there is an association between alterations in OMPs and differential 
colonisation of the airways of COPID patients by differing strains (Sethi & 
Murphy, 2001). Exposure of macrophages to these proteins leads to release of 
proinflammatory cytokines including CXCL8, IL-10 and TNFa (Berenson et al., 
2005). Moreover, H. influenzae acts synergistically with TNFa to activate NF-KB, 
leading to increased production of a variety of inflammatory mediators 
(Watanabe et aL, 2004). Additionally, an upregulation of the mucin gene 
MUC5AC is elicited in response to recognition of H. influenzae by epithelial 
cells, which may contribute to chronic bronchitis (Wang et aL, 2002). 
1.1.5.3. Streptococcus pneumoniae 
S. pneumoniae is the most common cause of community acquired pneumonia 
in adults, but it can also cause otitis media and meningitis (Melegaro et aL, 
2006). S. pneumoniae is a lancet-shaped Gram-positive cocci, whose virulence 
is determined by the presence or absence of a polysaccharide capsule. The 
ability of S. pneumoniae to survive in the lungs is largely due to the anti- 
phagocytic effect of the capsule, which prevents the binding of the complement 
protein, C3b, to the bacteria] cells (Sethi & Murphy, 2001). Whilst this capsule is 
not inflammatory, the polysaccharide bacterial cell wall induces an inflammatory 
response, as indicated by increased IL-1p, IL-6 and TNFa release from 
monocytes (Catterall, 1999). Many isolates of S. pneumoniae have developed 
penicillin/multiple antibiotic resistance, leading to the development of vaccines 
against different combinations of the ninety known seroyptes. However, to date 
these have been ineffective in preventing exacerbations in COPD patients 
(Granger et aL, 2006). 
1.1.6. Current COPD treatments 
There are currently no pharmacological agents that halt the progression of 
COPD. Whilst means of relieving symptoms are available, the only proven 
method for reducing the risk of developing COPD is smoking cessation (Barnes 
& Hansel, 2004). Current treatment may involve one or a combination of 
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bronchodilators and glucocorticoids, and in the case of infective exacerbations, 
antibiotics may also be prescribed. 
Prescription of one of three potential long acting bronchodilators is currently the 
mainstay for symptom treatment of COPD patients (GOLD, 2007). These 
agents are two long acting P2-adrenergic receptor agonists, formoterol or 
salmeterol, or a muscarinic receptor antagonist, tiotropium. The P2-agonists 
increase FEVi and health status (as indicated by responses to St. George's 
respiratory questionnaire, which measures the impact on overall health, daily 
life and perceived wellbeing) (Cazzola & Donner, 2000). They act by relaxing 
smooth muscle contraction, via agonism of the P2-adrenergic receptor. This 
activates adenyl cyclase within the smooth muscle cells, and production of 
cyclic adenosine monophosphate (cAMP) (Johnson & Rennard, 2001), leading 
to increased intracellular calcium, reduced activity of myosin light-chain kinase, 
and finally, relaxation (Anderson, 2006). P2-agonists also have anti- 
inflammatory activity; formoterol reduces the production of granulocyte- 
macrophage colony stimulating factor (GM-CSF) by airway smooth muscle cells 
in response to IL-1p stimulation and from bronchial epithelial cells in response 
to TNFa (Kaur et aL, 2008; Loven et a/., 2007). However, the use of these 
agents in COPD is controversial, as poor reversibility (a spirometric analysis of 
an increase in FEVI of >15% following inhalation of a short acting P2-agonist) is 
one of the hall-marks of the disease and is used to differentiate COPD from 
asthma (BTS Guidelines, 1997). Therefore the improvement in symptoms 
reported by patients as a result Of P2-agonist inhalation is likely to be due to the 
non-bronchodilatory actions (Ram & Sestini, 2003). 
Tiotropiurn is an anticholinergic agent that acts on muscarinic acetylcholine 
receptors, and increases FEW health status, and decreases dyspnoea 
(Casaburi et a/., 2002). Additionally, tiotropiurn inhalation may reduce 
exacerbation frequency (Brusasco et al., 2006). Tiotropiurn acts by reducing 
contraction of smooth muscle cells and binds to either muscarinic receptor M2 
or M3 receptors with a longer duration of action at M3. Binding to either receptor 
prevents the effects of acetylcholine activation of Rho-kinase, which in turn 
activates myosin light chain phosphatase, resulting in relaxation (Gosens et al., 
2006). 
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Glucocorticoids are anti-inflammatory agents that act by binding to 
glucocorticoid receptors (GR) within the cytoplasm of target cells (Suissa et al., 
2007). This causes the dissociation of GR from chaperone proteins, which 
allows the receptor to translocate to the nucleus. Here, the 
glucocorticoid/receptor complex can bind to glucocorticoid response elements 
(GRE) in the promoter regions of specific genes (Barnes et al., 2003). In most 
cases this interaction leads to gene transcription (known as transactivation), 
however, in some cases genes may be repressed. Many of the genes that are 
transcribed via GRE activation are anti-inflammatory, these include SLPI and IL- 
10 (Adcock et al., 2004). Glucocorticoids also have a downregulatory effect on 
many inflammatory genes (transrepression), through a variety of mechanisms. 
Glucocorticoid receptors interact with transcription factors that regulate the 
transcription of inflammatory genes and repress their production (Barnes, 
2006). Alternatively, gene transcription is suppressed by glucocorticoid induced 
inhibition of the unwinding of DNA around histone proteins. This is elicited by a 
reduction in histone acetyltra nsfe rase (HAT) activity (Ito et al., 2000). 
Glucocorticoids are widely prescribed to reduce inflammation in asthma. Based 
on this efficacy they are often prescribed to COPD patients. However, long term 
studies have reported only nominal improvements in the lung function of these 
patients (Pauwels et aL, 1999; Vestbo et aL, 1999). This has lead to widespread 
controversy over their use in COPD. It has been argued that the small 
proportion of patients who benefit from inhaled corticosteroids may have 
asthma concomitant with COPD, and that it is symptoms associated with the 
former that are alleviated (Barnes, 2003). This insensitivity to glucocorticoids is 
thought to be associated with reduced activity of histone deacetylating (HDAC) 
enzymes. Reduced expression of HDAC2/5/8 and reduced total HDAC activity 
has been demonstrated in COPID patient peripheral lung tissue and alveolar 
macrophages respectively (Ito et aL, 2005). 
Combinations of glucocorticoids and bronchodilators have been examined to 
assess whether this increases their efficacy. The "Towards a Revolution in 
COPD Health" (TORCH) study combined fluticasone and salmeterol and 
demonstrated a significantly reduced decline in lung function compared to 
placebo (Celli et aL, 2008). A meta-analysis of similar studies found that this 
combination did not alter mortality, but exacerbation frequency was reduced. 
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When combined with the TORCH findings, this suggests that combination 
inhalers may be of greater therapeutic use than a single component alone 
(Nannini et aL, 2007). 
As discussed previously, there are various potential causes of COPID 
exacerbations (section 1.1.5. ), however, antibiotics are the mainstay treatment 
(Celli & Barnes, 2007). The agents used include so-called "first line" antibiotics 
such as amoxicillin and doxycycline and "second line" antibiotics, such as 
macrolides and quinolones (Dimopoulos et aL, 2007). The modes of action 
differ from one treatment to another, whilst macrolides kill bacteria by binding to 
a ribosomal subunit and preventing protein synthesis, amoxicillin, like other 
penicillin derivatives, prevent synthesis of the bacterial cell wall (Blumberg & 
Strominger, 1974; Garza-Ramos et aL, 2001). There is controversy surrounding 
the use of anti-bacterial agents, as many studies have suggested they are 
ineffective in some patients (Puhan et aL, 2007). Potential causes for this 
include bacterial resistance to antibiotics and a non-bacterial cause of the 
exacerbation. 
1.2. Pulmonary host defence against pathogens 
Multiple mechanisms exist for maintaining sterility within the lung. These include 
physical barriers which filter particles from the air and a cough reflex. If inhaled 
particles evade these defences, they are removed by innate immune 
mechanisms, involving soluble factors which bind to particles to signal their 
presence to phagocytic macrophages. Some organisms have evolved 
mechanisms of evasion; therefore a third line of defence, the adaptive immune 
system, is responsible for their elimination. 
1.2.1. Physical barriers 
When air enters the airways via the nose or mouth, it contains particles, toxic 
gases and microorganisms such as bacteria and fungal spores. There are 
various barrier functions which prevent the transport of these potential irritants 
into the lung; initially, particles are trapped by mucus secreted by the epithelial 
layer in the nasal passage (Schwab & Zenkel, 1998). This mucus consists of 
two layers, the periciliary layer and a gel-like mix of glycosylated 
macromolecules. These molecules, termed mucins, have a variety of O-glycan 
side chains, which allows binding of particles with greatly differing chemical 
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properties (Knowles & Boucher, 2002). Inhaled particles bound to the mucus 
are cleared by the synchronised beating of cilia on the surface of the epithelia 
(Stannard & O'Callaghan, 2006). This ciliated, mucus producing epithelium is 
also present throughout the upper airways; therefore, particles which evade the 
nasal defences may bind to mucus in the trachea. The clearance of mucus from 
the airways is also aided by the cough reflex, whereby the respiratory muscles 
contract rapidly, propelling the mucus upwards (Nicod, 1999). 
1.2.2. Adaptive Immunity 
The adaptive immune system is highly specific and allows for a fast response 
should the same pathogen be encountered again. Adaptive immunity can act 
against all types of pulmonary pathogens, but is essential in the removal of 
mycobacterium, fungi and viruses, all of which may evade the innate immune 
system (Curtis, 2005). This response primarily involves T-lymphocytes, which 
can be divided into ap or y6 cells according to the variable portion of their 
antigen recognition receptor. ap receptors are described as either CD4+ or 
CD8+, depending on which of the two surface molecules they express 
predominantly. CD8+ cells are cytotoxic lymphocytes which target cells that are 
infected with intracellular pathogens, via ligation of MHC class I (Janeway et aL, 
2004). Following recognition of extracellular pathogens presented by MHC class 
11 antigens, CD4+ cells activate macrophages, dendritic cells and CD8+ T-cells. 
These lymphocyte subsets can be further separated according to their profile of 
synthesised cytokines. The majority of CD4+ T-cells can be described as either 
T helper (Th)l or Th2. The former produces IFNy, which activates macrophages 
via the signal transducers and activators of transcription (STAT)l pathway 
(Punturieri et aL, 2004). Whereas, Th2 cells produce IL-4,5,10,13, which 
support humoral immunity, via antibody production (Moore et aL, 2001). This 
same classification according to cytokine release can also be used to describe 
CD8+ cells (termed T cytotoxic (Tc)l and Tc2). The proportions of each subset 
present in the alveolar space is tightly controlled in healthy individuals, via 
negative feedback. IFNy released by Thl cells suppresses proliferation of Th2 
cells, whereas IL-10 from Th2 cells reduces cytokine production by Thl cells 
(Santana & Rosenstein, 2003). However, there is evidence that this balance 
may be dyregulated in COPD, as an increase in Thl T-cells has been identified 
in both blood and BAL from these patients (Hodge et al., 2007a). y6 T-cells are 
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less common than their ap chain counterparts, but are located on mucosa, 
including that present in the lungs. Their precise role is pathogen dependent, 
but they are thought to play an immunoregulatory role early in the course of an 
infection (Moore et a/., 2001). The presence of these cells has been shown to 
be essential for eliciting an immune response to specific bacterial strains. For 
example, y6 T-cell knock-out mice are susceptible to Klebsiella pneumoniae, a 
bacterium present in approximately 3% of sputum samples from COPD patients 
during exacerbations, but are not susceptible to Mycobacterfurn tuberculosis 
(D'Souza et al., 1997; Ko et aL, 2008; Moore et al., 2000). 
B-cells also play a role in the adaptive immune system within the lung, via the 
release of humoral components such as antibodies in response to recognition of 
pathogens. B-cells become activated upon ligation of CD40, and to stimulation 
by cytokines. This leads to either antibody producing plasma cells, or to 
memory cells, which will produce antibodies when they encounter the antigen in 
the future. The antibodies produced are immunoglobulins (1g). The most 
common form is IgG, although IgA, IgM and IgE are also produced. 
Immunoglobulins neutralise pathogens by binding to their surface, thus 
preventing interactions with other host cells. Alternatively, they can act with 
complement proteins to form "membrane attack complexes", or opsonise 
pathogens to signal their presence to phagocytes. In the lung, memory B-cells 
are located in the alveolar and interstitial spaces where the pathogen was first 
encountered, in order to allow for prompt release of antibodies in the event of 
future infection (Bice et aL, 1987). However, an excess of circulating B-cells can 
have negative effects. B-cells are increased in the small airways of severe 
COPID patients when compared to non-smoking controls, and furthermore, the 
majority of B-cells in lymphoid follicles isolated from subjects with emphysema 
were found to be undergoing clonal expansion, suggesting that they have 
encountered an antigen excess (either cigarette smoke or pathogens) (Hogg et 
aL, 2004; van der Strate et aL, 2006). These cells will persist in the airways, 
even in the absence of the original antigen and may contribute to the chronic 
inflammation seen in the lungs of COPID patients. 
1.2.3. Innate immunity 
Whilst the adaptive immune system can take days or weeks to eliminate 
pathogens, by contrast the innate immune system responds immediately to 
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invasion. Innate immunity evolved in multicellular organisms as a mechanism 
for distinguishing self and foreign matter. The innate immune system consists of 
soluble proteins, which bind microbial products, and phagocytic cells which 
migrate into tissues from the bloodstream at sites of inflammation, or into tissue 
to wait for potentially harmful microorganisms (Martin & Frevert, 2005). In the 
lungs, this system involves secreted proteins that either act directly on 
pathogens or signal their presence to alveolar macrophages to initiate 
phagocytosis. Alternatively, macrophages can directly recognise a bacterium, 
which also triggers engulfment. These mechanisms are presented in Fig. 1.3. 
Anti-microbial proteins, such as defensins, collectins, lactoferrin and lysozyme, 
are secreted by epithelial cells and leukocytes in the airways. Defensins are 
peptides that are produced by epithelial cells and can be both constitutively 
expressed or produced in response to recognition of microorganisms. They act 
by either damaging the membranes of pathogens via pore formation, or by 
preventing protein synthesis, thus slowing proliferation (Hiemstra, 2006). The 
collectins are a family of polypeptides that include the mannose binding lectin 
(MBL) and surfactant proteins A and D (SPA/D). (Holmskov et al., 2003). In 
addition to directly neutralising bacteria, these molecules can also trigger the 
complement cascade. Other antimicrobial molecules include lactoferrin, which 
reduces bacterial proliferation by competing for iron, and the antiproteases SLPI 
and elafin (Mateos et al., 1998; Sallenave, 2002). Lysozyme plays a particularly 
important role in defence against Gram positive bacteria, as it is able to bind to 
peptidoglycan and break glycosidic bonds, thus disturbing the bacterial cell 
membrane (Palaniyar et aL, 2002). 
In addition to these proteins, the complement system also plays a role in 
pulmonary defence against inhaled pathogens. Proteins in this system can 
combine to form a "membrane attack complex" which creates pores in the 
membranes of microbes (Czermak et aL, 1998). The complement protein, C5a, 
can act as a chemoattractant to recruit neutrophils, prompting the release of 
antimicrobial peptides (Guo & Ward, 2005). Finally, complement can bind to the 
surface of pathogens, and this opsonisation triggers a signal for engulfment by 
macrophages. Immunoglobulins, such as IgG, which is the second most 
abundant protein in BAL fluid after albumin, can also opsonise particles and this 
alerts phagocytes to their presence. Binding of these IgG proteins to pathogens 
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is then recognized by Fc receptors on macrophages, and initiates the 
phagocytic process (Aderem & Underhill, 1999). 
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The innate immune system is composed of soluble proteins such as antimicrobial peptides (e. g. 
defensins, lysozyme surfactant proteins A and D (SPA/SPD) and lactoferrin), which bind to the 
surface of bacteria, immunoglobulins which neutralise bacteria and complement proteins which 
form membrane-attack complexes. Additionally each of these can signal to cells such as 
neutrophils and macrophages to initiate cellular mechanisms for the destruction of pathogens, 
e9 phagocytosis. 
1.2.4. Macrophages in the lung 
Macrophages differentiate from monocytes following migration from the blood 
through the vascular endothelial cells into the lung tissue. The speed at which 
they migrate is increased when the endothelial cells are activated. This 
activation is driven by proinflammatory cytokines and bacterial products such as 
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LIDS, therefore, when tissue is inflamed monocytes will accumulate quicker 
(Luscinskas & Gimbrone, Jr., 1996). Migration of monocytes involves a variety 
of adhesion receptors, including ICAM-1 and VCAM-1 (Ridley, 2001). 
Endothelial cells also release chemoattractants which can act in an autocrine 
fashion to stimulate interaction with monocytes (Springer, 1994). 
There are two major macrophage subtypes found in the lung, namely alveolar 
macrophages and interstitial macrophages. Alveolar macrophages are located 
within the alveolar sacs, and contribute to 90-95% of the population of cells 
found in BAL (Hards et al., 1970). They are highly phagocytic, cytotoxic, and 
chernotactic (Johansson et al., 1997), and their role in the removal of potentially 
pathogenic microorganisms via phagocytosis is essential in maintaining the 
normally sterile environment found within the lung. Alveolar macrophages are 
potent producers of mediators that initiate a local inflammatory response, 
resulting in an influx of neutrophils and additional macrophages. These 
mediators initially include lipids such as LT134 and prostaglandins, together with 
cytokines and chemokines, such as ILAP, TNFa, IL-6, GM-CSF and CXCI-8 
(Chung, 2001). The second macrophage subtype found in the lung is interstitial 
macrophages. These cells are located in the lung connective tissue and 
constitute approximately 40% of all macrophages in the lung (Crowell et aL, 
1992; Geiser, 2002). Interstitial macrophages are smaller and phagocytose 
fewer heat inactivated yeast particles when compared with alveolar 
macrophages (Fathi et aL, 2001). Interstitial macrophages have been reported 
to have a greater proliferative capacity than alveolar macrophages in murine 
models, but there is currently no evidence that interstitial macrophages 
proliferate in the human lung (Marten & Hansel[, 2005). 
The primary role of the macrophage in the lung is phagocytic clearance of 
inhaled pathogens and particles. However, they also have other roles in the 
pulmonary immune system (such as those discussed in section 1.2.3. ) The 
functions of macrophages differ depending on their activation state. Mills et a/ 
(2000) suggested that macrophages can be divided into either an M1 or M2 
phenotype, which are associated with "classical" and 'alternative" activation 
respectively. These phenotypes can be separated according to production or 
expression of a variety of mediators and receptors, as described in Fig. 1.4. 
Classically activated macrophages (Ml) are specialised for cytotoxic actions 
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against intracellular pathogens. This is important as some pathogens, such as 
mycobacteria and Pneumocystis firoveci, have evolved mechanisms to evade 
intracellular killing by macrophages (Van Ginderachter et aL, 2006). The 
cytotoxic activity of classically activated macrophages is increased by lysosome 
fusion and the production of antimicrobial peptides, proteases and oxygen 
radicals (Mosser, 2003). Additionally, M1 activation upregulates, the release of 
proinflammatory cytokines and chemokines, such as IL-1p, IL-6, TNFa, 
CXCL8,10 and CCL3,4,5 (Chen et a/., 2003; Mantovani et al., 2002). Initially, 
M1 macrophages are primed by IFNy from Thl cells (Schroder et aL, 2006). 
Subsequently, they are activated by LPS, peptidoglycan or IFNy, leading to an 
upregulation of MHC class 11 and down-regulation of the mannose receptor 
(Dalton et al., 1993; Ezekowitz & Gordon, 1984). Alternatively activated 
macrophages (M2) are important in defence against parasitic infections and 
extracellular pathogens (Gordon, 2003). These cells can be further sub-divided 
according to the activating stimuli: M2a macrophages are activated by IL-4 and 
IL-13, M2b are activated by ILAP and LPS, and M2c cells are activated by IL- 
10, TGFP and glucocorticoids (Mantovani et aL, 2004). Of these the M2a 
subtype are the best studied. These cells demonstrate increased release of 
leukocyte chemoattractants, such as CCL17,18,22, anti-inflammatory cytokines 
such as IL-10 and TGFP and the soluble receptor ILARa (Goerdt & Orfanos, 
1999). M2 activation can lead to the loading of soluble antigen onto MHC class 
11 and increased mannose receptor expression (Stein et aL, 1992). 
Macrophages can also be activated during innate immune responses; during 
this process, pattern recognition molecules (e. g. LPS), immunoglobulins or 
complement bind to receptors and initiate phagocytosis, however, upon 
recognition the cell also releases proinflammatory cytokines and ROS (Gordon, 
2003). 
Based on these findings, it is likely that macrophages in the lungs of COPID 
patients are of the M1 subtype. This assumption arises from the finding that 
numbers of IFNy secreting Thl CD4+ cells are increased in the BAL of COPD 
subjects (Di Stefano et al., 2004), and secondly due to the presence of LPS as 
a result of bacterial colonisation of the lungs. There are currently no markers to 
distinguish each of these subtypes; therefore it is not possible to confirm which 
type is prevalent in the pulmonary macrophage population. 
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Figure 1.4. Pheno! ypic differences between M1 and M2 macrophages. 
The expression of cytokines, chemokines and receptors by each macrophage subtype is 
displayed. Arrows represent the relative expression of the protein by each cell type, with green 
arrows representing M1 activated macrophages, red arrows representing M2 macrophages 
activated by IL-10, arrows representing M2 macrophages activated by IL-4 or IL-13 and 
blue arrows representing macrophages activated by either IL-10, IL-4 or IL-13 . Adapted 
from 
Mantovani et al. (2002) 
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1.2.5. Macrophage Phagocytosis 
Alveolar macrophage phagocytosis plays an essential role in the innate immune 
response to airborne pathogens. Phagocytosis begins by recognition of the 
pathogen as foreign and can occur either directly or indirectly, involving a 
variety of different receptors, as described in Figure 1.5. The direct mechanism 
of recognition involves the detection of repeated patterns of molecular structure 
on the surface of microorganisms, such as the Gram-negative bacterial coat 
protein, LPS or heat shock protein-60 (HSP-60) (Hazenbos & Brown, 2006). 
The alveolar macrophage surface receptors involved in these processes include 
toll like receptors (TLRs), mannose receptors, integrins and scavenger 
receptors. Alternatively, pathogens can be detected indirectly by recognition of 
humoral components from serum, which bind to the surface of pathogens, a 
process known as opsonisation. 
CR Gram -ve bacteria 
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Akký SR 
"'711%* Fc 
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40ý SR CR 
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Figure 1.5. Schematic diagram of the receptors involved in recoqnition of bacteria and apoptoti 
cells by macrophaqes. 
The receptors involved in direct recognition of particle include scavenger receptors (SR), 
mannose receptors (MR), toll like receptor (TLRs) and CD14/36. Those involved in indirect 
recognition include Fc receptors (Fc) and complement receptors (CR). 
The opsonising proteins involved include antibodies and complement proteins 
which are recognised by Fc and C3b or C3bi receptors respectively (Greenberg 
& Grinstein, 2002). Complement proteins are present in the lung, and are 
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increased following an inflammatory stimulus, such as LPS (Bolger et a/., 2007). 
However, the activity of complement produced by fibroblasts and type 11 
pneumocytes in the lung is reduced compared to that of serum complement. 
This is thought to be due to inhibition by surfactant protein A, and suggests that 
this form of opsonisation is not the primary method of pathogen recognition in 
the lung (Watford et aL, 2000; Watford et aL, 2001). The immunoglobulins IgG, 
IgA and IgM are all present in the lung, as identified by analysis of BAL samples 
(Yoshizawa et al., 1995). The concentrations of these are increased in patients 
with lung diseases including hypersensitivity pneumonitis and interstitial 
pneumonia. 
Expression of the associated opsonisation receptors has also been studied in 
COPD. FcyRlll (CD16) receptor expression is reduced on COPID alveolar 
macrophages when compared to non-smoker cells (Lofdahl et aL, 2006), 
however, that of the complement receptor CD11b is similar on alveolar 
macrophages from non-smokers and COPD subjects (Pons et aL, 2005). 
There are two known mechanisms of engulfment; i) sinking phagocytosis where 
the particle is drawn into the cytoplasm as the macrophage membrane 
envelopes it and ii) phagocytic cup formation, where pseudopod extensions 
form around the particle (Allen & Aderem, 1996). The former is associated with 
recognition of complement proteins bound to pathogens, whereas the latter is 
responsible for uptake following Fc receptor ligation. Both of these processes 
are followed by closing of the phagosome and fusion of the cell membrane, 
which is accompanied by downstream signalling events, such as acidification of 
the vesicle, fusion with a lysosome and release of antimicrobial enzymes that 
catalyse the breakdown of the engulfed pathogen (Aderem & Underhill, 1999). 
These processes are depicted in Fig. 1.6. 
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Figure 1.6. Schematic diaqram of Macrophage Phagocytosis 
Phagocytosis begins with the recognition of a particle (Diagram A), this is then ingested either 
by sinking phagocytosis (131) or phagocytic cup formation (132), antimicrobial enzymes then 
catalyse the breakdown of the pathogen (C & D) 
Phagocytic cup formation begins with lipid membrane remodelling following 
phosphorylation of receptor-associated immunoreceptor tyrosine-based 
activation motifs (ITAM) and recruitment of Sylk tyrosine kinase (Aderem & 
Underhill, 1999). There is evidence that alternative mechanisms may be 
involved in direct recognition, as Syk knockout mice are capable of 
phagocytosis via non-Fc mediated routes, but many other similarities exist 
between these processes (Crowley et al., 1997). Following recognition, actin is 
polymerised due to activation of Rac and Cdc42 (members of the Rho family of 
small GTPases) and the phosphoinositide-3 (PI-3) kinase signalling pathway 
(Hall, 2005; Swanson & Hoppe, 2004). This causes the recruitment of multiple 
members of the myosin superfamily, F-actin, protein kinase Ca and 
myristoylated alanine rich C kinase substrate (MARCKS), resulting in 
pseudopod extension (Allen & Aderem, 1996; Greenberg & Grinstein, 2002; 
Myat et al., 1997). The process of zippering then begins, whereby the 
pseudopods advance around the particle, which together with a membrane 
fusion process, is sufficient to completely enclose particles within a phagosome 
(Henry et al., 2004; Swanson et al., 1999). Now internalised, the phagosome 
matures by a series of interactions with endocytic vesicles and fuses with 
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lysosomes to form a phagolysosome. Within this vesicle oxidative burst and 
release of antimicrobial enzymes degrade the particle (Hazenbos & Brown, 
2006). 
Although there are more macrophages in the lung of COPD patients than non- 
smokers and smokers without obstruction, there is evidence that their ability to 
phagocytose is blunted. Uptake of three different strains of H. influenzae was 
reduced in alveolar macrophages isolated from COPD patients and the 
phagocytic response of monocyte derived macrophages (MDM) from COPD 
patients to fluorescently labeled E coli is also reduced (Berenson et a/., 2006; 
Finney-Hayward et al., 2005). As well as their importance in the phagocytosis of 
pathogens, clearance of apoptotic cells (termed efferocytosis) is another 
essential function of macrophages (Fig. 1.5). This process is important as it 
prevents the release of potentially damaging proinflammatory components from 
within the apoptosing cell (Hodge et al., 2003). Many receptors have been 
found to be involved in the recognition of apoptotic cells; these include CD36, 
CD14 and the phosphatidylserine receptor (Vandivier et al., 2002). There is also 
evidence that bridging molecules, such as annexin 1, facilitate the ligation of the 
phagocytosis receptor and the ligand on the apoptosing cells (Fadok & Henson, 
2003). The process of efferocytosis is of particular relevance to the lung 
immune system, as increased apoptotic cells are a feature of many pulmonary 
diseases. For example, increased apoptotic cells have been observed in 
sputum samples from cystic fibrosis patients, possibly due to reduced clearance 
by macrophages (Vandivier et al., 2002). Similarly, in COPID, efferocytosis by 
alveolar macrophages is reduced, which may contribute to the chronic 
inflammation seen in the lungs of these patients (Hodge et al., 2003). 
1.2.6. Models of COPD 
Given the complexity of COPID, a variety of different model systems have been 
designed to investigate specific aspects of the disease. Animal models have 
been central to many novel discoveries, for example, the association between 
the action of elastases and emphysema was demonstrated by instilling 
proteolytic enzymes into the lungs of rats (Gross et aL, 1965). The role of 
enzymes has also been widely investigated using transgenic mice (Shapiro, 
2007). Here, the gene of interest is either removed or introduced, in order to 
assess its role in the disease process. COPD-like disease can be induced in 
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mice following chronic cigarette smoke exposure. Alternatively, specific disease 
components can be investigated, for example, lung and systemic inflammation 
can be studied in mice following long-term inhalation of LIPS (Vernooy et al., 
2002). However, concerns have been raised as to the relevance to the human 
disease (Costa & Kodavanti, 2003). These include structural differences of 
rodent and human lungs, exemplified by fewer branchings and submucosal 
glands (Shapiro, 2007). Therefore, a number of human cell based models have 
also been employed in order to study disease mechanisms. These involve 
primary cells removed from the lung or use of commercially available cell lines, 
both of which are manipulated and studied outside of the body. For investigating 
COPID macrophage function, alveolar macrophages obtained from BAL are the 
'$gold standard". However, the procedure for their removal is invasive, and 
sometimes injurious (Haftotuwa et al., 2002). Additionally, cellular yields vary 
greatly especially in COPID patients, as the volume of fluid recovered is 
inversely proportional to the degree of emphysematous damage (Lofdahl et aL, 
2005). Other options for the investigation of alveolar macrophages involve 
monocytic cell lines, such as THP-1 and U937, which can be differentiated to 
macrophages (Auwerx, 1991). However, these cells do not reflect those of 
COPID patients, as they were originally obtained from patients without airflow 
obstruction. To overcome this issue, human monocyte derived macrophages 
(MDM) have been investigated. Monocytes can be quickly and easily obtained 
from peripheral blood, in substantial numbers. These cells are then incubated in 
conditions that induce their differentiation. In addition to temperature and carbon 
dioxide requirements, growth factors are also important. GM-CSF and 
monocyte stimulating factor (M-CSF) are both capable of inducing monocyte 
differentiation (Akagawa et al., 2006), however, the use of these factors will 
produce functionally different macrophages. GM-CSF stimulated MDM are more 
similar to alveolar macrophages, in respect to activation of P13K and protein 
kinase C (PKC) pathways, and microtubule rearrangement. Therefore, this 
model has been used in this thesis (Sulahian et al., 2008). 
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1.3 Hypothesis 
The reduced clearance of bacteria from the airways of patients with COPID 
could lead to increased numbers of exacerbations and contribute to chronic 
inflammation. This may be due to defects in the innate immune system. One 
aspect of this is examined by the following hypothesis: 
Bacterial colonisation present in the lungs of COPD patients is due to defective 
macrophage phagocytosis. Therefore, monocyte-derived-macrop h ages isolated 
from COPID patients will engulf significantly less phagocytosis targets than cells 
isolated from subjects without COPD. This hypothesis was examined by: 
Designing a phagocytosis assay to quantify the uptake of fluorescently 
labelled polystyrene beads and h eat-i n activated bacteria (Chapter 3). 
2. Comparing phagocytosis of macrophages isolated from non-smokers, 
smokers and COPD subjects (Chapter 4). 
3. Investigating the effect of commonly prescribed pharmacological therapies 
on phagocytosis (Chapter 5). 
4. Investigating signalling responses of macrophages in response to 
pathogenic bacteria (Chapter 6 and 7). 
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Chapter 2 
Materials and Methods 
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2.1 Materials 
Streptococcus pneumoniae serotype 9V, strain 10692 was a gift from Dr William 
Hanage (Molecular Epidemiology, Imperial College London) and non-typeable 
Haemophilus influenzae strain 1479 was supplied by Dr Paul Langford 
(Paediatric Infectious Disease, Imperial College London). 
Other materials were purchased from the following suppliers: 
Material Supplier 
3MM Chr chromatography paper Whatman, Maidstone, UK 
4-(2-hydroxyethyl)-l - 
piperazineethanesulfonic acid 
(HEPES) 
Sigma-Aldrich, Dorset, UK 
4', 6-diamidino-2-phenylindole 
dihydrochloride hylrate (DAPI) 
Sigma-Aldrich, Dorset, UK 
96 well black plates Costar, Fisher Scientific, 
Loughborough, UK 
Agar Sigma-Aldrich, Dorset, UK 
Albumin, Bovine Fraction V solution 
(BSA) 
Sigma-Aldrich, Dorset, UK 
Alexafluor 488 carboxylic acid Molecular Probes, Invitrogen, Paisiey, 
UK 
Amphotericin B Sigma-Aldrich, Dorset, UK 
Araldite resin Agar Scientific, Essex, UK 
Azithromycin Sigma-Aldrich, Dorset, UK 
Beef brain infusion Sigma-Aldrich, Dorset, UK 
Bio-Rad protein assay Biorad, Munich, Germany 
Bromophenol blue Sigma-Aldrich, Dorset, UK 
Budesonide Sigma-Aldrich, Dorset, UK 
Calf heart infusion Sigma-Aldrich, Dorset, UK 
Carboxylated unlabelled microspheres Molecular Probes, Invitrogen, Paisley, 
UK 
CAY1 0444 Sphnigosine-1 -phosphate 
antagonist 
Cayman Europe, Tallinn, Estonia 
Cell dissociation solution Sigma-Aldrich, Dorset, UK 
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Colchicine Sigma-Aldrich, Dorset, UK 
Coverslips, Raymond A. Lamb, Eastbourne, UK 
Cytochalasin B Sigma-Aldrich, Dorset, UK 
DAB substrate Vector Laboratories, California, USA 
DEPC-treated water Ambion, Applied Biosystems, 
Warrington, UK 
Dexamethasone Sigma-Aldrich, Dorset, UK 
Dextran Sigma-Aldrich, Dorset, UK 
D-glucose BDH, Poole, Dorset, UK 
Dimethyl sulphoxide (DMSO) Sigma-Aldrich, Dorset, UK 
Dulbecco's phosphate buffered saline Sigma-Aldrich, Dorset, UK 
ECL Detection Reagents GE Healthcare, Buckinghamshire, UK 
Escherichia coli (K-1 2 strain) 
BioParticles 
Molecular Probes, Invitrogen, Paisley, 
UK 
Ethanol BDH, Poole, Dorset, UK 
Ethylenediaminetetraacetic acid 
(EDTA) 
Sigma-Aldrich, Dorset, UK 
Evans Blue Sigma-Aldrich, Dorset, UK 
FACSflow Beckton Dickinson, Oxford, UK 
Filter bottles Fisher Scientific, Loughborough, UK 
Fluorescently labelled carboxylate- 
modified polystyrene microspheres 
Molecular Probes, Invitrogen, Paisley, 
UK 
Foetal bovine serum Gibco, Invitrogen, Paisley, UK 
Formaldehyde Sigma-Aldrich, Dorset, UK 
Formoterol Sigma-Aldrich, Dorset, UK 
Full-range rainbow molecular weight 
marker 
GE Healthcare, Buckinghamshire, UK 
FTY720 Cayman Europe, Tallinn, Estonia 
Glucose Sigma-Aldrich, Dorset, UK 
Glycerol Sigma-Aldrich, Dorset, UK 
Hank's balanced salt solution Sigma-Aldrich, Dorset, UK 
High capacity cDNA reverse 
transcription kit 
Applied Biosystems, California, USA 
HRP labelled Goat Anti-Mouse IgG Dako, Cambridgeshire, UK 
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HRP labelled Goat Anti-Rabbit IgG Dako, Cambridgeshire, UK 
Human-6 Expression BeadChips Illumina, San Diego, USA 
Hybond ECL Amersharn Pharmacia Biotech, GE 
Healthcare, Buckinghamshire, UK 
Hyperfilm ECL Amersharn Pharmacia Biotech, GE 
Healthcare, Buckinghamshire, UK 
Illumina Totalprep RNA Amplification 
kit 
Ambion, Applied Biosystems, 
Warrington, UK 
JTE-013 Sphingosine-1 -phosphate 
receptor antagonist 
Cayman Europe, Tallinn, Estonia 
Lab-tek permanox slides Costar, Fisher Scientific, 
Loughborough, UK 
L-Glutamine Gibco, Invitrogen, Paisley, UK 
Lead acetate Sigma-Aldrich, Dorset, UK 
Lead citrate Sigma-Aldrich, Dorset, UK 
Lead nitrate Sigma-Aldrich, Dorset, UK 
Light Green Sigma-Aldrich, Dorset, UK 
LS colums and collection tubes Miltenyi Biotec, Bisley, Surrey, UK 
MACS Monocyte isolation kit 11 Miltenyi Biotec, Bisley, Surrey, UK 
Methanol BDH, Poole, Dorset, UK 
Microscope slides Raymond A. Lamb, Eastbourne, UK 
Mini complete protease inhibitor 
cocktail tablets 
Roche, Mannheim, Germany 
Mouse monoclonal acetylated a tubulin 
antibody 
AbCam, Cambridge, UK 
Mouse monoclonal actin antibody Sigma-Aldrich, Dorset, UK 
Mouse monoclonal S1P3 antibody Cayman Europe, Tallinn, Estonia 
Mouse monoclonal tubulin (acetyl K40) 
antibody 
AbCam, Cambridge, UK 
NIH 3T3 Whole Cell Lysate AbCam, Cambridge, UK 
Nocodazole Sigma-Aldrich, Dorset, UK 
Nuclease-free water Ambion, Applied Biosystems, 
Warrington, UK 
NuPage MOPS SDS running buffer Invitrogen, Paisley, UK 
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NuPage Novex bis-tris electrophresis 
gels 
Invitrogen, Paisley, UK 
Nylon mesh filters Falcon, Cowley, Oxford, UK 
Osmium tetroxide Agar Scientific Ltd., Essex, UK 
Paraformaldehyde Sigma-Aldrich, Dorset, UK 
PE Mouse Anti-Human CD14 antibody Sigma-Aldrich, Dorset, UK 
PE Mouse Anti-Human CD16 antibody Sigma-Aldrich, Dorset, UK 
PE Mouse Anti-Human CD1a antibody BD Pharmingen, Oxford, UK 
PE Mouse Anti-Human HLA-DR 
antibody 
Beckton Dickinson, Oxford, UK 
PE Mouse IgG2a, K Isotype Control Beckton Dickinson, Oxford, UK 
Penicillin Gibco, Invitrogen, Paisley, UK 
Percoll Amersham Pharmacia Biotech, GE 
Healthcare, Buckinghamshire, UK 
Phosphatase inhibitors Sigma-Aldrich, Dorset, UK 
Phosphate buffered saline tablets 
(PBS) 
Sigma-Aldrich, Dorset, UK 
Polyoxyethylene-sorbitan monolaurate 
(Tween-20) 
Sigma-Aldrich, Dorset, UK 
Polystyrene FACS Tubes Beckton Dickinson, Oxford, UK 
Pooled human serum Sigma-Aldrich, Dorset, UK 
Proteose peptone Sigma-Aldrich, Dorset, UK 
QlAshredders Qiagen, Crawley, UK 
Rabbit monoclonal HDAC6 antibody AbCam, Cambridge, UK 
Rabbit monoclonal S1 P2 antibody Cayman Europe, Tallinn, Estonia 
Rabbit polyclonal Sirtuin 2 antibody AbCam, Cambridge, UK 
Recombinant human GM-CSF Biosource, Invitrogen, Paisley, UK 
RNA 6000 Nano LabChip kit Agilent Technologies, Wokingham, UK 
Rnase-free Dnase set Qiagen, Crawley, UK 
RNAzap Ambion, Applied Biosystems, 
Warrington, UK 
Rneasy mini kit Qiagen, Crawley, UK 
Roswell Park Memorial Institute media 
(RPMI)-1640 
Sigma-Aldrich, Dorset, UK 
I 
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RPE labelled rabbit anti-human 
immunoglobulins 
Dako, Cambridgeshire, UK 
RPE labelled rabbit anti-mouse 
immunoglobulins 
Dako, Cambridgeshire, UK 
Saponin Sigma-Aldrich, Dorset, UK 
Sodium azide Sigma-Aldrich, Dorset, UK 
Sodium chloride (NaCl) in water Macopharma, London, UK 
Sodium deoxycholate Sigma-Aldrich, Dorset, UK 
Sodium dodecyl suplphate (SDS) Sigma-Aldrich, Dorset, UK 
Sodium cacodylate Sigma-Aldrich, Dorset, UK 
Sodium phosphate (Na2HP04*12H20) Sigma-Aldrich, Dorset, UK 
Sphingosine-1 -phosphate ELISA kit Echelon Biosciences, Utah, USA 
Sphingosine kinase inhibitor Cayman Europe, Tallinn, Estonia 
Sterile needles BDH, Poole, Dorset, UK 
Streptavidin-Cy3 GE Healthcare, Buckinghamshire, UK 
Streptomycin Gibco, Invitrogen, Paisley, UK 
Syringes 3S Healthcare, London, UK 
Taqman gene expression arrays Applied Biosystems, California, USA 
Taqman universal master mix Applied Biosystems, California, USA 
Theophylline Sigma-Aldrich, Dorset, UK 
Tiotropium 
Toludine Blue Sigma-Aldrich, Dorset, UK 
Triton X-1 00 Sigma-Aldrich, Dorset, UK 
Trizma base (TRIS) Sigma-Aldrich, Dorset, UK 
Tryphan blue BDH, Poole, Dorset, UK 
Vacutainers 4.5ml KS EDTA 15% 3S Healthcare, London, UK 
Vacutainers, 6ml 3S Healthcare, London, UK 
Vectastain ABC elite kit- Mouse IgG Vector laboratories, California, USA 
Vybrant phagocytosis kits Molecular Probes, Invitrogen, Paisley, 
UK 
P-mercaptoethanol Sigma-Aldrich, Dorset, UK 
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2.2. Methods 
2.2.1. Subject selection 
Healthy normal subjects and smokers were recruited by the National Heart and 
Lung Institute and the Royal Brompton Hospital, London. COPD subjects were 
recruited from the Royal Free Hospital, London or Wexham Park Hospital, 
Slough, and samples were transported by motorcycle courier to the National 
Heart and Lung Institute. This journey resulted in a delay in processing time of 
approximately 1h when compared to samples obtained from the Royal 
Brompton Hospital. All subjects gave written informed consent as approved by 
the Royal Brompton and Harefield NHS Trust Ethics Committee. Alveolar 
macrophages from bronchoalveolar lavage were obtained from consenting 
patients at St. Mary's hospital, London or Wexham Park Hospital, Slough. 
Approval was given by all associated ethics committees. 
2.2.1.1. Non-smokers 
Non-smokers were aged between 21-85 years, with normal baseline lung 
function as predicted for age, sex and height (see section 2.2.2.1). Subjects had 
no history of respiratory disease and normal bronchial reactivity (see section 
2.2.2.2). Additionally, non-smoker subjects had no smoking history and were 
not taking any regular medications. 
2.2.1.2. Smokers 
Smokers were aged between 21-85 years, with normal lung function as 
predicted by age, sex and height, no history of respiratory disease and were not 
taking any regular medications. Smoker subjects had a smoking history of at 
least 10 pack years, with one pack year being defined as 20 cigarettes per day 
for one year. 
2.2.1.3. COPD tien 
COPID subjects were aged 40-85 years, with an FEVI: FVC ratio of <0.7 and 
post-bronchodilator FEVI% predicted <85%. Additionally, COPD subjects had 
no history of other respiratory diseases and a smoking history of at least 10 
pack years. 
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2.2.1.4. Exclusion ctiteria 
Subjects were excluded if they met any of the following exclusion criteria: 
clinically significant findings in medical records or on examination (except those 
associated with COPD in the COPD group), inability to give informed consent. 
Women were excluded if pregnant or breastfeeding. 
2.2.2 Measurements 
All clinical measurements were performed by the nursing staff of the respiratory 
departments of the Royal Brompton, Royal Free and Wexham Park hospitals. 
2.2.2.1 Spirometry 
Forced expiratory volume in one second (FEVI) and forced vital capacity (FVC) 
were measured using a spirometer (Vitalograph, Buckingham, 
Buckinghamshire). Values are expressed as either absolute or as a percentage 
of a value predicted for age, sex and height. A baseline value was obtained by 
taking the highest of three attempts at 1 min intervals. Predicted values were 
calculated according to Crapo tables, which correlate age, sex and height with 
lung function (Crapo et aL, 1981). 
2.2.2.2 Bronchial reactivity 
A challenge method of bronchial provocation was employed. This involved 
inhalation of methacholine chloride in increasing doses, ranging from 0.0625- 
64mg/ml in 0.9% (/,, ) sodium chloride or histamine in increasing doses ranging 
from 0.0625-32mg/ml, then measurement of FEVI spirometry (see section 
2.2.2.1). 
First, following baseline spirometry measurement, patients were asked to inhale 
normal saline from a nebuliser attached to a breath-activated dosimeter (Mefar 
Dosimeter M133, Brescia, Italy). The nebuliser delivers a1s nebulisation of 9pl 
of normal saline (0.9% (w/v) sodium chloride), after which the patient is asked to 
hold their breath for 6 s. FEV, was measured 2 min after each inhalation. This 
was repeated 5 times. The same procedure was then carried out for increasing 
concentrations of methacholine or histamine until a fall in FEV, of 20% or 
greater from the post-saline value was detected. 
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The dose of challenge causing a fall in FEV, of 20% (PC20) was then calculated 
by linear interpolation using the following formula: 
109 (PC20) log [A] + 0.301 x FEVISA) - 0.8 x FEV, (saline) 
FEVI (A) - FEVI(B) 
Where [A] 2nd highest concentration of methacholine or histamine reached. 
FEVI(saline) = FEV, following inhalation of saline. FEVI(A) = FEV, following 
inhalation of the 2 nd highest concentration. FEVI(B) = FEV, following inhalation 
of the highest concentration. 
2.2.3 Cell Isolation 
2.2.3.1 Monocyte detived macrophages 
Whole blood was obtained from patients by nursing staff at Wexham Park 
hospital, Slough and the Royal Free and Royal Brompton hospitals, London. 
In order to isolate monocytes, 60ml of human blood was collected into tubes 
containing EDTA to give a final concentration of 2% (w/v). Blood was divided into 
3 x: 20ml aliquots, each of which were then mixed with 10ml dextran solution 
(6% dextran (w/v) in Dulbecco's phosphate buffered saline (D-PBS)) and the 
final volume adjusted to 50ml with D-PBS. The tubes were inverted to mix and 
maintained at room temperature (RT) for 25 min to sediment the red blood cells. 
The top, leukocyte rich, layer was then transferred to clean tubes and the 
volume adjusted to 50ml with D-PBS, followed by centrifugation at 400 xg for 
10 min at 411C. The cell pellets were resuspended in D-PBS and centrifuged as 
above to wash. 
The cell pellet contains a mixture of leukocytes, therefore the granulocytes were 
separated from the peripheral blood mononuclear cells (PBMC) fraction using 
Percoll gradients. A 100% Cl,, ) Percoll solution was prepared by combining 
21.6ml Percoll and 2.4ml 10x phosphate buffered saline (PBS). From this 
solution, Percoll fractions of 81%, 68% and 55% (Q in D-PBS were prepared. 
Gradients were prepared by transferring 4ml of the 81% C1. ) solution into a 
15ml Falcon tube, which was overlaid with 4 ml of 68% (v/, ) Percoll solution. 
The cell pellet from above was resuspended in 3ml of 55% (v/, ) Percoll and then 
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overlaid onto the pre-prepared gradient. The cells were then separated 
according to density by centrifugation at 750 xg for 25 min at 411C. 
The PBMC were harvested from the 55%/68% interface and the 
polymorphonuclear (PMN) cells from the 68%/81% interface. PBMC were then 
washed with D-PBS, resuspended in 1ml of D-PBS and cell counts performed 
using a haernocytometer following staining with 1: 10 Kimura stain (0.05% (v/v) 
toludine blue, 0.03% Clv) light green, 10% (/,, ) saponin, 0.07M phosphate 
buffer). 
Monocytes were then separated from the PBMC fraction using a Miltenyi 
Monocyte Isolation Kit 11 according to manufacturers instructions. Cells were 
resuspended in 30pl of separation buffer (D-PBS, 0.5%/, BSA, 2nM EDTA) per 
10' cells. 1 OpI FcR Blocking Reagent and Biotin-Antibody Cocktail were added 
per 107 total cells and incubated on ice for 10 min. After this time, 30pl of buffer 
and 20pl of anti-biotin microbeads were added per 107 total cells. Cells were 
then incubated for 15 min on ice, followed by washing with separation buffer 
then resuspended in 500pl buffer ready for separation. An LS MACS column 
was attached to a magnet and rinsed with 3ml of buffer. The cell suspension 
was then added to the column and the run through from the column (the 
negative fraction, representing the enriched monocytes) was collected. A further 
9ml buffer was run through the column and collected. The resulting effluent was 
centrifuged and resuspended in lml complete medium (RPMI 1640,10% Clv) 
FCS, 10mglml (1% (/, )) penicillin/streptomycin, 2mM (1% L-glutamine). 
To culture MDM, monocytes were counted and resuspended at 1X106 cells/ml in 
complete medium. GM-CSF was added to a final concentration of 2ng/ml. Cells 
were then transferred to 96 well black, clear bottomed tissue culture plates at 
1.6xlO'5 cellstwell, or 6 well tissue culture plates at U106 cellstwell. Cells were 
then incubated at 370C, 5% C02 for 12 days, with fresh media containing GM- 
CSF replaced on days 4 and 8. 
2 23.2. Standardisation of MDM number 
In order to ensure minimal variability between wells and subjects, cell counts 
and protein quantification assays were performed (as described in sections 
2.2.3.1 and 2.2.13.1 respectively). There was no significant difference in the cell 
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counts or volumes of protein between cells from individual subjects (Fig. 2.1 & 
2). 
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Figure 2.1. Comparison of MDM cell counts in multiDle wells. 
Monocytes were isolated from non-smoking subjects and cultured towards an MDM phenotype 
for 12 d. Cells were then removed and counted using a haernocytometer. Data are presented as 
cell counts from individual wells, with the horizontal line representing the mean value, n=6. 
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Figure 2.2. Compahson of protein content from multiple wells. 
Monocytes were isolated from non-smoking subjects and cultured for 12 d towards an MDM 
phenotype. A Biorad protein assay was then performed to quantify the amount of protein 
contained in each well. Data are presented as protein concentrations from individual wells, with 
the horizontal line representing the mean value, n=24-32. 
There was no difference between cell counts or protein quantities between 
patients or between subject groups (Fig 2.3 & 4). 
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Fiqure 23 Comparison of MDM cell counts from non-smokers, smokers and COPD subiects. 
Monocytes were isolated from non-smoker (a), smoker (A) and COPD subjects (T) and 
cultured for 12 d towards an MDM phenotype. Cells were then removed and counted using a 
haernocytometer. Data are represented as cell counts from individual wells, with the horizontal 
line representing the mean value, n=6 for each group. 
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Figure 2.4. Comparison of Protein content from non-smokers, smokers and COPQ subects. 
Monocytes were isolated from non-smoker (e), smoker (A) and COPID subjects (T) and 
cultured for 12 d towards an MDM phenotype. A Biorad protein assay was then performed in 
order to quantify the amount of protein contained in each well. Data are represented as protein 
concentrations from individual wells, with the horizontal line representing the mean value, n=8 
for each group. 
2.2.3.2 Alveolar macrophages 
Alveolar macrophages were obtained from bronchoalveolar lavage (BAL) fluid 
obtained from patients undergoing investigative fibreoptic bronchoscopy 
performed by Dr R. Russell (Wexham Park Hospital, Slough), Drs L. Han or S. 
Elkin (St. Mary's Hospital, London). 
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0.6mg atropine and 5-10mg miclazalarn was administered intravenously to the 
patient undergoing bronchoscopy. Local anaesthesia was administered to the 
upper airways, prior to the insertion of the bronchoscope into the trachea via the 
nasal passage. Lungs were lavaged by addition then aspiration of 100ml warm 
0.9% (v/, ) saline. 
BAL fluid was kept on ice prior to processing within 1 h. Under sterile conditions 
the BAL fluid was passed through 100prn filters and centrifuged at 500 xg for 
10 min. The supernatant was removed by aspiration and the cell pellet 
resuspended in 1ml complete medium supplemented with 0.25pg/ml 
amphotericin B. Cells were counted using Kimura staining (see section 2.2.3.1) 
then resuspended at U106macrophages/ml in medium, and transferred to 96 
well tissue culture plates (100pl per well), prior to overnight incubation (370C, 
5% C02) to allow cells to adhere. 
2.2.4 Measurement of expression of cell surface markers 
For flow cytometric analysis of surface markers, cells were removed from 6-well 
plates by addition of Iml cell dissociation solution, and incubation for 15 min at 
RT followed by aspiration. Cells were then transferred to FACS tubes and 
centrifuged at 400 xg for 10 min. Pellets were resuspended in 1 00pl PAB (D- 
PBS with 5% (w/v) BSA and 0.1% r/v) sodium azide). Antibodies were then 
added at the dilutions specified in Table 2.1, according to the manufacturer's 
recommendations: 
Antibody Dilution 
Isotype control 1: 50 
Anti-CD14 1: 100 
Anti-CD16 1: 10 
Anti-C D1a 1: 100 
Anti-HLA-DR 1: 50 
Table 2.1. Anti-bodies and conditions used for surface marker expression guantification. 
Cells were then incubated at RT in the dark for 30 min. As the CD1a primary 
antibody was not conjugated to a fluorescent label, a rabbit anti-mouse RPE 
conjugated secondary antibody was then added at a dilution of 1: 250 to this 
tube and incubated for a further 30 min at RT in the dark. 
69 
All samples were then washed by addition of 1ml PAB and centrifugation at 400 
xg for 5 min. The cell pellet was then resuspended in 300pl FACS flow (0.5% 
("/, ) paraformaldehyde, dH20) ready for analysis. Samples were analysed using 
a Becton Dickinson FACScan machine using CellQuest software. Cells were 
gated according to forward and side scatter values correlating to those of 
macrophages. For each condition 5000 events were recorded. Histograms of 
fluorescence in the FL1 channel were analysed using WinMDl software. 
2.2.5 Preparation of Heat Killed Fluorescently Labelled Bacteria 
2.2.5.1 Propagation of bacteria 
2.2.1.1.1 Haemophilus influenzae 
Frozen cultures of Non-typeable H. influenzae strain 1479 were streaked onto 
agar plates containing Brain Heart Infusion (BHI) nutrient agar (20% ('/, ) calf 
heart infusion, 25% rl,, ) beef brain infusion, 1% (*/,, ) proteose peptone, 1.35% 
(*/, ) agar, 0.5% ('%) NaCl, 0.2% r/v) Na2HP04*12H20,0.2% C/v) glucose). 
Plates were incubated for 18h at 370C. 20ml aliquots of BHI broth (20% (*/, ) calf 
heart infusion, 25% (w/, ) beef brain infusion, 1% (/, ) proteose peptone, 0.5% 
(*/v) NaCl, 0.2% (w/v) Na2HP04*12H20i 0.2% (w/v) glucose) in Universal tubes 
were then inoculated with H. influenzae and incubated on a shaker incubator at 
370C (200 revolutions per minute (RPM)). In order to determine the growth rate, 
500pl of bacteria were removed each hour and transferred to a cuvette, and 
optical density (OD) read at 660nm in a spectrophotometer. Additionally, serial 
dilutions of bacteria were plated onto BHI plates and incubated overnight. 
Colony forming units (CFU) were counted the following day, and the data was 
used to derive a growth curve (Fig 2.1. ). When the cultures reached log phase, 
bacterial solutions were divided evenly into 50ml Falcon tubes (2ml per tube) 
and 18ml fresh broth added, and cultured until the OD corresponding to log 
growth phase was obtained. Bacteria were harvested by centrifugation at 400 x 
g for 1 min and washed repeatedly in D-PBS. 
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Figure 2.1. Population growth curve for H. influenzae. 
H. influenzae were cultured in BHI broth for 10h. Optical density at 600nm (OD600) was 
measured and CFU counts were performed each hour for 10 h. 
Z2.1.1.2 StreDtococcus Pneumonlae 
S. pneumoniae serotype 9V, strain 10692 was cultured on Horse Blood agar 
plates overnight at 370C. The resulting colonies were then used to inoculate 131-11 
broth cultures and measurements of optical density and colony forming unit 
were carried out as described in section 2.2.5.1 (Fig. 2.2). 
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Figure 2.2. Population growth curve for S. pneumoniae. 
S. pneumoniae were cultured in BHI broth for 10h. Optical density at 600nm (ODroo) was 
measured and CFU counts were performed each hour for 10 h. 
2.2.5.2 Heat killing 
Lyophilized E. coli, strain K-1 2 was resuspended in D-PBS (1 g1ml). Similarly, H. 
influenzae and S. pneumoniae cultures were resuspended in D-PBS. H. 
influenzae and S. pneumoniae were heat killed by incubation at 600C for 2 h, 
whereas E coli required 6h at 800C. 
Following heating, the bacteria were washed 4 times by centrifuging for 10min 
at 300 x g, then aspirating media and replacing with fresh PBS. In order to 
ensure the efficacy of the heat killing, 10pl of each of the bacteria suspensions 
was streaked onto LB nutrient agar plates and incubated overnight at 370C and 
colony counts performed. A count of zero was considered heat killed. 
2.2.5.3 Fluorescent Labelling of Heat Inactivated Bactefia 
Bacteria were fluorescently labelled using Alexafluor 488 dye. Alexafluor 488 
was reconstituted in DMSO (2mg/ml) and 20p] added to lml aliquots of bacteria 
containing solutions, and incubated in the dark, at RT overnight. The labelled 
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bacteria were washed repeatedly in D-PBS to remove unbound label and 
resuspended in D-PBS. The dry weight of the bacteria was determined by 
drying 100pl aliquots of each of the bacteria in a hybridisation oven for 30 min 
then measuring the weight of the residue. 
2.2.6. Phagocytosis assays 
2.2.6.1. Beads 
Alexafluor 488 labelled, carboxylate modified polystyrene microspheres (2pm 
diameter) were diluted to concentrations ranging from 0.5-50xl 06 beads/ml in 
complete medium. 100pl of the bead solutions were added to wells containing 
either MDM or alveolar macrophages and incubated at 370C, 5% CIO C02 for 
times indicated. 
After incubation, unbound beads were removed by aspiration of medium, and 
plates were washed with D-PBS. Fluorescence of extracellular particles was 
quenched by addion of 100pl Trypan blue (2% Cl, )) per well for 1 min, then 
excess fluid was removed and fluorescence determined by measurement on a 
plate reader (see section 2.2.7.1) or FACS (see section 2.2.7.2. ). 
2.2.6.2. Bacteria 
All bacteria were sonicated for 1 min in a sonicating water bath prior to use to 
separate individual bacteria. Bacteria were diluted to the appropriate 
concentrations in HBSS and 100pl transferred to wells containing either alveolar 
macrophages or MDM. Plates were then incubated at 370C, 5% C02 for times 
indicated. 
Following incubation, cells were washed and fluorescence of extracellular 
bacteria was quenched as described in section 2.2.6.1. 
2.2.7. Quantification of Phagocytosis 
In order to quantify the amount of particles that had been ingested, the 
fluorescence of the phagocytosing cells was determined. This was achieved 
using two methods: 
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2.2.7.1. Fluorimetty 
A BMG Fluostar fluorescence plate reader was used to quantify the 
phagocytosis of all particles. Fluorescence was determined by reading 
fluorescence from the bottom of the wells at excitation A 480nm and emission A 
520nm. 
2.2.7.2. Fluorescent Activated Cell Sorting (FA CS) 
For flow cytometric analysis, cells were removed from plates by adding 100pl 
cell dissociation solution for 15 min at RT. Cells were aspirated and transferred 
to FACS tubes and centrifuged at 400 xg for 10 min. Pellets were resuspended 
in 300pl FACS fix (FACS flow, 0.5% (/, ) paraformaldehyde, dH20) ready for 
analysis. Samples were analysed using a Becton Dickinson FACScan machine 
using CellQuest software. Cells were gated according to forward and side 
scatter values (Fig 2.3. ) For each condition 5000 events were recorded. 
Histograms of fluorescence in the FLI channel were analysed using WinMDl 
software. 
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Fiaure 2.3. FACS plot demonstratinq gating of events according to forward and side scatter 
values. 
MDM were incubated for 4h with 1001JI Of 50xI06 polystyrene beads/ml in complete medium, 
then washed and resuspended in 300pl FACS fix and analysed on a Becton Dickinson 
FACScan machine. Plot represents 5000 events. 
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2.2.8 Opsonisation 
Particles are recognised either directly or indirectly by receptors on the 
macrophage surface; the role of the latter, via recognition of immunoglobulins 
by Fc receptors, was investigated by measuring the phagocytosis of polystyrene 
beads opsonised by incubation with human serum. 
Polystyrene beads were incubated in Iml pooled human serum for I h. Beads 
were then centrifuged at 400 xg for 10 min and resuspended at 0.5-50A O51ml 
prior to use in phagocytosis assays as described in section 2.2.6.1. 
In order to establish whether beads were opsonised, beads that had been 
incubated in the presence or absence of serum were washed by centrifugation 
at 400 xg followed by aspiration of medium and resuspension in sample buffer 
(62.5mM Tris-HCL, 10% C1. ) glycerol, 1% (w/v) SDS, 1% Clv) P-mercaptoethanol, 
0.01% (*/, ) bromophenol blue). Beads were then heated at 900C for 5 min then 
centrifuged as before and supernatants transferred to clean tubes. Proteins 
within the supernatants were separated using sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) by applying an electrical 
current of 100mA, 100V to 4-12% gradient gels immersed in MOPS running 
buffer (25OmM MOPS, 25OmM Tris, 5mM EDTA, 1% (w/, ) SDS). Protein bands 
were then stained by incubation for 15 min at RT with Coomassie blue (0.1% 
(w/,, ) Coomassie Brilliant Blue R-250,50% (v/v) methanol and 10% Clv) glacial 
acetic acid in dH20) and washed by incubation for 15 min with destain (40% CQ 
methanol and 10% Cl,, ) glacial acetic acid in dH20) at RT. Pooled human serum 
was also added to the gel as a positive control. Images were captured digitally 
using UVP GelDoc-IT imaging system and Labworks software. 
2.2.9. Confocal Microscopy 
3x1O5 monocytes were cultured on Lab-tek Permanox chamber slides towards 
an IVIDIVI phenotype by incubation for 12 days in the presence of 2ng/ml GIVI- 
CSF (see section 2.2.3.1). Fluorescently labelled beads or bacteria were added 
to chambers and incubated as indicated. Particles or bacteria that were not 
phagocytosed were removed by aspiration, and chambers were washed 
repeatedly with D-PBS. Cells were then fixed by incubating with 4% r/v) 
paraformaldehyde for 10 min, followed by 8% (w/v) paraformaldehyde for 20 
min. 
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2.2.9.1. Staining 
Cells were washed with D-PBS and nuclei were stained by incubation with DAM 
(250pM) for 3 min. Cells were then washed again and cell cytoplasm stained by 
incubation with Evans blue dye (0.1% (*/, ) in D-PBS) for 1 min. Following 
repeated washing in D-PBS the chambers were removed from the microscope 
slides and a coverslip was mounted using Citifluo. Slides were then stored at 
40C in the dark. 
2.2.9.2. Visualisation 
Slides were viewed on a Leica TCS 4D Confocal microscope with a Krypton- 
Argon laser to detect fluorescence of the FITC/yellow-green/Alexafluor 488 
fluorochromes. Images of the three stains (DAPI (blue), Evans Blue (red) and 
the fluorochromes (green)) were overlaid using Adobe PhotoshopTm software. In 
order to visualise the location of the particles, images were taken at sequential 
slices throughout the slides then remodelled into orthogonal views using Zeiss 
AxioVision software. 
2.2.10. Electron microscopy 
In order to visualise the process of phagocytosis of bacteria, MDM were 
incubated with H. influenzae (1mg/mI, 4 h) then dehydrated, embedded in 
Araldite resin, cut in to O. 1pm sections then viewed on a transmitting electron 
microscope (TEM). 
2.2.10.1. Fixation 
Initially, jX106 MDM/well cultured in 6-well plates (see section 2.2.3.1) were 
fixed with 2.5% (w/v) glutaraldehyde in sodium cacodylate buffer (0.05M sodium 
cacodylate in dH20), 1ml/well, then washed repeatedly in sodium cacodylate 
buffer. Secondary fixation was performed by incubation with 'Iml 1% (w/, ) 
osmium tetroxide in sodium cacodylate buffer for 1 h. Cells were then removed 
from plates and washed repeatedly with distilled water by centrifugation at 250 x 
g for 10 min. 
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2.2.10.2. Dehydration 
Samples were then suspended in molten 2% (*/v) agar, which was left to set at 
40C. Cells were then dehydrated by incubation with 1ml increasing 
concentrations of methanol as follows: 70% Clv) methanol for 15 min, 90% (v/v) 
methanol for 15 min, 100% (v/v) methanol for 15 min, 100% methanol for 30 
min. 
2.2.10.3. Embedding 
Samples were then cleared by incubation with 1ml propylene oxide for 30 min. 
Cells were infiltrated with 0.5ml of propylene oxide and Araldite resin for 30 min, 
followed by incubation with Araldite alone for 16 h. Samples were then 
embedded in moulds containing Araldite and solidified by incubation at 600C for 
72 h. 
2.2.10.4. Sectioning 
Ultrathin sections of the moulds were then cut. Firstly, excess Araldite was 
removed from moulds using a razor blade. Fresh glass blades were then 
mounted onto a microtome to cut 1prn sections into water. These were then 
transferred to glass slides for visualisation by light microscopy. Once the 
location of the cell pellet was confirmed, 0.1pm sections were cut using a 
microtome. These sections were then transferred to copper specimen support 
frames. The frames were then negatively stained by submersion in 0.5% (*/, ) 
uranyl acetate for 30 s at RT, and then washed in distilled water. Samples were 
stained using Sato's lead citrate (1% (*/,, ) lead citrate, 1% (W/, ) lead nitrate, 1% 
(wl, ) lead acetate, 2% (w/,, ) sodium citrate, 0.7% (v/v) NaOH), followed by 
repeated washing in distilled water. Grids were then transferred to the TEM for 
visualisation. Cells of interest were viewed at increasing magnifications (3000x, 
10000x, 30000x). 
2.2.11. Immunocytochernical Analysis of Macrophages 
2.2.11.1. Preparation of cytospins 
Monocytes or alveolar macrophages were isolated as described in sections 
2.2.3.1 and 2.2.3.2. Cells were then transferred to cytospin funnels at a 
concentration of 5x1 04 cells in 500PI complete media, and attached to cytospin 
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slides and filters. The slides and funnels were then centrifuged for 5 min at 100 
g. Slides were then air dried and fixed by addition of 3 drops of absolute 
ethanol. 
2.2.11.2. Preparation of adherent MDM 
3A 05 monocytes were cultured on Lab-tek Permanox chamber slides towards 
an MDIVI phenotype by incubation for 12 days in the presence of 2ng/ml GM- 
CSF (as described in section 2.2.3.1). Media was then aspirated from wells, and 
cells were fixed by addition of 3 drops of absolute ethanol. Slides were then air 
dried. 
2.2.11.3. CD68 staining of adherent macrophages 
Slides containing monocytes, alveolar macrophages or MDIVI were washed by 
submersion in PBS, prior to CD68 staining using the Vectastain ABC Elite kit, 
as instructed by the manufacturer. Initially, slides were incubated with 1.5% '1v 
normal horse serum for 20 min at RT. Excess serum was then removed by 
blotting with tissue, and normal horse serum (as before) with 1: 400 dilution of 
CD68 monoclonal antibody, or normal horse serum alone for negative controls, 
was added to each slide. Slides were then incubated for 30 min at RT, prior to 
washing by submersion of slides in PBS for 5 min. A secondary antibody 
solution was then added to all slides for incubation for 30 min at RT. Slides 
were then washed as before and then incubated with ABC reagent for 30 min at 
RT. Diaminobenzidine tetrahydrochloride (DAB) was used as a peroxidase 
substrate, by incubating slides with Vectastain DAB solution, as instructed by 
the manufacturer, for 5 min at RT. Slides were then washed, then 
counterstained by incubation with Mayers haemalum for 10 min at RT. Finally, 
slides were washed by submersion in running water for 5 min, then air dried 
prior to attachment of a coverslip. 
2.2.11.4. Visualisation 
Slides were viewed under 25x magnification on a light microscope. Images 
were stored digitally. CD68 staining appears as a brown stain, whilst cell 
cytoplasms appear red. 
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2.2.12. Enzyme linked lmmunosorbent assay 
In order to quantify the production of sphingosine-1 -phosphate (SIP) by 
macrophages, cell supernatants were removed from MDM after 12 d and 
analysed using an S1 P ELISA kit (Echelon Biosciences, Utah, USA), as 
instructed by the manufacturer. 
A 96-well cell culture plate was blocked by addition of 150pl of blocking buffer 
and incubation at RT for 1 h. The plate was then washed 4 times by addition 
then removal of 300pl PBS. Anti-SlP antibody was then combined with 4ml 
antibody diluent to produce the anti-SlP solution. 63pl of this solution was then 
transferred to each well. A standard curve was prepared by dilution of S1P in 
delipidised human sera, at concentrations ranging from 0.06-2pM. The MDM 
supernatants were diluted in delipidised sera, by combining 30pl sample with 
270pl sera. 188pl of either the SlP standard concentrations or the diluted 
samples were transferred to the wells and the plate was shaken for 30 s. The 
plate was then incubated at 270C for 1 h. Following this the plate was washed 4 
times by addition then removal of 300pl PBS. An HRP-streptavidin solution was 
prepared by addition of 12.5ml of the blocking solution to 2.75pi of 1mg/ml 
strptavidin-HRP. 100pl of this solution was then transferred to each well of the 
plate, which was then incubated for 1h at 270C. The plate was then washed 4 
times using 300pl PBS, and 100pl of TMB substrate was added to each well. 
The plate was incubated for 4 min prior to addition of 50pl H2S04 tOstop the 
reaction. The absorbance of the plate at 450nm was then quantified using a 
spectrophotometer plate reader. In order to quantify the S1P concentration of 
each sample, the absorbance values were compared to the standard curve 
created using the known concentrations of S1 P. 
2.2.13. Western blotting 
Analysis of specific proteins was performed using western blotting. Protein was 
extracted from cells and separated according to size by gel electrophoresis. The 
proteins were then transferred onto a nitrocellulose membrane by applying an 
electrical current to the gel. The membrane can then be probed for the protein 
of interest using a primary antibody. The presence of the antibody is then 
detected by binding of a labelled secondary antibody. The relative amounts of 
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the protein are visualised by chemiluminescence and exposure to a 
photographic film, which can then be quantified using densitometry. 
2.2.13.1. Protein Extraction 
MDM were incubated in the presence or absence of H. influenzae (1mg1ml, 1h) 
then washed repeatedly in ice cold D-PBS. Cells were then lysed by the 
addition of 50pl/well RIPA lysis buffer (150mM NaCl, 1% ('/,, ) Triton X-100,0.5% 
(wl, ) sodium deoxycholate, 0.1% r/v) SIDS, 5OmM Tris-HCL) containing 
protease and phosphatase inhibitors, at 40C. 
Lysates were transferred to fresh Eppendorf tubes then mixed by vortexing and 
centrifuged (10000 x g, 10 min, 40C). The resulting supernatants were 
transferred to clean chilled Eppendorf tubes for measurement of protein levels 
using a BioRad protein assay: 4pl of each sample was diluted in 16pl D-PBS, 
5pI was then transferred in triplicate to a 96 well plate. 1mg/ml BSA in D-PBS 
was diluted to produce a standard curve in the range 0.125-1 mg/ml (5pl per well 
in triplicate) along with D-PBS only controls (for use as zero measurements). 
200pl BCA (Bradford protein assay reagent, diluted 1: 5 in water) was then 
added to each well. Absorbance was measured at 600nm using a 
spectro photo meter. Unknown protein concentrations were determined by 
interpolation of the standard curve (Fig. 2.4). 30pg of protein was then 
transferred to fresh Eppendorf tubes and mixed with sample buffer (62.5mM 
Tris-HCL, 10% Cl, ) glycerol, 1% rQ SDS, 1% Cl, ) P-mercaptoethanol, 0.01% 
(%) bromphenol blue) to a final volume of 30pl. Samples were then heated for 1 
min at 900C, in order to denature proteins. 
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Figure 2.4. Protein standard measurements for use in protein quantification. 
BSA was diluted in D-PBS then measured at 600nm using a spectrophotometer to derive a 
standard curve from which unknown protein concentrations can be calculated. 
2.2.13.2. Gel Electrophoresis 
4-12% gradient Bis-Tris polyacrylamide gels were used for separation of 
proteins according to size. The gels were secured in a gel tank along with 
MOPS running buffer (250mM MOPS, 250mM Tris, 5mM EDTA, 1% (w/v) SIDS). 
1 Opi of a molecular weight marker was added to the gel. 30pl of each sample 
was then added to individual wells using gel loading pipette tips. The gel tank 
was then fully assembled and connected to a power source, and proteins 
resolved at I OOV for 2 h. 
2.213.3. Transfer of proteins to nitrocellulose 
Gel transfer tank cassettes were assembled containing sponge pads and 
blotting paper (3MM Chr chromatography paper, Whatman) both soaked in 
transfer buffer (0-191M glycine, 0.02M Tris-HCI, 20% Cl, ) methanol). The gels 
and a Hybond nitrocellulose membrane were then placed on to the filter card 
and the cassette was closed. An ice block was then placed in the transfer tank 
with the cassettes, and transfer buffer was added. The tank was then connected 
to the power source, and proteins transferred at 200mA, 200V for 1 h. 
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2.2.13.4. Immunodetection 
To avoid non-specific binding by antibodies, the nitrocellulose was then blocked 
by incubation in 12ml 4% BSA dissolved in TBS-Tween 20 (0.5M Tris 
Base, 9% (*/v) NaCl, 0.5% Tween 20) for Ih at RT. The BSA blocking 
solution was then replaced with fresh BSA/TBS-Tween-20 containing an 
antibody raised against the protein of interest, and incubated for 16 h at 40C. 
The membrane was then washed repeatedly in TBS-Tween-20 to remove 
unbound antibody, then transferred to a solution of BSA/TBS-Tween-20 
containing an appropriate HRP conjugated secondary antibody and incubated 
for Ih at RT. 
Membranes were then washed repeatedly in TBS-Tween 20 to remove 
unbound antibody, then incubated with 10ml enhanced chemiluminescence 
(ECL) detection solutions (according to manufacturers instructions) for 2 min at 
RT. The blot was wrapped in clingfilm and exposed to a sheet of Hyperfilm for 
1-5 min. Films were developed using an AFP Imaging (New York, USA) 
developer. Bands of interest appeared on the film and were analysed using 
UVP GeIDoc-IT imaging system and Labworks software. 
In order to detect alternative proteins, membranes were stripped of antibodies 
by incubation with 12ml stripping buffer (62.5mM Tris-HCL, 2% C/v) SIDS, 
100mM P-mercaptoethanol, heated to 600C in a fume cupboard) for 1 min. The 
membranes were then washed repeatedly with TBS-Tween 20. The 
membranes could then be blocked, then incubated with antibodies as described 
above. 
2.2.14. Gene expression profiling 
The gene expression profile of MDM incubated in the presence and absence of 
H. influenzae was analysed using the Illumina Whole Genome Expression 
Analysis microarray system. The Human-6 Expression BeadChip consists of six 
arrays containing probes derived from human genes in the National Centre for 
Biotechnology Information, Reference Sequence and UniGene databases. 
Approximately 48,000 different bead types, each with a unique oligonucleotide 
probe, are pooled and added to microwells on the chip surface. Probes that 
correspond to a specific gene of interest are covalently bound to the beads and 
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every bead type is represented at least 30 times on each array. After chip 
assembly, the array is mapped to determine the site of each bead type. 
Whole genome gene expression is assessed using a direct hybridisation 
approach. To amplify starting material, an in vitro transcription amplification is 
performed. This process uses reverse transcription followed by a T7 RNA 
polymerase-based linear amplification step. Once cRNA has been hybridised 
onto the chips, they are scanned using the Illumina BeadArrayTm reader, a sub- 
micron resolution scanner. The map of the location of each bead type is then 
used to assess the relative expression levels of each of the genes. 
2.2.14.1. RNA isolation 
MDM were cultured in 6-well plates (see section 2.2.3.1) then incubated with or 
without heat killed H. influenzae (1mg/ml, I h). Total RNA was isolated from 
using the Qiagen RNeasyO miniprep RNA extraction kit as indicated by the 
manufacturer. Cells were lysed in RLT buffer containing 1% Cl") P- 
mercaptoethanol. The resulting lysate was then homogenised using a 
QiashredderTm column, according to manufacturers instructions. Following 
centrifugation for 1 min at 10000 xg the effluent from the Qiashredder column 
was mixed with an equal volume of 70% ("/, ) ethanol and transferred to a spin 
column. The spin column was then centrifuged at 10000 xg for I min, and 
washed by addition of RIPE buffer followed by centrifugation (10000 x g, 1 min). 
Contaminating DNA was removed by incubation with RNase-free DNase (15 
min, RT). Samples were washed with RW then RIPE buffers (by centrifugation at 
10000 xg for 1 min) before bound RNA was eluted from the column by addition 
of 50pl RNase-free and incubation for 10 min at RT. The RNA was collected 
from the column following centrifugation at 10000 xg for 2 min. 
2.2.14.2. RNA analysis 
The quality of the RNA samples was quantified using the RNA 6000 Nano 
AssayTm kit with the Agilent 2100 BioanalyseP. For this, a chip was prepared 
according to manufacturers instructions. Running gel was prepared by 
combining gel matrix and dye. This was then injected into the base of the chip 
using the chip loading station. 1pl of RNA samples was added to the chip, as 
was a standard RNA ladder (Fig. 2.5). The chip was then read on the 
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Bioanalyser (Fig. 6). The resulting profile was then be used to determine RNA 
quality, where an 18S: 28S ratio of 1.9-2.1 indicates little or no degradation. 
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Fiqure 2.5. Quantification of RNA concentrations. 
RNA isolated from MDM was analysed using a Bioanalyser. Panels a) and b) represent an 
electropherogram and gel image (respectively) of an RNA size reference ladder. Panels c) and 
d) are example electropherograrn and gel images of an RNA sample. 
RNA concentration was also measured using a second method of 
quantification. 1 pl of RNA sample was analysed by a Nanodrop'8' ND-1 000 UV- 
Vis spectrophotometer, following a zero reading of RNase-free water. This 
recorded the RNA concentration in ng/pl and the 260/280 ratio, which indicates 
the proportion of RNA to DNA, with a ratio of =2.0 suggesting a pure RNA 
sample. 
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2.2.14.3. RNA amplification 
Total RNA was converted to labelled cRNA for hybridisation onto the gene 
expression chips using the Illuminao Totalprep RNA amplification kit as 
indicated by the manufacturer. 
The first step involved synthesis of first strand cDNA from 100ng total RNA 
resuspended in 11pl nuclease-free water. 1 unit/reaction oligo (T7)primer (to 
synthesise DNA with a T7 promoter sequence), 2 units/reaction first strand 
buffer, 4 units/reaction deoxynucleotide triphosphates (dNTPs), 1 unit/reaction 
RNase inhibitor and 1 unit/reaction Arrayscript reverse transcriptase was added 
to each sample. All samples were then incubated in a hybridisation oven for 2h 
at 420C. 
Second strand synthesis was then performed by the addition of 63 
units/reaction nuclease free water, 10 units/reaction second strand buffer, 4 
units/reaction dNTPs, 2 units/reaction DNA polymerase and 1 unit/reaction 
RHase H. The samples were then incubated on a thermal cycler at 160C for 2 h. 
The cDNA was then purified using a spin filter column. 250pl DNA binding 
buffer was added to all samples, which were then mixed and added to a spin 
column. These were then centrifuged for 1 min at 1X104 X g. Samples were 
washed to remove RNA primers, enzymes and salts that may inhibit 
transcription by addition of 500pl wash buffer and centrifugation for I min at 
10000 x g. The cDNA was then eluted from the column by addition of 19pl 
nuclease free water and incubation at RT for 8 min then centrifugation for 2 min 
at 10000 x9 
Labelled cRNA was then transcribed from the cDNA by incubating the samples 
with 2.5 units/reaction T7 reaction buffer, T7 enzymes and biotin labelled-NTPs. 
All samples were then incubated for 16 h at 370C. cRNA was purified using a 
filter column and RNA binding buffer. 350pl RNA binding buffer and 250pl 100% 
ethanol was then added to all samples, which were then transferred to a spin 
column. These were then centrifuged for 1 min at 10000 x g. Samples were 
then washed to remove unincorporated NTPs, salts, enzymes and inorganic 
phosphates by addition of 650pl wash buffer and centrifugation for 1 min at 
10000 x g. The biotinylated cRNA was then eluted from the filter columns by 
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addition of 100pl nuclease free water, incubation at RT for 8 min then 
centrifugation for 2 min at 10000 x g. 
cRNA concentration and quality were then tested using the RNA 6000 Nano 
AssayTm kit (Fig. 2.6) and the Nanodrop" ND-1000 UV-Vis spectrophotometer 
(see section 2.2.14.2). The required yield for continuation of the procedure is 
between 20-50pg/sample. The expected cRNA profile is a distribution of sizes 
from 250-5500 nucleotides (nt) with most of the cRNA at 1000-1500 nt. 
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Figure 2.6. Example of Bioanalyser electropherogram (a) and gel image (b) of biotinyLated 
cRNA. 
2.2.14.4. Hybridisation of cRNA onto expression chip 
1.5pg cRNA was resuspended in 10pl nuclease free water. Samples were then 
combined with a hybridisation buffer. The hybridisation chamber was then 
assembled by securing an Illumina Human-6 expression beadchip into a 
chamber insert and filling a buffer reservoir with humidity control buffer. 
Samples were then heated for 5 min at 65"C before being added to an inlet port 
on the chip (6 samples per chip). The hybridisation chamber was then sealed 
and incubated in a hybridisation oven for 16 h at 580C. Following this incubation, 
the chips were washed by submersion for 10 min in wash buffer heated to 55"C, 
then at RT in wash buffer for 10 min. A further wash was carried out by 
submerging chips in 100% ethanol for 10 min, prior to a final wash in wash 
buffer for 10 min at RT. 
Chips were then blocked by incubation with a blocking buffer at RT for 10 min, 
then transferred to blocking buffer containing Streptavidin-Cy3 for a further 10 
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min. After incubation, the chips were washed by submersion in wash buffer for 
10 min at RT, then dried by centrifugation at 275 xg for 4 min at 25"C. 
2.2.14.5. Analysis 
Once dry, the bead chips were immediately scanned on the Illumina BeadArray 
Reader. Results were then visualised and analysed using Illumina BeadStudio 
software. 
2.2.15. TaqMan Real Time PCR 
The expression of specific genes was quantified using real time polymerase 
chain reaction analysis (RT-PCR). Primer and probe sets for each of the genes 
of interest were purchased for use with the TaqMan system (Applied 
Biosystems, California, USA). The RNA isolated previously from MDM in the 
presence and absence of H. influenzae (section 2.2.14.1) was initially converted 
to cDNA. This procedure was performed using the High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, California, USA). A master mix 
was prepared by combining the following (per reaction): RT buffer (2pl), dNTP 
mix (0.8pl), random primers (2pl) reverse transcriptase (1pl), RNase inhibitor 
(1 pl) and nuclease-free water (1 Opl). I Opl of this master mix was then combined 
with lpg RNA (resuspended in 10pl of nuclease-free water) in eppendorf tubes. 
The tubes were then loaded onto a thermal cycler and heated for 10 min at 
250C, 120 min at 370C and 5 sec at 850C. 
cDNA concentrations were then quantified using a Nanodrope ND-1000 UV-Vis 
s pectrophoto meter as described in section (2.2.14.2). The PCR reaction was 
performed as follows: for each of the samples, 1 ng cDNA was suspended in 9pl 
RNAse-free water and transferred to a 96-well reaction plate. To this 1 pl of the 
appropriate TaqMane probe (either for the gene of interest or the endogenous 
control, HPRT) and 10pl TaqMano Universal PCR Master Mix was added. The 
reaction plate was the loaded into the 7500 Real Time PCR System (Applied 
Biosystems, California, USA) for analysis. 
2.2.16. Statistics 
Comparisons between groups (either cell types or disease groups) were carried 
out using Kruskall-Wallis (ANOVA) tests followed by Dunn's post correctional 
tests. Comparisons between treatments were carried out using Wilcoxon signed 
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rank tests, comparing medians of samples to controls. Correlation coefficients 
were obtained using Spearman's rank correlation. EC50 values were obtained 
by log transforming concentration values, then calculating a non-linear fit curve 
for each subject's data. Ap value of <0.05 was considered significant. All 
analyses were performed using GraphPad Prism software. Data obtained by 
Illumina microarrays was analysed using BeadStudio and R software, by Dr 
Bernard North, Imperial College Statistical Advisory Service. Analysis of 
Taqman data was performed using SDS software (Applied Biosystems, 
California, USA). 
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Chapter 3 
Development of a 
Monocvte-d e rived Macror)haae 
Phagocytosis As 
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3.1. Introduction 
The study of alveolar macrophages is hampered by the invasive nature of the 
extraction procedure. Whilst bronchoscopies on non-smokers, smokers and 
stable or mild COPD patients has been assessed as safe, there are a limited 
number of willing volunteers leading to a lack of available samples (Hattotuwa 
et aL, 2002). Furthermore, whilst the volume of lavage obtained is higher in non- 
smokers and healthy smokers than COPD patients, fluid obtained from non- 
smokers has a significantly reduced macrophage yield than the two other 
groups (Lofdahl et al., 2006). As an alternative to using alveolar macrophages, 
a monocyte-derived macrophage (MDM) model has been established (Finney- 
Hayward, 2002). MDM have been used previously to investigate various 
macrophage functions including responsiveness to inflammatory stimuli (Norata 
et al., 2005), activity following infection by various microorganisms (Atkinson et 
aL, 2000; Ciborowski et al., 2007; Peotta et al., 2001; Xiong et aL, 2003) and 
interactions with other cell types (Magnarin et aL, 2000). Phagocytosis by MDM 
has also been investigated, with studies carried out to date examining reduced 
phagocytosis of opsonised red blood cells by HIV infected MDM (Azzam, 2006; 
Leeansyah et al., 2007), the reduced clearance of apoptotic cells by MDM from 
patients with systemic lupus erythernatosus (Bijl et al., 2006; Grevink et al., 
2005), uptake of Staphylococcus aureus and E. coli in MDM isolated from 
patients with Crohn's disease (Mpofu et al., 2007) and the ability of MDM to 
phagocytose polystyrene microspheres (Liao et al., 1994). 
The rationale behind the MDM method stems from the finding that 
macrophages differentiate from monocytes following migration from the blood 
through the vascular endothelium into the tissue. Reproducing this process in 
vitro allows for the production of cells that are similar to those found resident in 
the tissues. Monocytes are also precursors for dendritic cells and the fate of the 
cells that migrate out of the bloodstream into the lung is dependent both on their 
environment and their respective monocyte subset (Tacke & Randolph, 2006). 
"Classical" monocytes express high levels of CD14, whilst "non-classical" 
monocytes (5-10% of the population) express low levels of CD14 and CD16 
(Passlick et al., 1989). This latter subset have been shown to be more 
proinflarnmatory and increase in number during infections (Nockher & 
Scherberich, 1998). It is essential to ensure that MDM used to investigate 
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phagocytosis are physically similar to alveolar macrophages, therefore MDM 
expression of CD68 (an intracellular transmembrane protein that is exclusively 
expressed by cells of the monocyte/macrophage lineage), CD14 (the LIPS 
receptor), CD16 (FcyRII), CD1a (a dendritic cell marker) and HLA-DR (MHC 
class 11 antigen presentation receptor) will be measured and compared to that of 
alveolar macrophages. 
This chapter aims to assess whether MDM are a good model of alveolar 
macrophages in respect to their ability to engulf both inert polystyrene beads 
and physiologically relevant bacteria. The beads are carboxylate modified, 
similar to that of many pathogenic bacteria (Benz & Schmidt, 2002) and will be 
a similar size to E coli, 2pm in diameter (Miao et aL, 2003). These features will 
allow for a comparison of how MDM respond to potentially pathogenic particles 
(i. e. bacteria) and inert particles (beads). The bacteria used are the two most 
common pathogens associated with COPID exacerbations, S. pneumoniae and 
H. influenzae (Sapey & Stockley, 2006). Additionally, in order to determine if 
there is a difference specifically associated with pulmonary bacteria, the 
enterobacterium E. coli will also be used. 
In order to design a phagocytosis assay for use in future experiments, optimal 
incubation times and concentrations of phagocytic prey will be investigated. 
Confocal and electron miscropcopy images of engulment will be employed to 
further confirm the process of phagocytosis by MDM, and the effect of 
opsonisation by human serum proteins will be assessed to analyse the role of 
Fc and complement receptors. 
91 
3.2. Materials and methods 
3.2.1. Subject selection 
Healthy non-smoking subjects were recruited as described in section 2.2.1. 
3.2.2. Isolation and culturing of IVIDIVI 
Monocytes were isolated from whole blood as described in section 2.2.3.1. The 
isolated cells were then cultured for 12 d at 370C in complete media 
supplemented with 2nglml GM-CSF in 96-well culture plates. 
3.2.3. Isolation of alveolar macrophages 
Alveolar macrophages were isolated from subjects undergoing fibreoptic 
bronchoscopy as described in section 2.2.3.2. Cells were then cultured for 16 h 
in 96 well plates at 370C in complete media supplemented with 0.25pg/ml 
amphotericin B. 
3.2.4. Analysis of CD68 expression by monocytes, MDM and alveolar 
macrophages 
Slides containing monocytes, alveolar macrophages or MDM were produced as 
described in section 2.2.11.1. -2., then washed by submersion in PBS, prior to 
CD68 staining using the Vectastain ABC Elite kit. Initially, slides were blocked 
with normal horse serum, then a CD68 monoclonal antibody, or normal horse 
serum alone for negative controls. Slides were then washed prior to addition of 
a secondary antibody solution. Folowing this, slides were incubated with ABC 
reagent then diaminobenzidine tetrahydrochloride (DAB) (a peroxidase 
substrate). Slides were then washed and counterstained by incubation with 
Mayer's haemalum, then air dded prior to attachment of a coverslip. Slides were 
visualised using a light microscope and x 25 magnification. 
3.2.5. Analysis of expression of surface markers on macrophages 
using Flow Cytornetry 
MDM and alveolar macrophages were isolated from non-smoker subjects. 
Adherent cells were removed by addition of 200pi cell dissociation solution and 
incubation for 30 min at RT. Cells were transferred to 15ml Falcon tubes and 
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washed by addition of iml PAB (D-PBS with 5% (*/,, ) BSA and 0.1% (w/v) 
sodium azide) followed by centrifugation at 400 xg for 5 min. Cell number was 
determined as described in section 2.2.3.1.1x105 cells were transferred to 
polystyrene FACS tubes in a volume of 100pl PAB. One of IgGI isotype control, 
CD14, CD16, CD1a or HLA-DR antibodies (all conjugated to FITC fluorophores) 
was then added to each tube as described in section 2.2.4. Cells were then 
incubated for 1h at RT in the dark. Following this, unbound antibody was 
removed by addition of 1ml PAB and centrifugation at 400 xg for 5 min. 300PI 
FACS fix (0.5% (vIv) paraformaldehyde, dH20) was then added to each sample 
following aspiration of supernatant. 
Cells were then analysed using a Becton Dickinson FACScan, as described in 
section 2.2.4. In order to analyse the relative proportions of each receptor, the 
mean fluorescence intensity (MFI) and percentage expression of each antibody 
was recorded. 
3.2.6. Phagocytosis assays 
MDM or alveolar macrophages were isolated and cultured as described in 
section 3.2.2 and 3.2.3.100pl fluorescently labelled polystyrene beads or heat 
inactivated bacteria were added at the concentrations indicated to macrophages 
for times indicated. 
Following incubation, unphagocytosed beads or bacteria were removed by 
aspiration of media, and washing by addition then aspiration of 100pl D-PBS. 
100pi trypan blue (2% was then added for 1 min in order to quench 
autofluorescence. A measurement of phagocytosis was determined using either 
a fluorescence plate reader or FACS analysis. 
For values obtained using a plate reader, control values of background 
fluorescence (cells without beads or bacteria) were averaged and subtracted 
from the fluorescence values of the treated cells. 
In order to calculate the volume of bacteria that had been ingested, 
fluorescence values were compared to those of known concentrations of 
bacteria (Fig. 3-1). 
93 
P. 0% 0% 9% 
C., 
cu 
ih- 
0 
m 
iL 
0 E. coll' 
,&S. pneumoniae 
v H. influenzae 
Fiqure 3.1. Standard curves of known concentrations of bacteria. 
Solutions of E. coli (0), S. pneumoniae (A) or H. influenzae (V) were resuspended at various 
concentrations in HBSS. 100pl of each solution was then transferred in duplicate to a black 96 
well cell culture plate. The plate was then analysed using a fluorescence plate reader. 
For FACS analysis, cells were removed from plates by adding 100pl cell 
dissociation solution and incubating for 15 min at RT. Cells were transferred to 
FACS tubes and centrifuged at 400 xg for 10 min. Pellets were resuspended in 
300pl FACS fix ready for analysis. Cells were gated according to forward and 
side scatter values and for each condition 5000 events were recorded. 
3.2.7. Confocal microscopy 
MDM were cultured on 8-well chamber slides for 12 days in the presence of 
2ng/ml GM-CSF as described in section 2.2-9. Cells were then incubated with 
either fluorescently labelled polystyrene beads or heat inactivated bacteria at 
the concentrations and times indicated. Following this, unphagocytosed beads 
or bacteria were removed by aspiration and cells were washed by addition then 
aspiration of 300pl D-PBS. Cells were then fixed using paraformalclehyde and 
nuclei and cytoplasm were stained by addition of DAR and Evans Blue 
respectively. Coverslips were then applied. 
Slides were viewed on a Leica TCS 4D Confocal microscope with a Krypton- 
Argon laser to detect fluorescence of the FITC/yellow-green/Alexafluor 488 
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fluorochromes. Images were overlaid using Photoshop software and sequential 
slices were then remodelled into orthogonal views using Zeiss AxioVision 
software. 
3.2.8. Electron microscopy 
MDM were incubated with H. influenzae (1mg/ml, 4 h) then fixed by addition of 
glutaraldehyde. Cells were then washed by addition then aspiration of sodium 
cacodylate buffer, as described in section 2.2.9.1. Secondary fixation was 
performed by incubation with osmium tetroxide. Cells were then removed from 
plates and washed repeatedly with distilled water by centrifugation at 250 xg for 
10 min. Samples were then suspended in molten 2% (*/v) agar, then 
dehydrated by incubation with increasing concentrations of methanol. 
Cells were then infiltrated with 0.5ml of propylene oxide and Araldite resin for 30 
min, followed by incubation with Araldite alone for 16 h. Samples were then 
embedded in Araldite, which were solidified by incubation at 600C for 72 h. 
Ultrathin sections of the moulds were then cut as described in section 2.2.9.4. 
Slices were then transferred to copper support frames, and stained using uranyl 
acetate and Sato's lead citrate. Grids were then transferred to the TEM for 
visualisation. Cells of interest were viewed at increasing magnifications (3000x, 
10000x, 30000x). 
3.2.9. Effect of opsonisation on phagocytosis 
Particles are recognised either directly or indirectly via recognition of 
immunoglobulins and complement bound to the target particle's surface. The 
role of the latter in recognition of polystyrene beads was investigated by 
measuring the phagocytosis of beads opsonised by incubation with human 
serum. 
Polystyrene beads were incubated in 1ml commercially available pooled human 
serum for 1 h. Beads were then centrifuged at 400 xg for 10 min and 
resuspended at 0.5-50A 06/ml prior to use in phagocytosis assays as described 
in section 2.2.6.1. 
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In order to establish whether the beads were opsonised, beads that had been 
incubated in the presence or absence of serum were washed by centrifugation 
at 400 xg and resuspensded in sample buffer (62.5mM Tris-HCL, 10% (v/, ) 
glycerol, 1% (*/,, ) SDS, 1% Cl,, ) P-mercaptoethanol, 0.01% (w/, ) bromophenol 
blue). Beads were then heated at 900C for 5 min then centrifuged as above and 
supernatants transferred to clean tubes. Proteins in the supernatants were 
separated using SIDS-PAGE and compared with human serum by applying an 
electrical current of 100mA, 100V to 4-12% gradient gels immersed in MOPS 
running buffer (250mM MOPS, 250mM Tris, 5mM EDTA, 1% (w/, ) SDS). Protein 
bands were then stained by incubation for 15 min at RT with Coomassie blue 
(0.1% (*/, ) Coornassie Brilliant Blue R-250,50% C1. ) methanol and 10% Cl") 
glacial acetic acid in dH20) and washed by incubation for 15 min with destain 
(40% ý&) methanol and 10% (v/,, ) glacial acetic acid in dH20) at RT. Gels were 
captured digitally using UVP GelDoc-IT imaging system and UVP Labworks 
software. 
3.2.10. Statistics 
Comparisons between groups (either cell types or disease groups) were carried 
out using Kruskall-Wallis (ANOVA) tests followed by Dunn's post correctional 
tests and ap value of <0.05 was considered significant. All analyses were 
performed using GraphPad Prism software. 
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3.3. Results 
3.3.1. Expression of macrophage surface markers on IVIDIVI 
As alveolar macrophage extraction involves an invasive and potentially injurious 
procedure, monocyte-derived models of macrophages have previously been 
used for examination of macrophage function. Prior to carrying out phagocytosis 
assays using MDM, it was essential to ensure that these cells resemble alveolar 
macrophages, in respect to their expression of surface markers. 
Therefore immunohistochemical staining for CD68, an intracellular molecule 
which is expressed exclusively on cells of the monocyte/macrophage lineage 
was performed. The expression of this marker by monocytes, MDM and 
alveolar macrophages was compared, and found to be similar across all three 
cell types (Fig. 3.2). 
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Fioure 3.2. Expression of CD68 by MDM. monocytes and alveolar macroi)haaes 
Cytospins were prepared using monocytes and alveolar macrophages, and MDM were cultured 
on Labtek chamber slides. Cells were then fixed and stained using an immunocytochemistry kit, 
with either a CD68 antibody or an isotype control. Slides were then visualised using a light 
microscope with a 25x objective lens. Cellular staining (haemalum) is purple/blue, CD68 is 
red/brown. Photomicrographs are representative of three experiments. 
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In order to confirm that MDM were physically similar to alveolar macrophages, 
expression of four other surface markers was assessed by flow cytometry. The 
proportion of cells that were positively stained (Fig. 3.3A) and the relative 
number of receptors detected on each cell, as compared to the control samples 
(mean fluorescence intensity, Fig. 3-31B) for the markers CD14, CD16, CD1a 
and HLA-DR were quanitifed. 
There was no significant difference in either the proportion of positively labelled 
cells or the mean fluorescence intensities of CD14, CD16, CD1a or HLA-DR 
between MDM and alveolar macrophages. This suggests that MDM resemble 
alveolar macrophages with respect to physical characteristics. 
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Figur, 3.3. Flow cytometric analysis of surface markers by alveolar macrophages and MDM. 
Alveolar macrophages (m) and MDM (m) were incubated with either an isotype control, CD14, 
CD16, CDia or HLA-DR antibody. Cells were then analysed by flow cytometry, and the 
percentage of cells that were positively labelled (Panel A) and the fold increase in mean 
fluorescent intensities, when compared to that of the isotype control (Panel B) were calculated 
for each. Data are presented as mean±SEM, Alveolar macrophage n=5, MDM n=7. 
99 
3.3.2. Establishment of conditions for phagocytosis of polystyrene 
beads. 
Having established physical similarities between alveolar macrophages and 
MDM, other macrophage functions were investigated. A primary function of 
these cells is phagocytosis. Therefore conditions were established to measure 
phagocytosis of polystyrene beads. 
3.3.2.1. Time course of phagocytosis 
In order to establish the optimal incubation time for phagocytosis assays, MDM 
were isolated from non-smoking individuals and incubated for 2,4 and 6h with 
fluorescent polystyrene beads. Fluorescence of ingested beads was quantified 
using either a plate reader or FACS analysis. 
When quantified by fluorimetry, MDM phagocytosed fluorescently labelled 
polystyrene beads in a time dependent manner (Fig. 3.4). 
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Fiqure 3.4. Effect of incubation time on r)haqOcVtOsis of Polystyrene beads by MDM - quantified 
bLfq2dm9! DL 
MDM were cultured for 12 days as described in section 2.2.3.1. Cells were then incubated with 
100pi fluorescent beads (50A06beads/ml) for the times indicated. Fluorescence of internalised 
beads was read by a fluorescence plate reader. Data are presented as mean: tSEM, n=6. 
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In order to validate this measurement of phagocytosis, cells were removed from 
the plate and FACS analysis performed to measure fluorescence of internalised 
particles. 
Overlaid histograms of fluorescence of cells exposed to polystyrene beads for 
increasing incubation times showed a population shift towards the right, 
indicating that phagocytosis was time dependent (Fig. 3.5). From the histogram, 
the number of beads/cell can be determined up to >4 beads/cell (Fig. 3.6). 
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Fiqure 3.5 Effect of incubation time on phaqocvtosis of Polys! yrene beads by MDM - quantified 
by flow c)qometry. 
MDM were isolated from non-smoking subjects and incubated with 100pl of fluorescently 
labelled polystyrene beads (50xi 06 beads/ml) for 6h (red line), 4h (black line) or 2h (green line) 
Fluorescence of internalised beads was detected by FACS and analysed using histogram plots. 
Data presented is a representative histogram of 8 individual experiments. 
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Fiqure 36 Effect of incubation time on phaqocVtosis of polystyrene beads by MDM - quantified 
by flow cytomet[y 
Non-smoking subject MDM were incubated with fluorescent beads (100pl per well, 
50x1 06 beads/ml) for 2h (m), 4h (n) or 6h (w). The cells were then removed from the plate and 
analysed using a FACS machine. The percentages of total cells that were represented by each 
peak were calculated (Fig 3.6). Data are presented as mean±SEM, n=8. 
From these data a time point of 4h was selected as it produced a sub-optimal 
uptake of beads. 
3.3.2.2. Effect of increasing concentration of beads on phagocytosis. 
In order to ascertain the optimal concentration of beads to be used in 
phagocytosis assays, MDM were incubated with solutions of between 0.5- 
50x1 06 beads/ml. Phagocytosis was then quantified using both fluorimetry and 
FACS analysis. 
Phagocytosis of fluorescently labelled polystyrene beads increased in a 
concentration dependent manner, as quantified using a fluorescence plate 
reader (Fig. 3.7). Similarly, FACS analysis demonstrated increased 
phagocytosis as indicated by an increase in fluorescence of cells with 
concentration of beads (Fig. 3.8 and 3.9). 
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Figure 3.7. Effect of concentration of Polystyrene beads on pha-gocytosis by MDM - quantified 
by fluorimetry. 
MDM were incubated for 4h with beads solutions at concentrations indicated. Fluorescence of 
internalised beads was then quantified using a fluorescence plate reader. Data are presented 
as mean±SEM, n=7. 
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Fig 3.8. Effect of concentration of beads on Phaqoc)qosis by MDM - quantified by flow 
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MDM isolated from non-smoking subjects were incubated with 100pi bead solutions at 
50x1 06 beads/ml (red), 1OX106 beads/ml (black), 5x106beads/ml (green) or 1X106 beads/ml (blue) 
for 4h. Cells were then removed and fluorescence of internalised beads was analysed using 
FACS. Data are displayed as overlaid histogram plot, representative of 8 individual 
experiments. 
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Figure 3.9 Effect of bead concentration on phagocytosis by MDM, 
MDM were incubated with 100pi beads at X, 06/Ml (0), 50 06/Ml (0), 1OX106/Ml ( m) or 5OX106/Ml 
(s) for 4 h. Fluorescence of internalised beads was analysed using a FACS machine. 
Percentages of total cells in each peak were calculated (Fig. 3.8), representing the number of 
beads internalised per cell. Data is presented as mean±SEM, n=7, 
Using these data, a concentration of 50x1 06 beads/ml was selected for uptake of 
beads. 
3.3.3. Confocal Microscopy of Bead Phagocytosis 
in order to confirm that beads were being internallsed and not simply adhering 
to cell surfaces, MDM were cultured on chamber slides and incubated with 
polystyrene beads at increasing concentrations. These slides were then viewed 
using a confocal microscope (Fig. 3.10) 
Images taken sequentially through the cells showed the beads to be completely 
within the cell cytoplasm (Fig. 3.10). Additionally the Images demonstrated the 
dose dependent increase in phagocytosis with concentration of beads added to 
wells. 
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A 
i 4,, re 3 10 Confocal imaqes of fluorescent beads phaqocytosed by MDM. 
MDM were incubated for 4h either without beads (Panel A), or with beads at concentrations of 
1X106/Ml (B). 5x 1 06/Ml (C), lOxlOr3/ml (D) or 50006/ml in chamber slides. Cells were stained 
with DAR (cytoplasm. blue) and Evans Blue dye (nuclei, red) and viewed using a confocal 
microscope with a x40 objective lens Figure is representative of 4 experiments 
3.3.4. Effect of opsonisation on phagocytosis of polystyrene beads 
by MDM 
In order to determine whether opsonisation altered phagocytic responses of 
MIDIVI, beads were incubated with human serum. There was no significant 
difference in phagocytosis between opsons ed and non-opsonised beads as 
analysed by fluorescence plate reader (Fig. 3.11). Similarly, there was no 
difference in histogram plots of fluorescence following analysis by FACS (Fig. 
3.12) 
105 
U) 
w C., 
C 
a, U 
U) 
a, 
0 
LL 
[Beads (X, 06/Ml)] 
Fiqure 3.11 Comparison of phagocytosis of opsonised and non-opsonised beads. 
MDM were incubated with 100pl of opsonised (m) or non-opsonised (M) beads at concentrations 
indicated for 4h. Fluorescence of internalised beads was then quantified using a fluorescence 
plate reader. Data presented as mean±SEM, n=3. 
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Fiqure 3.12. Overlaid FACS analysis of phaqOcvtosis of opsonised and non-opsonised beads b 
MDM- 
MDM were isolated from non-smoking subjects and incubated with opsonised (red) or non- 
opsonised beads (black) at 50x1 06 beads/ml for 6h (Panel A), 5xl 06 beads/ml for 6h (B), 
1OX106 beads/ml for 4h (C) and 50x1O 6 beads/ml for 2h (D). Phagocytosis was then quantified by 
FACS analysis. Histogram plots of FL1 channel fluorescence were overlaid in order to compare 
the effect of opsonisation. Plots presented are representative of 3 experiments. 
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The lack of effect of opsonisation on the phagocytic response of MDM led to the 
possibility that the beads had not been opsonised by serum proteins. Therefore, 
opsonised beads were stripped of any surface proteins using SDS-PAGE 
sample buffer and the free proteins were analysed by SDS-PAGE. SDS-PAGE 
gels showed that beads were coated with serum proteins in contrast to 
unopsonised beads (Fig 3.13). Therefore, opsonisation of beads by serum 
proteins did not promote phagocytosis by MDM. 
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Figure 3.13. Efficacy of opsonisation of polystyrene beads 
Opsonised and non-opsonised beads were heated to remove bound proteins and the resulting 
supernatants were separated using SDS-PAGE, with molecular weight marker and a serum 
only positive control. The gel was then stained with Coomassie Blue. Figure is representative of 
3 experiments. 
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3.3.5. Comparison of phagocytosis of Polystyrene beads by MDM 
and alveolar macrophages 
To ensure that MDM bead phagocytosis reflected that seen in lung derived 
macrophages, comparative experiments using alveolar macrophages were 
performed. 
MDM and alveolar macrophages were incubated with beads and phagocytosis 
was measured using a fluorescence plate reader. There was no significant 
difference in phagocytosis of beads between MDM and alveolar macrophages 
at any concentrations examined (Fig 3.14). 
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Fiqure 3.14. Comparison of beads phagocytosis bv MDM and alveolar macrophages 
Alveolar macrophages (m) and MDM (n) were incubated for 4h with fluorescently labelled beads 
at concentrations indicated. Phagocytosis was then quantified by measurement of fluorescence 
on a plate reader. Data are presented as mean±SEM, alveolar macrophages n=7, MDM n=7. 
3.3.6. Establishment of conditions for phagocytosis of bacteria 
3.3.6.1. Time course of phagocytosis 
In order to establish the optimal incubation time for phagocytosis assays, MDM 
were isolated from non-smoking individuals and incubated for 0.5,1,2,4 and 
6h with fluorescently labelled heat inactivated E. coli, S. pneumoniae or H. 
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10 50 
influenzae. Fluorescence of ingested bacteria was quantified using either a 
plate reader or FACS analysis. 
When quantified by fluorimetry, MDM phagocytosed all three fluorescently 
labelled heat inactivated bacteria in a time dependent manner (Fig. 3.15). 
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Fiqure 3.15. Effect of incubation time on pha-qocytosis of bacteria by MDM - quantified by 
fluorimetry. 
MDM were incubated with 100pl E. coli (Panel A. ) S. pneumoniae (B) or H influenzae (C) 
(1mg1ml) for the times indicated. Fluorescence of internalised beads was read by a 
fluorescence plate reader. Data are presented as mean±SEM, n=6. 
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In order to validate this measurement of phagocytosis, cells were removed from 
the plate and FACS analysis performed to measure fluorescence of Internalised 
particles. 
Overlaid histograms of fluorescence of cells exposed to bacteria for increasing 
incubation times showed a population shift towards the right, indicating that 
phagocytosis was time dependent (Fig. 3.16). From the histogram, the 
percentage of MDM phagocytosing bacteria at each time point can be 
calculated (Fig. 3-17). 
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Fig 3.16. Effect of incubation time on Phaqocvtosis of bacteria by MDM - quantified by flo 
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MDM isolated from non-smoking subjects were incubated either with no bacteria (red line) or 
100pl E coli (panel A), S. pneumoniae (B) or H. influenzae (C) (1mg/ml) for 6h (purple), 4h 
(turquoise), 2h (blue), 1h (green) or 30 min (black). Cells were then removed and fluorescence 
of internalised bacteria was analysed using FACS. Data are displayed as overlaid histogram 
plot, representative of 5 individual experiments. 
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Figure 3.17. Effect of incubation time on Phagocytosis of bacteria by MDM. 
MDM were incubated with 1 00pl E. coli (0), S. pneumoniae (A) or H. influenzae (T) at 1 mg/ml 
for 0.5-6 h. Fluorescence of internalised bacteria was analysed using a FACS machine. The 
percentages of cells with increasing fluorescence following incubation were calculated, 
representing the cells that had phagocytosed. Data are presented as mean±SEM, n=5. 
From these data a time point of 1h was selected to give a sub-optimal 
response. 
3.3.6.2. Effect of increasing concentration of bacteria on phagocytosis. 
In order to ascertain the optimal concentration of bacteria to be used in 
phagocytosis assays, MDM were incubated with solutions of between 0.001- 
10mg/ml. Phagocytosis was then quantified using both fluorimetry and FACS 
analysis. 
Phagocytosis of fluorescently labelled bacteria increased in a concentration 
dependent manner, as quantified using a fluorescence plate reader (Fig. 3.18). 
Similarly, FACS analysis demonstrated increased phagocytosis as indicated by 
an increase in fluorescence of cells with concentration of bacteria (Fig. 3.19 and 
3.20). 
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Fiqure 3.18. Effect of concentration of bacteria on phagocytosis by MDM - quantified by 
&Tiý 
MDM were incubated for 1h with E coli (Panel A), S. pneumoniae (Panel B) or H. influenzae 
(Panel C) at concentrations ranging from 0-001-10mg/ml for 1 h. Fluorescence of internalised 
beads was then quantified using a fluorescence plate reader. Data are presented as 
mean±SEM, n=6. 
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MDM isolated from non-smoking subjects were incubated with either no bacteria (red line) or 
100pl E. coli (panel A), S. pneumoniae (B) or H. influenzae (C) solutions at concentrations 
3mg/mI (black), 1mg/mI (green), 0.3mg/ml (blue), O-1mg/mI (purple), 0.03mg/ml (turquoise), 
0.01mg/ml (yellow), 0.003mg/mi (maroon) for 1 h. Cells were then removed and fluorescence 
was analysed using FACS. Data are displayed as overlaid histogram plot, representative of 3 
individual experiments. 
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Fiqure 3.20. Effect of bacteria concentration on phagocvtosis by MDM. 
MDM were incubated with 100pl E. coli (0), S. pneumoniae (A) or H. influenzae (V) at 
concentrations ranging from 0.001-3mg/ml for 1 h. Fluorescence of internalised bacteria was 
analysed using a FACS machine. Percentages of total cells in each peak were calculated (Fig. 
3.19), representing the number of beads internalised per cell. Data are presented as 
mean±SEM, n=3. 
From these data a concentration of 1mg/mI was selected as this produced sub- 
optimal uptake of all the bacterial species. Growth curve data obtained in 
Chapter 2 suggests that an OD of 0.6 (which is the density of stock solutions) 
represents a concentration of 3x1O9CFU/mI S. pneumoniae and 1.5xlOgCFU/ml 
H. influenzae. Therefore, using an approximate number of cells per well of 
WO', a concentration of 1mg/ml will result in a multiplicity of infection of 
approximately 300 for S. pneumoniae and 150 for H. influenzae. 
3.3.7. Confocal Microscopy of Bacteria Phagocytosis 
In order to confirm that bacteria were being internalised and not adhering to cell 
surfaces, MDM were cultured on chamber slides and incubated with E. coli, S. 
pneumoniae or H. influenzae at increasing concentrations. These slides were 
then viewed using a confocal microscope. Images taken sequentially through 
the cells were combined to form an orthogonal view that displays the position of 
a single bacteria through the x, y and z axes. These images showed the 
bacteria to be completely within the cell cytoplasm (Fig. 3.21). 
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Fiqure 3.21. Confocal images of fluorescently labelled bacteria phaqocytosed bv MDM. 
MDM were incubated for 1h with either E. coli (panel A), S. pneumoniae (B) or H. influenzae 
(C) at a concentration of 1mg/ml. Cells were stained with DAR (cytoplasm, blue) and Evans 
Blue dye (nuclei, red) and viewed using a confocal microscope with a x40 objective lens. 
images were captured from above the cells (A. i., B. i., C. i. ) or sequentially through the cell. 
These were then reformed to give orthogonal views (A. ii., B. ii., C. ii. ) 
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3.3.8. Electron Microscopy of Bacteria Phagocytosis 
In order to confirm that internalisation of bacteria by MDM occurred by 
phagocytosis and to investigate the method of uptake, MDM were Incubated 
with 1mg1mI H. influenzae for I h. Cells were then fixed and stained, then 
embedded in resin. O. 1pm slices of the cells were then cut and further stained 
before being viewed on a transmitting electron microscope (Fig. 3.22). 
Images obtained show bacteria to be fully engulfed by the cells (Fig. 3.22F). 
Additionally images show the 3 main stages of phagocytosis: Image A shows a 
bacteria on the surface of an MDM, images B and C shows formation of a 
phagocytic cup around bacteria, this is proceeded by complete encapsulation 
by pseudopodia as indicated in images D and E. The bacteria are then 
transported into the cell cytoplasm within a phagosome (image F). 
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Fiqure 3.22. Electron microscopy of fluorescently labelled bacteria phaqocvtosed by MDM. 
MDM were incubated for 1h with either H. influenzae at a concentration of 1mg/ml. Cells were 
fixed and embedded prior to slicing and viewing on a transmission electron microscope. Images 
were digitally taken using a 30000x objective lens. Arrows indicate bacteria. 
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3.3.9. Comparison of bacterial phagocytosis by MDM and alveolar 
macrophages 
To ensure that MDM bacteria phagocytosis reflected that seen in lung derived 
macrophages, comparative experiments using alveolar macrophages were 
performed. MDM and alveolar macrophages were incubated with bacteria and 
phagocytosis was measured using a fluorescence plate reader. 
There was no significant difference between uptake of E. coli, S. pneumoniae or 
H. influenzae by alveolar macrophages and MDM (Fig. 3.23). 
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)f bacteria phaqocvtosis bv MDM and alveolar macroi)haqes. 
Alveolar macrophages (AM, m) and MDM (n) were incubated for 4h with fluorescently labelled E. 
coli (Panel A), S. pneumoniae (Panel B) or H. influenzae (Panel C) at 1 mg/ml. Phagocytosis 
was then quantified by measurement of fluorescence on a plate reader. Data are presented as 
mean±SEM, n=6. 
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3.3.10. Effect of phagocytosis of bacteria on IVIDIVI viability 
In order to investigate the effect of phagocytosis on cell viability, MDM cultured 
In 96-well plates were incubated in the absence or presence of E. coli, S. 
pneumoniae and H. influenzae for 1h at 37*C, 5% C02, and a 3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTr) assay was 
performed. Initially, MTT was resuspended in HBSS at a final concentration of 
5mg/ml. Media was then removed from cells and replaced by 100PI MTT 
solution. Plates were then incubated at room temperature for 30 min. After 
incubation, 100pl dimethyl sulphoxide (DMSO) was added to each well. The 
absorbance of the wells at wavelength 570nm was quantified using a 
spectrophotometer plate reader. There was no significant difference in viability 
of MDM in the presence or absence of E coli, S. pneumonlae and H. influenzae 
(Fig. 3.24). 
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Figure 3.24. Effect of i)haqocvtosis of bacteda on MDM viability. 
Bas; line Post-phaýocytosls 
Monocytes were isolated from non-smoker subjects and cultured towards an MDM phenotype. 
Cells were then incubated in the presence or absence of E coli (panel A), S. pneumoniae (B) or 
H. influenzae (C), after which cell viability was quantified. Data are presented as individual data 
points, n=6. 
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3.4. Discussion 
Monocytes can be obtained from peripheral blood in high number by means of a 
relatively simple procedure. This makes them an attractive alternative to 
alveolar macrophages for studying phagocytic function by cells Isolated from 
patients with different disease states. The MDM used in the experiments 
described here were first compared to alveolar macrophages to ensure they are 
physically similar. Both cell types and monocytes have similar expression 
patterns for CD68, suggesting that these cells are all of the 
monocyte/macrophage lineage. Furthermore, MDM and alveolar macrophages 
do not significantly differ in their expression of CD14, CD16, CD1a or HLA-DR, 
which suggests that MDM are phenotypically similar to alveolar macrophages. 
In order to design an assay for measuring phagocytosis of fluorescent 
polystyrene beads, a number of different conditions were tested. This involved 
varying incubation times and bead concentrations, and demonstrated that the 
uptake of beads by MDM is dependent on both of these factors. Furthermore 
this relationship appears to be linear in nature. This suggests that MDM have a 
large capacity for continued uptake of particles, although the upper limit for 
engulfment of beads cannot be confirmed by these data, due to the logarithmic 
scale used to measure fluorescence by FACS analysis. 
In a study of the effect of particle size on the method of uptake by alveolar 
macrophages, it was shown that particles with a diameter <100nm are taken up 
by the process of pinocytosis, which is usually involved in the transportation of 
solutes and does not require actin polymerisation (Pratten & Lloyd, 1986). By 
contrast, larger particles are taken up by phagocytosis and require the formation 
of a phagosome (Aderem & Underhill, 1999). The beads used in the 
experiments presented here were 2prn in diameter (making them similar in size 
to an E. coll) therefore it can be assumed that the process of phagocytosis is 
responsible for their transportation into the cells. Furthermore, a recent study by 
Champion et aL (2008) found that maximal phagocytosis occurred when 
polystyrene particles had a diameter of 2-3pm, suggesting the beads used in 
this study are a suitable target for comparison of phagocytosis by MDM from 
subjects with different disease states. 
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When polystyrene beads were coated with serum proteins to mimic the process 
of opsonisation, there was no increase in phagocytosis. This suggests that 
uptake of these particles does not involve the ligation of Fc or complement 
receptors. It has been shown previously that opsonisation increased uptake of 
E. coli by MDM (Liu et al., 2006), suggesting that opsonisation has a greater 
effect on recognition of bacteria than on inert particles, such as polystyrene 
beads. Other studies have demonstrated that opsonisation affects only the 
initial binding of the beads, not the speed of internalisation (Champion et al., 
2008). Therefore the improved binding to the cell conferred by opsonins may be 
less relevant during the 4h incubation period used here. As these beads do not 
possess the repeated patterns of molecular structure that are recognised by 
TLR and scavenger receptors, internalisation is therefore likely to be evoked by 
alternative receptors such as clathrin (Koval et al., 1998). Alternatively, 
internalisation may be due to anionic attractions between beads and cell 
surface (Thiele et aL, 2003). 
Phagocytosis of physiologically relevant bacteria was also investigated. 
Fluorimetry and FACS analysis showed MDM uptake of H. influenzae and S. 
pneumoniae as well as that of the enterobacterium E. coli to be time and 
concentration dependent. Unlike polystyrene beads, however, uptake of 
bacteria did not follow a linear relationship with increasing time or concentration 
(e. g. incubating for 4 hours did not result in twice the amount of bacteria 
ingested after 2 hours). This may be due to a feedback mechanism which 
dictates that prior phagocytosis of bacteria reduces the likelihood of further 
uptake. This has been previously suggested by Erwig et aL (1999) who found 
that rat bone marrow-derived macrophages that had previously phagocytosed 
apoptotic neutrophils ingested less cells upon subsequent exposure. As no 
such pattern occurred with uptake of polystyrene beads, this suggests that 
differences in recognition of different phagocytic prey may be important. 
Two different methods for quantifying phagocytosis were used; FACS and 
fluorimetry. These methods showed the same patterns of uptake of beads and 
bacteria under all conditions tested. As fluorimetry is the simpler method, it was 
used for all future experiments. 
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When comparing uptake of polystyrene beads and bacteria by different types of 
macrophages, MDM demonstrated a similar phagocytic response to that of 
alveolar macrophages, suggesting that they are a good model for particle 
ingestion in the lung. This has been shown previously by Finney-Hayward et al. 
(2005) who found that MDM and alveolar macrophages phagocytosed similar 
amounts of fluorescently labelled E. coli, with both engulfing more than 
monocytes. However, differences have been found in phagocytosis of H. 
influenzae by MDM and alveolar macrophages (Berenson et al., 2006). This 
may be due to the method used to differentiate the MDM, as this is highly 
dependent on the culture environment used and differentiation times, but may 
also result from the presence of subsets of macrophages with different 
functional capacities. 
Electron microscopy images of MDM phagocytosing H. influenzae demonstrate 
that phagocytic cup formation occurs during particle engulfment. This method is 
classically associated with Fc receptor ligation, as opposed to complement 
receptor recognition (Allen & Aderem, 1996). Immunoglobulins present in the 
fetal calf serum which is added to MDM media has been shown to bind poorly to 
human Fc receptors (Jungi et aL, 1989), therefore it can be assumed that the 
bacteria were not opsonised. This suggests that the direct method of 
recognition, via scavenger receptors, may share some similarities in engulfment 
with that of Fc receptor mediated uptake. 
In conclusion, these data suggest that MDM are able to completely engulf 
pathologically relevant bacteria and non-specific particles by a process of 
phagocytic cup formation. Furthermore, MDM provide a model of alveolar 
macrophage phagocytic function, which can be used to investigate uptake by 
cells isolated from subjects with different disease states. Therefore, in order to 
investigate phagocytosis in COPD, MDM will be incubated with either beads (at 
5Ox1O6mI for 4h) or bacteria (1mg/mI for 1h) and fluorescence will be quantified 
using a fluorescence plate reader. 
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4.1. Introduction 
Bacterial colonisation is a feature of the airways of many COPD patients. It Is 
thought that approximately 50% of exacerbations are caused by bacterial 
infections (Monso et aL, 1995), leading to a reduction In lung function and 
disease worsening (Makris et aL, 2006). Exacerbations of COPD are one of the 
most common cause of hospitalisation of patients within the NHS, costing E250 
million per year, making them an important economic issue (Barnes, 2007). One 
reason for the increased incidence of infections in the respiratory tract of COPD 
patients might be failure of macrophages to clear pathogens due to reduced 
phagocytosis 
The first report of reduced bacterial clearance by cells isolated from COPD 
patients found that neutrophils from these patients engulfed less E. coli than 
those from non-smoking subjects (Muns et aL, 1995). Furthermore, clearance of 
E. coli by monocytes and neutrophils was reduced in patients with COPD 
(Prieto et aL, 2001). Phagocytosis of yeast particles (Candida albicans) by 
alveolar macrophages from COPD subjects was reduced when compared to 
cells isolated from non-smokers (Ferrara et aL, 1996). Subsequently, Hodge et 
aL (2003) have also shown that uptake of apoptosing airway epithelial cells by 
alveolar macrophages is reduced in COPD compared to non-smoker subjects, 
however phagocytosis of polystyrene beads was similar in alveolar 
macrophages from the two groups. Most recently, Berenson et aL (2006) 
demonstrated that alveolar macrophages isolated from COPD patients are 
deficient in their ability to phagocytose H. influenzae. In this same study, uptake 
by MDIVI was similar in non-smoker and COPD subjects. This was in contrast to 
work by Finney-Hayward et aL (2005) who found that uptake of E. coli was 
reduced in MDM from COPD patients when compared to non-smoker and 
smoker subject cells. 
The cause of this defective uptake in COPI) macrophages has yet to be 
elucidated. It has been suggested that prior phagocytosis reduces the likelihood 
of further uptake by these cells, possibly by down regulation of surface 
molecules, such as scavenger receptors (Berenson et aL, 2006; Hodge et aL, 
2003). Differences in expression of cell surface receptors, that identify 
potentially pathogenic microorganisms, may account for the deficient phagocytic 
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ability identified in COPID subjects. For example, TLR2, which is Involved In 
recognition of Gram positive bacteria, Is downregulated in alveolar 
macrophages from COPID subjects and smokers (Droemann et a/., 2005). 
Additionally, cells expressing low levels of CD44, a cell surface glycoprotein 
involved in clearance of the extracellular matrix protein hyaluronan, were 
increased in COPID subjects (Pons et a/., 2005). No differences in Fc, 
complement or scavenger receptor expression have been reported, however 
many receptors remain unexamined. An alternative explanation for defective 
phagocytosis could be dysfunctional binding characteristics or downstream cell 
signalling. For example, the presence of genetic variations In the mannose 
binding lectin (a serum protein which binds to carbohydrates on the surfaces of 
pathogens) within a population of COPID patients have been shown to correlate 
with an increased frequency of hospital isations due to exacerbations (Yang et 
al., 2003). 
Since phagocytosis in COPD is defective there have been several 
investigations into improving this macrophage function. Various 
pharmacological agents increase uptake by COPD phagocytes: bombesin, a 
neuropeptide, increased phagocytosis by both alveolar macrophages and 
monocytes from non-smoker and COPD subjects (Meloni et aL, 1996). 
Similarly, immunoferon, also known as glycophosphopeptical, increased uptake 
of E. coli by neutrophils and monocytes isolated from COPD patients (Prieto et 
al., 2001). The macrolide, azithromycin, increased alveolar macrophages 
uptake of apoptosing airway epithelial cells from COPD patients (Hodge et aL, 
2003; Hodge et aL, 2006a) and the statin, lovastatin increased uptake of 
apoptotic neutrophils by both MDM and alveolar macrophages isolated from 
COPD patients (Morimoto et aL, 2006). However, the underlying mechanisms of 
these responses have not been elucidated. 
The aim of this chapter is to investigate macrophage phagocytosis using the 
MDM model validated in Chapter 3. Cells will be isolated from non-smokers, 
smokers and COPD subjects, and their phagocytic ability will be examined. 
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4.2. Materials and methods 
4.2.1. Subject selection 
Healthy non-smoking, smoking and COPD subjects were recruited as described 
in section 2.2.1. 
4.2.2. Isolation and culturing of MDM 
Monocytes were isolated from whole blood as described in section 2.2.3.1. The 
isolated cells were then cultured in 96-well culture plates for 12 d at 370C in 
complete media supplemented with 2ng/ml GM-CSF. 
4.2.3. Phagocytosis assays 
MDM were isolated and cultured as described in section 2.2.3. Fluorescently 
labelled polystyrene beads or heat inactivated bacteria (100pl) were added to 
macrophages at the concentrations indicated for times indicated. 
Following incubation, beads or bacteria that had not been engulfed were 
removed by aspiration of media, and washing with 100pl D-PBS. Fluorescence 
of unphagocytosed bacteria bound to the surface of the macrophages was 
quenched by the addition of trypan blue (2% Cl, )) for 1 min. Phagocytosis was 
determined using a fluorescence plate reader (excitation A 480nm and emission 
A 520nm). Control values of background fluorescence (cells without beads or 
bacteria) were averaged and subtracted from the fluorescence values of the 
treated cells. 
In order to calculate the volume of bacteria that had been ingested, 
fluorescence values were compared to those of known concentrations of 
bacteria. 
4.2.4. Effect of pharmacological agents on phagocytosis 
MDM were cultured from whole blood obtained from non-smoker, smoker and 
COPD subjects as described in section 4.2.2. Cells were then incubated with 
the indicated concentrations of cytochalasin B, nocodazole, colchicine, taxol, 
trichostatin A (TSA) or a dimethylsulphoxide (DMSO) vehicle control suspended 
in complete medium for 1h at 370C. Media was then aspirated and drug 
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solutions were replaced as before. Solutions of either E. coli, S. pneumoniae or 
H. influenzae were added to wells to give a final concentration of I mg/ml. Cells 
were incubated for 1h prior to quantification of phagocytosis using a 
fluorescence plate reader as described in section 4.2.3. 
4.2.5. Western blotting 
MDIVI were cultured from whole blood obtained from non-smoker, smoker and 
COPD subjects as described in section 4.2.2. then lysed by the addition of 
5OpVwell RIPA lysis buffer containing protease and phosphatase inhibitors. 
Measurement of protein levels was carried out using a BioRad protein assay as 
described in section 2.2.13.1.30pg of protein was then mixed with sample 
buffer to a final volume of 30pl. Samples were denatured by heated at 900C for 
1 min. 
4-12% gradient Bis-Tris polyacrylamide gels were used for separation of 
proteins according to size. 10pl of a molecular weight marker or 30pg of each 
sample was added to wells, the gel tank was connected to a power source and 
proteins were resolved at 10OV, 100mA for 2 h. Proteins were then transferred 
from the gel to a nitrocellulose membrane using a transfer tank attached to a 
power source at 200mA, 200V for 1 h. 
To prevent non-specific binding of antibodies, the nitrocellulose membrane was 
blocked by incubation in 12ml 4% (w/, ) BSA dissolved in TBS-Tween 20 for 1h 
at RT. This was then replaced with BSAITBS-Tween 20 containing an antibody 
raised against the protein of interest and incubated for 16 h at 40C. The 
membrane was then washed repeatedly to remove unbound antibody, then 
transferred to a solution of BSA/TBS-Tween 20 containing an appropriate HRP 
conjugated secondary antibody and incubated for 1h at RT. 
This antibody was then visualised by incubating the membrane with ECL 
detection solutions for 2 min at RT. The intensity of the protein present was 
detected by developing Hyperfilm after exposure to the membrane. Bands were 
analysed using UVP GelDoc-IT imaging system and Labworks software. 
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4.2.6. Statistics 
Comparisons between groups (either cell types or disease groups) were carried 
out using Kruskall-Wallis (ANOVA) tests followed by Dunn's post correctional 
tests. Comparisons between treatments were carried out using Wilcoxon signed 
rank tests, comparing medians of samples to controls. Correlation coefficients 
were obtained using Spearman's rank correlation. EC50 values were obtained 
by log transforming concentration values, then calculating a non-linear fit curve 
for each subject's data. Ap value of <0.05 was considered significant. All 
analyses were performed using GraphPad Prism software. 
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4.3. Results 
4.3.1. Subject demographics 
The characteristics of non-smoker, smoker and COPD subjects used In this 
study are shown in Table 4.1. COPD patients were significantly older than both 
non-smoker and smoker subjects. There was no difference In smoking history 
between COPID and smoker subjects, but both had a significantly greater 
number of pack years than non-smokers. COPID patients had a significantly 
reduced FEVI, FEVI % predicted, FVC and FEVI: FVC ratio than non-smoker 
and smoker subjects. There was no difference In lung function parameters 
between the non-smokers and smokers. 
Non-smokers 
Smokers (n=17) COPD (n=19) 
(n=20) 
Age (years) 48 ±3 53 ±2 70 ± 2*" 
Sex (M: F) 11: 9 10: 7 11: 8 
Smoking history 
0.0±0.0+ 33.3 4.6 45.0 ± 4.9* 
(pack years) 
FEV, (1) 3.3 ± 0.15 2.9 0.3 1.2 0.1*+ 
FEVi % 
102.7 ± 2.6 93.8 3.8 50.6 4.0*+ 
predicted 
FVC (1) 4.2 0.2 3.8 0.3 2.4 0.3*+ 
FEVI: FVC 0.8 0.03 0.8 0.02 0.5 0.03** 
Table 4.1. Study participant demographics 
Data are presented as mean±SEM. I pack year represent 20 cigarettes per day for I year. 
represents p<0.001 vs. non smokers, + represents p<0.001 vs. smokers. 
4.3.2. Comparison of phagocytosis of beads by MDM Isolated from 
non-smoking, smoking and COPD subjects. 
In order to investigate whether smoking or COPD altered the phagocytic 
response of MDM for polystyrene beads, experiments were performed using 
50A06beads/ml for 4h and measurements made using fluorimetry. However, 
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there was no significant difference in the phagocytic response of MDM from any 
subject group (Fig 4.1). 
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Fiqure 41 Effect of disease state on phaqocytosis of Polystyrene beads 
MDM were isolated from non-smoking (m), smoking (a) and COPD (m) subjects and incubated 
with beads for 4h at concentrations indicated. Fluorescence of ingested beads was measured 
using a fluorescence plate reader. Data are presented as mean±SEM, non-smoker n=9, smoker 
n=1 3, COPD n=1 1. 
4.3.3. Comparison of phagocytosis of bacteria by MDM isolated from 
non-smoking, smoking and COPD subjects 
Having determined that MDM from COPID subjects have a similar capacity for 
phagocytosis of beads when compared with cells from non-smokers and 
smokers, the ability of these cells to ingest physiologically relevant bacteria was 
measured. MDM were isolated from non-smoking, smoking and COPID subjects 
and incubated with heat killed fluorescently labelled E. coli, H. influenzae or S. 
pneumoniae. Phagocytosis was then quantified using fluorimetry. 
MDM from all subject groups phagocytosed E. coli in a concentration dependent 
manner (Fig 4.2). MDM isolated from non-smoking and smoking individuals 
phagocytosed at least two-fold more E. coh than cells from COPID subjects at all 
concentrations tested. There was no significant difference in phagocytosis of E 
coli between smokers and non smokers. 
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Fiqure 4.2. Effect of disease state on phagocytosis of Escherichia coft. 
IVIDIVI were isolated from non-smoking (n), smoking (m) and COPD (w) subjects and incubated 
with heat inactivated, fluorescently labelled, E. coli for 1 h. Ingestion of bacteria was quantified 
using a fluorescence plate reader. Data are presented as mean±SEM, non-smoking n=16, 
smoking n=1 1, COPD n=1 7, * represents p<0.05, ** represents p<0.01. 
MDM from all subject groups also phagocytosed S. pneumoniae in a 
concentration dependent manner (Fig. 4.3). However, MDM from non-smoking 
individuals phagocytosed at least three-times more of this bacteria than cells 
from COPID subjects at all concentrations used. MDM isolated from smokers 
also engulfed significantly more bacteria than COPD cells. There was no 
significant difference in uptake of bacteria between the smokers and non- 
smokers. 
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Fiqure 4.3. Effect of disease state on phaqocytosis of Streptococcus pneumoniae 
IVIDIVI were isolated from non-smoking (m), smoking (n) and COPD (n) subjects and incubated 
with heat inactivated, fluorescently labelled, S. pneumoniae for 1 h. Ingestion of bacteria was 
quantified using a fluorescence plate reader. Data are presented as mean±SEM, non-smoking 
n=16, smoking n=11, COPD n=12, * represents p<0.05, ** represents p<0.01. 
In order to determine whether this response in COPID cells also occurred with a 
Gram negative bacteria that had been shown to colonise the airways of COPID 
patients, the phagocytic responses of MDM towards H. influenzae were also 
evaluated. 
MDM from all subject groups phagocytosed H. influenzae in a concentration 
dependent manner (Fig 4.4). MDM from non-smoking subjects phagocytosed at 
least three-times more H. influenzae than cells isolated from COPD subjects at 
all concentrations examined, and this difference was significant at all 
concentrations except 0.03mg/ml. Cells from smokers phagocytosed 
significantly more H. influenzae than those from COPID subjects at 1 mg/ml, and 
there was no difference between non-smokers and smokers. 
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Fiqure 4.4. Effect of disease state on phaqocytosis of Haemophilus influenzae 
IVIDIVI were isolated from non-smoking (m), smoking (n) and COPD (m) subjects and incubated 
with heat inactivated, fluorescently labelled, H. influenzae for 1 h. Ingestion of bacteria was 
quantified using a fluorescence plate reader. Data are presented as mean±SEM, non-smoking 
n=1 5, smoking n=1 1, COPD n=16, * represents p<0.05, ** represents p<0.01. 
The attenuation of the phagocytic response of MDM from COPID patients might 
be attributed to differences in age or smoking history of the subjects included in 
this study (see Table 4.1). To investigate these possibilities, correlations 
between uptake of bacteria and age, lung function or the number of cigarettes 
smoked were performed. 
There were no significant correlations between age of subjects and the 
phagocytic responses of MDM for any of the three bacteria (Fig. 4.5). 
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Fiaure 4.5. Correlation between phagocytosis of bacteria and aqe. 
The relationship between age and phagocytosis of E. coli (panel A), S. pneumoniae (panel B), 
H. influenzae (panel C). Data is presented as individual data points where 0 represents non- 
smokers, * represents smokers and A represents COPD patients, the line represents 
correlation between age and amount of bacteria engulfed for all groups. 
By contrast, there was a significant positive correlation between phagocytosis of 
both E. coli and H. influenzae by MDM from all groups tested and FEV, % 
predicted (Fig. 4.6a and c). However, no such relationship was demonstrated 
with S. pneumoniae (Fig. 4.6b) 
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Figure 4.6. Correlation between phagocytosis of bacteda and FEV, % predicted 
The relationship between FEV, % predicted and phagocytosis of E. coh (panel A), S. 
pneumoniae (panel B), H. influenzae (panel C). Data is presented as individual data points 
where n represents non-smokers, * represents smokers and A represents COPD patients, The 
line represents correlation between FEV, % predicted and amount of bacteria engulfed for all 
groups 
Since FEV, % predicted is a measure of lung function, the relationship between 
a measure of airway obstruction, the FEV, -. FVC ratio, and phagocytosis was 
also determined. Again, there was a significant positive correlation between 
FEV1: FVC ratio and phagocytosis of E. coli and H. influenzae by MDM from all 
subjects, but not S. pneumoniae (Fig. 4.7). 
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Fiqure 4.7. Correlation between phaqocytosis of bacteria and F-EV,: FVC ratio. 
The relationship between FEVI-. FVC ratio and phagocytosis of E. coli (panel A), S. pneumoniae 
(panel B), H. influenzae (panel C). Data is presented as individual data points where 0 
represents non-smokers, 9 represents smokers and A represents COPID patients, the line 
represents correlation between FEVj: FVC ratio and amount of bacteria engulfed for all groups. 
Since there appeared to be a relationship between lung function parameters 
and engulfment of Gram negative bacteria, it was possible that patients with 
more severe disease (i. e. worse lung function) may also exhibit a greater 
reduction in phagocytic response. Therefore, the COPD patients were stratified 
according to GOLD criteria. GOLD stage 2 is defined by an FEVj: FVC <0.70 
and FEV, % predicted 50-80%, stage 3 is defined as FEV,: FVC <0.70 and 
FEV, % predicted 30-50%, and stage 4 is defined as FEV, -. FVC <070 and 
FEV, % predicted <30%. When patients were stratified, there was a trend 
towards reduced phagocytosis with increasing disease severity, although this 
was not significant due to the low "n" value (Fig. 4.8). 
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Figure 4.8. Correlation between Pha-qocvtosis of bacteria and GOLD stage 
IVIDIVI were isolated from COPD subjects and incubated with 1mg/ml heat inactivated, 
fluorescently labelled E. coh (m), S. pneumoniae (n) or H. influenzae (a) for 1h. Ingestion of 
bacteria was quantified using a fluorescence plate reader. Data are presented as mean±SEM, 
stage 2 n=8. stage 3 n=8, stage 4 n=2. 
Since smoking is the major risk factor for developing COPID, the relationship 
between the number of cigarettes smoked and phagocytic responses of MDM 
were evaluated. There was no correlation between phagocytosis of any of the 
three bacteria by MDM and the smoking history of the subjects (Fig. 4.9). 
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Fiqure 4.9. Correlation between phaqocvtosis of bacteria and smokinq history 
The relationship between pack years and phagocytosis of E. coli (panel A), S. pneumoniae 
(panel B), H. influenzae (panel C). Data is presented as individual data points where * 
represents smokers and A represents COPD patients, the line represents correlation between 
pack years and amount of bacteria engulfed for all groups. 
It remained a possibility that current smoking habits might influence the 
phagocytic response of MDM. Therefore, in order to assess whether current 
smoking affected phagocytosis by COPD MDM, uptake by cells isolated from 
current smokers was compared to that of cells from ex-smokers. However, 
there was no significant difference between uptake by MDM from current and 
ex-smokers (Fig. 4.10). 
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Figure 4 10. Comparison of current and ex-smokers 
MDM were isolated from current non-smoking (m) or ex-smoking (m) COPID subjects and 
incubated with 1mg/mI heat inactivated, fluorescently labelled E. coft, S. pneumoniae or H. 
influenzae for 1h. Ingestion of bacteria was quantified using a fluorescence plate reader. Data 
are presented as mean±SEM, current smokers n=5, ex-smokers n=10. 
These data demonstrate that MDM from COPID patients have defective 
phagocytic responses for phagocytosing bacteria. This is not related to age or 
smoking history but is indicative of disease and worsening lung function. 
Therefore, the mechanism underlying this defect was investigated further by 
examining rearrangement of the MDM cytoskeleton during phagocytosis. 
4.3.4. Effect of cytoskeletal disruptors on phagocytosis of bacteria 
Actin microfilaments and tubulin microtubules have been shown to be critical for 
phagocytosis (Harrison & Grinstein, 2002). However, their roles differ 
depending on the type of particle engulfed. For example, Fc receptor mediated 
phagocytosis only requires intact microfilaments, but not microtubules, whereas 
complement receptor mediated uptake requires both cytoskeletal components 
(Newman et al., 1991). Therefore, the role of cytoskeletal rearrangement during 
the phagocytosis of pathogenic bacteria was determined. This was achieved by 
comparing responses of cells from non-smoker, smoker and COPD subjects to 
determine whether cytoskeletal rearrangement differs with disease status and 
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contributes to altered phagocytic responses. In order to investigate this, cells 
were treated with disruptors of actin and tubulin polymerisation, and their 
subsequent ability to engulf bacteria was quantified. Data are presented as 
percentage phagocytosis, with bacterial uptake by untreated cells taken as 
100%, and subsequent treatments compared to these values. 
Treatment with the actin disruptor, cytochalasin B, at IlOpM significantly 
decreased phagocytosis by non-smoker, smoker and COPID MDM of both H. 
influenzae and S. pneumoniae (Fig. 4.11a and b). This finding demonstrates 
that the bacterial engulfment occurring is an active process which requires actin 
rearrangement. The EC50 values for the phagocytic response towards H. 
influenzae in the presence of cytochalasin B did not significantly differ between 
disease groups (non-smokers: 0.46±0.26pM, smokers: 1.21±0.82pM, COPD: 
0.44±0.31pM). For phagocytosis of S. pneumoniae, the EC50 values were also 
similar (non-smokers: 0.46±0.19pM, smokers: 0.78±0.67pM, COPD: 
1.67±0.67pM. Therefore there is no difference in the sensitivity of these cells to 
cytochalasin B, when phagocytosing either bacterium. 
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Fiqure 4.11. Effect of cytochalasin B on phaqocvtosis of bacteria. 
MDM were isolated from non-smoking (m), smoking (e) and COPID (n) subjects and incubated 
with cytochalasin B at concentrations indicated for 1 h. Media was then aspirated and 
cytochalasin B was added as before with 1mg/ml heat inactivated, fluorescently labelled, H, 
influenzae (panel A) or S. pneumoniae (panel B) for 1h. Ingestion of bacteria was quantified 
using a fluorescence plate reader. Data are presented as mean±SEM compared to values for 
controls, non-smoking n=6, smoking n=5, COPD n=6, * represents p<0.05 compared to 
controls. 
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As there was no difference in response to cytochalasin B by non-smoker, 
smoker or COPD MDM, it can be assumed actin rearrangement Is not 
responsible for altered phagocytic capacity. Therefore, the contribution of 
microtubules to uptake of bacteria was examined to assess whether this could 
account for the disease related disparity identified previously. 
Colchicine, which is an inhibitor of microtubule rearrangement, significantly 
reduced phagocytosis of H. influenzae by MDM isolated from non-smoker (at 
O. 1pM) and COPID subjects (at 0.1 and 1pM) (Figs 4.12a), and of S. 
pneumoniae by cells from all groups at all concentrations (Fig 4.12b). EC50 
values for this data cannot be calculated as concentration-dependent inhibition 
of phagocytosis by colchicine was not demonstrated. 
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Figure 4.12. Effect of colchicine on phaqocytosis of bacteria. 
MDM were isolated from non-smoking (n), smoking (n) and COPD (a) subjects and incubated 
with colchicine at concentrations indicated for 1 h. Media was then aspirated and colchicine was 
added as before with 1 mg/ml heat inactivated, fluorescently labelled, H. influenzae (panel A) or 
S. pneumoniae (panel B) for 1h. Ingestion of bacteria was quantified using a fluorescence plate 
reader. Data are presented as mean±SEM compared to values for controls, non-smoking n=6, 
smoking n=6, COPD n=7, * represents p<0.05 compared to controls. 
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Nocodazole, which prevents polymerisation of tubulin subunits, had no effect on 
phagocytosis of H. influenzae by cells isolated from non-smoker and smoker 
subjects, however at 0.01,0.1 and 1pM it significantly reduced uptake by COPD 
MDM (Fig. 4.13a). A significant reduction in phagocytosis of S. pneumoniae 
was demonstrated by cells from all groups (Fig. 4.13b). EC5o values for the 
phagocytic response of MDM for H. influenzae in the presence of nocodazole 
could not be calculated, as no relationship existed between concentration on 
the drug and inhibition of phagocytosis. However, for S. pneumoniae, EC5o 
values were calculated, and did not significantly differ between groups (non- 
smokers: 0.63±0.24pM, smokers: 0.27±0.18pM, COPD: 0.1 1±0.05pM). This 
suggests that there is no difference in sensitivity to disruption of microtubule 
rearrangement between the groups following exposure to S. pneumoniae. 
148 
AI 
%- 
1 
0 
6 qN 
0%- 
S 
ZE 
B 
1 
%0- 
1 
0 
0) 
0 
m 
r_ 
m CL 
CL ui 
-ec-, 
Figure 4 13. Effect of nocodazole on phagocytosis of bacteria 
MDM were isolated from non-smoking (w), smoking (m) and COPD (m) subjects and incubated 
with nocodazole at concentrations indicated for 1 h. Media was then aspirated and nocodazole 
was added as before with 1mg/mI heat inactivated, fluorescently labelled, H. influenzae (panel 
A) or S. pneumoniae (panel B) for 1h. Ingestion of bacteria was quantified using a fluorescence 
plate reader. Data are presented as mean±SEM, non-smoking n=6, smoking n=6, COPD n=7, * 
represents p<0.05. 
MDM from COPID patients appear to be more susceptible to microtubule 
disruption than cells from non-smoker and smoker groups, in respect to 
phagocytosis of H. influenzae. Therefore, the possibility that stability of the 
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microtubule component of the cytoskeleton may be important in regulation of 
the defective phagocytosis response of MDM in COPID, was investigated 
further. 
4.3.5. Expression of tubulin by MDM 
COPD MDM phagocytosed fewer H. influenzae in the presence of microtubule 
disruptors than cells from controls, which suggests that these cells may have a 
greater susceptibility to disruption of the microtubule network during uptake of 
this bacterium. It is possible that differences in the composition of the 
cytoskeleton in these cells may occur and the discrepancy in phagocytosis 
following microtubule disruption may be due to the amount of tubulin expressed 
by COPD IVIDIVI. In order investigate this, western blotting was carried out on 
proteins isolated from non-smoker, smoker and COPD MDM, and total tubulin 
quantified. There was no significant difference in tubulin expression levels 
between the three disease groups (Figure 4.14). 
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Figure 4.14. Expression o tubulin by MDM 
MDM were isolated from non-smoking, smoking and COPID subjects, proteins were isolated and 
resolved by SDS-PAGE prior to transfer to nitrocellulose before immunoblotting for tubulin 
(panel A). Densitometry was performed on the bands and data are presented as mean±SEM 
relative to actin expression. Non-smoking (m) n=1 2, smoking (w) n=7 and COPID (M) n=1 1 (panel 
B). 
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4.3.6. Expression of acetylated tubulin by MDM 
Microtubules can be described as either stable or dynamic depending on their 
rate of polymerisation/depolymerisation (Schulze & Kirschner, 1987). Dynamic 
microtubules have a half life of minutes whereas stable microtubules remain 
polymerised for many hours, and tend to be altered by post-translational 
modifications more than their dynamic counterparts (Harrison & Grinstein, 2002; 
Piperno et al., 1987). Different forms of microtubule post-translational 
modifications are proposed to have different functions (Hammond et aL, 2008). 
For example, polyglycylation and polyglutamylation are essential for forming 
axonemes and basal bodies, however acetylation is necessary for whole cell 
motility. Acetylation is also used as a surrogate marker of microtubule stability 
(Westermann & Weber, 2003). 
Although disease status did not affect the amount of tubulin in MDM, data from 
the use of microtubule disruptors suggested that stability of microtubules may 
be altered in COPD. Therefore, in order to investigate whether differences in the 
post-translational modifications of the microtubules from COPD patients is 
associated with increased susceptibility to disruption, the expression of 
acetylated tubulin was determined. Western blotting was performed to measure 
the level of acetylated tubulin in protein isolated from non-smoker, smoker, and 
COPID MDM. 
There was significantly less acetylated tubulin in cells isolated from COPID 
subjects compared to that observed in non-smoker cells (Fig. 4.15). There was 
no significant difference in levels of acetylated tubulin in MDM isolated from 
smokers and COPD patients. 
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Figure 4 15. Expression of acetylated tubulin by MDM. 
MDM were isolated from non-smoking (n), smoking (a) and COPD (n) subjects, proteins were 
isolated and resolved by SDS-PAGE prior to transfer to nitrocellulose before immunoblotting for 
acetylated tubulin (panel A). Densitometry was performed on the bands and data are presented 
as mean±SEM relative to actin expression for n=6-9 (panel 8) * represents p<O 05 
4.3.7. Effect of tubulin stabilisation on phagocytosis 
Tubulin is important in pseudopod formation (Harrison & Grinstein, 2002) and in 
trafficking of intracellular vesicles, such as phagosomes and late endocytic 
organelles (Tjelle et al., 2000). Therefore, the reduction in acetylation of tubulin 
identified in COPD MDM may contribute to the reduced clearance of bacteria. 
Furthermore, increasing acetylation may improve the phagocytic response. To 
investigate this, the effects of two pharmacological compounds known to 
stabilise tubulin, taxol, an anti-proliferative cancer treatment that has been 
shown to stabilise microtubules, and trichostatin A (TSA), a non-specific HDAC 
inhibitor, on uptake of H. influenzae were assessed. The concentrations of taxol 
and TSA were selected based on previous experiments. (Bode et al., 2007; 
Koch et al., 20K Newman et al., 1991; Peachman et al., 2004) 
Both taxol and TSA significantly increased the acetylation of tubulin by COPID 
MDM, as quantified by western blotting (Fig. 4.16). 
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Fiqure 4.16. Effect of taxol and TSA treatment on expression of acetylated tubulin. 
MDM were isolated from COPID subjects, then incubated for 1h with or without 1 OpM Taxol (0) 
or 100pM TSA (n). Proteins were isolated and resolved by SDS-PAGE prior to transfer to 
nitrocellulose before immunoblotting for acetylated tubulin (panel A). Densitometry was 
performed on the bands and data are presented as mean±SEM relative to actin expression for 
n=6 (panel B). * represents p<0.05. 
In order to investigate whether the taxoI/TSA induced increase in tubulin 
acetylation augmented the capacity of the MDM for bacterial clearance, the 
effect of taxol and TSA treatment on engulfment of H. influenzae was 
investigated. Phagocytosis of H. influenzae by COPID MDM was significantly 
increased in the presence of both taxol and TSA (Fig. 4.17). 
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Fi-qure 4.17. Effect of taxol and TSA on jDha-qocvtosis of H. influenzae. 
MDM were isolated from COPD subjects, then Incubated for 1h with or without 1OpM taxol 
(panel A) or 100pM TSA (panel B), then with H. influenzae for 1h. Ingestion of bacteria was 
quantified using a fluorescence plate reader. Data are presented as individual data points, n=8. 
4.3.8. Expression of tubulin cleacetylases by MDM 
Since the reduced acetylation of microtubules in MDM isolated from COPID 
patients appeared to alter the ability of these cells to phagocytose bacteria, it is 
possible that the enzymes responsible for acetylation of tubulin may be altered 
in COPD. The process of acetylation is carried out by an unknown 
a cetyltra nsfe rase enzyme, but histone deacetylase 6 (HDAC6) and sirtuin 2 
(SIRT2) have been identified as tubulin deacetylases (Westermann & Weber, 
2003). Therefore, western blotting was carried out to determine the expression 
of HDAC6 and SIRT2 in protein isolated from MDM from non-smoker, smoker 
and COPD subjects. 
These experiments indicated that there was no significant difference in 
expression of either enzyme between any of the three disease groups (Figs. 
4.18). 
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Fiqure 4.18. Expression of HDAC6 and SIRT2 by MDM. 
MDM were isolated from non-smoking (n), smoking (m) and COPD (m) Subjects, proteins were 
isolated and resolved by SDS-PAGE prior to transfer to nitrocellulose before immunoblotting for 
HDAC6 (panel A. i) or SIRT2 (panel BJ). Densitometry was performed on the bands and data 
are presented as mean±SEM relative to actin expression for n=6-9 (panel A. ii and B. ii). 
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4.4. Discussion 
The MDM model of macrophage phagocytosis validated in Chapter 3 was used 
to investigate whether COPD affects the ability of macrophages to engulf 
phagocytic prey. In the case of polystyrene beads, there was no difference 
between uptake by cells from controls (non-smoker and smoker) and COPD 
subjects. These findings demonstrate that cells from all three groups are 
capable of similar levels of phagocytosis as has been previously shown in a 
comparison of alveolar macrophages from non-smokers and COPD subjects by 
Hodge et aL (2003). However, polystyrene beads are not a physiologically 
relevant phagocytosis target, therefore the uptake of the bacteria, E. coli, S. 
pneumoniae and H. influenzae, was investigated. MDM isolated from non- 
smoker and smoker subjects phagocytosed significantly more of all three 
bacteria, than those from COPD subjects. Since COPD IVIDIVI can competently 
phagocytose polystyrene beads but not bacteria this suggests that the uptake of 
inert and potentially pathogenic phagocytosis targets are quite distinct. 
As there were no differences in the responses of cells from smokers and non- 
smokers, it is unlikely that cigarette smoking alone alters the process of 
macrophage phagocytosis of bacteria. This was further confirmed by the finding 
that despite COPD patients having smoked more cigarettes than the smokers 
used in this study, there were no correlations between the number of cigarettes 
smoked (pack years) and phagocytosis of any bacteda examined. Additionally, 
within the COPID group there was also no difference in phagocytic response 
between current and ex-smokers. Previous findings have suggested that acute 
exposure to cigarette smoke reduces phagocytic ability (Kirkham et aL, 2004; 
Ortega et aL, 1992; Ortega et aL, 1994; Thomas et aL, 1978). However, studies 
investigating the responses of chronic exposure and either continued smoking 
or recent cessation have demonstrated conflicting results. Phagocytosis of 
Usteria monocytogenes and complement coated polystyrene beads was similar 
by alveolar macrophages from current and ex-smokers (King, Jr. et aL, 1988; 
Skold et aL, 1989). Additionally, neutrophil phagocytosis of S. pneumoniae was 
unaffected by smoking status (Vander Top et aL, 2006). However, the ability of 
alveolar macrophages to phagocytose apoptosing airway epithelial cells is 
reduced in current smokers (Hodge et aL, 2007b). The discrepancy between 
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these findings may be due to the phagocytosis prey used, suggesting that 
current smoking affects uptake of specific types of particles. 
The reduced clearance of bacterial pathogens may account for the increased 
infections and associated decline in lung function observed in COPD. 
Therefore, the relationship between lung function parameters and phagocytosis 
was examined. Phagocytic responses of MDM to both E. coli and H. influenzae 
correlated with FEVI % predicted and FEVI: FVC ratio but no relationship was 
observed with S. pneumoniae. These data suggested a failure to clear Gram 
negative, but not Gram positive bacteria, was associated with reduced lung 
function. There was no significant difference in phagocytosis with Increasing 
disease severity (as indicated by the GOLD stage of the patients), although 
there was a trend towards reduced uptake of all three bacteria with increasing 
COPD severity. This suggests that in addition to accelerating the decline in lung 
function, reduced phagocytosis may contribute to long term disease 
progression. 
There was no correlation between age and phagocytic ability of MDM, 
suggesting that the increased average age of the COPD patients used in this 
study is not associated with reduced phagocytosis. Previous reports have 
suggested that phagocytosis of bacteria declines with age. Rat and mouse 
models of phagocytosis demonstrated both that ageing affected live Klebsiella 
pneumoniae uptake by neutrophils, but not alveolar macrophages (Mancuso et 
aL, 2001) and alternatively, that peritoneal macrophages show reduced 
phagocytic response with age (De la Fuente et aL, 2000). In humans, neutrophil 
phagocytosis of polystyrene beads, E. coli and Staphylococcus aureus was 
shown to decrease with increasing age (Nagel et aL, 1986; Wenisch et aL, 
2000). Similarly, phagocytosis by monocytes declines with age (Antonaci et aL, 
1984). The effect of ageing on macrophage phagocytosis in humans has yet to 
be fully investigated, and given the contradictions in rat and mouse findings 
clearly further investigation is needed, however, the findings presented here 
suggest that age does not alter MDM phagocytosis. 
The inability of COPD cells to clear bacteria to the same extent as that of 
subjects without airway obstruction may contribute to the presence of bactedal 
isolates in the lungs of some COPD patients, which in turn may lead to 
157 
increased airway inflammation and an increased exacerbation frequency. The 
reasons for this are unclear, but it is possible that bacteria release 
proinflammatory molecules such as LPS, peptidoglycan and outer membrane 
lipoproteins (Murphy, 2006), causing the influx of inflammatory cells such as 
neutrophils and release of mediators such as IL-6 and CXCL8, which has been 
observed in COPD patients during exacerbations (Bhowmik et a/., 2000; Qiu at 
al., 2003). This inflammatory response also Involves the release of proteinases 
such as MMP-9, which catalyses the breakdown of the extracellular matrix, 
leading to airway remodelling and obstruction (Mercer et al., 2005). This will 
then result in a reduction in FEVI and contribute to the shortness of breath 
experienced by patients during an exacerbation (Papi et al., 2006). Sputum 
production will also increase due to mucus hypersecretion by goblet cells in the 
epithelium, which is initiated by release of neutrophil elastase by the invading 
neutrophils (Mercer et al., 2005; Sethi, 2004; Voynow et al., 1999). All of these 
factors result in the worsening of symptoms that characterise an exacerbation. 
A study published previously by Berenson et aL (2006) found that alveolar 
macrophages from COPID patients phagocytose less H. influenzae compared 
with cells from smokers but not non-smokers. This same study reported no 
differences in responses of COPD MDM. The discrepancy between the data 
presented herein and that of Berenson et aL (2006) may be due to different 
methodologies used to differentiate monocytes to MDM. This is important as the 
eventual phenotype of the cells is highly dependent on the culture conditions. 
Berenson et aL used pooled human, AB serum for 7 days, whereas this study 
utilised FCS and GM-CSF for 12 days. Human serum was not used in these 
experiments as COPD has known systemic effects which may be reflected in 
the presence or absence of circulating mediators found in normal serum. For 
example, studies have demonstrated significantly higher serum concentrations 
of TNFa in COPD subjects which would not be replicated by the use of serum 
from healthy non-smokers (Gan et aL, 2004). Additionally, comparable 
expression of macrophage surface receptors and phagocytosis of both 
polystyrene beads and bacteria by non-smoker alveolar macrophages, and 
MDM was demonstrated during the validation of the MDM model (in Chapter 3), 
suggesting that this model accurately mirrors engulfment by primary lung 
macrophages. 
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The data presented thus far suggests that COPD MDM are defective In their 
phagocytosis of bacteria, and that this is associated with disease worsening. In 
order to identify mechanisms for reversing this defect, the cause of the reduced 
uptake was investigated. 
As the process of phagocytosis involves significant rearrangement of the 
cytoskeleton, the relative roles of actin and tubulin filaments were investigated 
using pharmacological compounds that interfere with the rearrangement of 
these proteins. The F-actin disruptor, cytochalasin B, significantly reduced the 
ability of MDM from all disease groups to phagocytose the two bacteria used, 
thus confirming that an active process involving actin rearrangement is taking 
place. Inhibition of phagocytosis by cytochalasin B was initially reported in 
neutrophils (Zigmond & Hirsch, 1972), and has since been repeated in 
macrophages by Newman et aL (1991), who found that MDM Fc and 
complement receptor-mediated phagocytosis was significantly reduced by 
incubation with this compound. 
Colchicine and nocodazole, both microtubule disruptors, have previously been 
shown to reduce phagocytosis. Yamaya et aL (1995) demonstrated decreased 
uptake of polystyrene beads by canine alveolar macrophages in the presence of 
colchicine, whereas nocodazole has been shown to reduce phagocytosis of 
latex beads by mouse bone marrow-derived macrophages (Cannon & 
Swanson, 1992). In the data presented here, both compounds caused a 
significant reduction in phagocytosis of H. influenzae by COPD MDM. By 
contrast, in all but one condition (non-smoker cells treated with OAPM 
colchicine), there was no effect on cells from non-smokers and smokers. This 
suggests that there may be differences in the susceptibility of MDM tubulin to 
disruption in different disease groups. This susceptibility may be due to the 
activation state of the macrophages; Khandani et aL (2007) found that 
incubating macrophages with the classically activating cytokine, IFNy, 
prevented the inhibition of phagocytosis by colchicine. Therefore, given that 
IFNy secreting T cells have been shown to be increased in the lungs and blood 
of COPD patients (Hodge et aL, 2007a), the MDM isolated from COPD patients 
may already be in an activated state, although this seems unlikely given that 
they were unstimulated in culture for 12 days prior to use in phagocytosis 
assays. 
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Whilst there was no difference in the total amount of tubulin expressed by MDM 
from non-smoker, smoker and COPD subjects, there was significantly less of 
the acetylated form in cells from COPI) patients. This Indicates that COPD may 
cause significant changes to the macrophage cytoskeleton and affects the 
ability of these cells to engulf bacteria. The finding that treatment with both taxol 
and TSA increased tubulin acetylation and engulfment of H. influenzae, 
suggests that stabilising the microtubule network augments phagocytosis. 
Whilst effects of stabilisation of microtubules on phagocytosis have not been 
reported previously, it has been shown that cells that over-express HDAC6, and 
therefore contain a high proportion of deacetylated tubulin, display increased 
motility, whereas those with higher levels of acetylated microtubules are less 
motile (Hubbert et aL, 2002). Other studies have reported that increased 
acetylation of tubulin, caused by reduction in HDAC6 activity, reduces 
macropinocytosis (Gao et al., 2007) and exocytosis of lL-1P secretory vesicles 
(Carta et al., 2006). This contrasts the findings described here, suggesting that 
tubulin plays different roles depending on the type of intracellular vesicle 
transport in question. Taxol has previously been shown to have no effect on 
neutrophil phagocytosis of C. albicans, therefore the effect of taxol reported 
here may be unique to engulfment by macrophages (Roberts et al., 1982). 
r: V , periments presented 
here that examined the effects of taxol and TSA were 
only performed on cells isolated from COPD subjects; therefore, it is unclear 
whether the observed increase in phagocytosis would also occur with cells that 
exhibit increased baseline tubulin acetylation such as those from control 
subjects (see Fig. 4.15). If this were also the case, it could be suggested that 
rather than acting directly on the source of the defective tubulin acetylation in 
COPD cells, TSA and taxol may have more global effects of which phagocytosis 
is a downstream consequence. Therefore, an important consideration in the 
interpretation of this data is the other known effect of the compounds used. For 
example, treatment of cultured tumour cells with TSA resulted in an up- 
regulated expression of 2% of all known genes, which is likely to include many 
that are not involved in tubulin acetylation. Both taxol and TSA induce apoptosis 
in various cell types, including endometrial and non-small cells lung cancer cells 
(Choi, 2005; Dowdy et aL, 2006). Therefore, it is possible that responses 
unrelated to the acetylation of tubulin are also induced by taxol and TSA in the 
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MDM used in this study. These effects may In turn affect phagocytotic 
responses. As TSA is a non-selective deacetylase inhibitor, it may also alter the 
activity of other HDAC enzymes, which could augment phagocytic activity either 
directly or indirectly. In order to discount this possibility, the use of other, more 
selective, but as yet unavailable, inhibitors needs to be examined. Additionally, 
the magnitude of the increase in phagocytosis observed in the presence of 
these drugs was relatively modest when compared to the disparity in baseline 
phagocytic ability identified in this chapter. This suggests that treatment with 
TSA and taxol would be insufficient to fully reverse the phagocytosis defect in 
COPID subjects. 
A possible explanation for the reduced acetylation of microtubules from COPID 
MDM is that regulation of tubulin modification may be defective in cells from 
these subjects. This defect may only be apparent in response to certain stimuli, 
given that their ability to engulf polystyrene beads was unaffected, and that 
nocodazole or colchicine treatment had the same effect on phagocytosis, of S. 
pneumoniae by MDM from all three groups. It is possible that differences occur 
between the involvement of microtubules, in phagocytosis of beads and Gram 
positive/negative bacteria. Fundamental differences in the role of microtubules 
have previously been demonstrated between Fc and complement receptor 
mediated phagocytosis; uptake of complement coated particles was inhibited by 
treatment with nocodazole and taxol, yet neither had any effect on Fc mediated 
phagocytosis (Aderern & Underhill, 1999; Newman et aL, 1991). Therefore, 
whilst the microtubule rearrangement by COPD MDM that is initiated during 
engulfment of inert particles, such as polystyrene beads, and Gram positive 
bacteria responds similarly to cells from control patients, that of uptake of Gram 
negative bacteria is altered. 
A cause of reduced acetylation of microtubules may involve altered expression 
or activity of the associated acetyltransferase, but this cannot currently be 
investigated as the specific enzyme involved has yet to be identified. Whilst its 
expression was not altered by disease status, HDAC6 activity may be increased 
in MDM from COPD subjects leading to the difference in amount of microtubule 
acetylation seen in these cells. The activity of other deacetylases have 
previously been shown to be altered in COPD; HDAC2 from lung biopsies 
obtained from COPD patients has decreased activity compared to that of 
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healthy controls (Ito et aL, 2005). Although alterations in HDAC6 activity have 
not been previously reported, it is plausible that this may be augmented by 
COPD. 
In conclusion, the data presented here suggests that macrophages Isolated 
from COPD patients are deficient in their ability to phagocytose bacteria. 
Furthermore, this deficiency may be associated with reduced tubulin 
acetylation. Discovering the cause of this defect may provide a novel 
pharmacological target for increasing bacterial clearance by these cells, and 
therefore reducing the exacerbation frequency and increasing the lung function 
of these patients. 
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Chapter 5 
Investigation into the Effects of 
Pharmacological Agents on MDM 
Phagocvtosis 
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5.1. Introduction 
The reduced phagocytic responses of MDM from COPID patients reported In 
Chapter 4 might be related to pharmacotherapy, and therefore may not be due 
to the disease. To investigate this, the effect of commonly prescribed treatments 
on the ability of MDM to phagocytose bacteria was examined. 
Whilst there are currently no pharmacological agents available to prevent the 
progression of COPID, means of relieving symptoms are available. As described 
in Chapter 1, treatment may involve one or a combination of corticosteroids and 
bronchodilators (such as P2 agonists, muscarinic receptor antagonists and 
xanthines). In the event of an infectious exacerbation, antibiotics may also be 
prescribed. 
Corticosteroids are widely prescribed to COPD patients, yet their efficacy is 
controversial. Whilst some studies have demonstrated a reduced mortality in 
patients prescribed corticosteroids (Macie et aL, 2006; Sin & Tu, 2001), others 
have argued that these findings are flawed (Suissa, 2003). Other studies have 
suggested that corticosteroids reduce the frequency of exacerbations by 15- 
20% (Calverley, 2004). The mechanism by which these compounds mediate 
this effect is not known, but one explanation might be the promotion of 
phagocytosis. There have been conflicting reports of how glucocorticoids affect 
phagocytosis: uptake of yeast particles by mouse peritoneal macrophages was 
decreased in the presence of either dexamethasone (Shezen et aL, 1985) or 
prednisolone (Grasso et aL, 1981). However, dexamethasone had no effect on 
phagocytosis of red blood cells by the mouse macrophage cell line, J774 (Ralph 
et aL, 1978). In contrast to these findings, human monocytes treated with 
dexamethasone engulfed more polystyrene beads that controls (Ehrchen et aL, 
2007). Semi-mature human MDM (that had been differentiating for 5 days) 
demonstrated a concentration dependent increase in phagocytosis of 
apoptosing neutrophils in the presence of methylprednisolone, dexamethasone 
and hydrocortisone, but not with non-glucocorticoid steroids (Liu et al., 1999). 
Furthermore, it was found that this increase was potentiated further when MDM 
were exposed to dexamethasone during the first 24 hours of differentiation 
(Giles et al., 2001). Investigations into the effects of budesonide on 
phagocytosis demonstrated that ingestion of fluorescently labelled E. coli by 
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alveolar macrophages from healthy Individuals was significantly reduced 
(Zetterlund et aL, 1998); but there was no effect on the uptake of zymosan by 
alveolar macrophages from smokers (Bergstrand et aL, 1990). This suggests 
that cigarette smoking may affect the steroid-induced phagocytic response. 
Bronchodilators include short or long acting P2-agonists, anticholinergics, or a 
combination thereof (Pauwels et aL, 2001). The effects Of P2-agonists on 
phagocytosis published previously have been contradictory: alveolar 
macrophages demonstrated reduced super oxide release (suggesting reduced 
phagocytosis) following incubation with zymosan in the presence of formoterol, 
but not with the short-acting P2-agonist, salbutamol. However, Zetterlund et & 
(1998) found that the P2-agonist terbutaline had no effect on phagocytosis of E. 
coft by alveolar macrophages. Similar findings were also demonstrated in 
guinea pig alveolar macrophages, where uptake of E. coli was unaffected by 
incubation with salbutamol, isoprenaline or dobutamine (Henricks et aL, 1988). 
These findings suggest that different 02-agonists may have different effects on 
engulfment. 
Theophylline is an adenosine receptor antagonist and phosphodiesterase 
inhibitor that is employed as a bronchodilator in COPD (Barnes, 2005). It was 
first shown to affect phagocytosis by Cox and Karnovsky (1973) who found that 
increasing concentrations of the drug inhibited uptake of starch particles by 
guinea pig neutrophils. However, uptake of S. aur-eus by human neutrophils was 
unaffected by theophylline treatment (Henricks et aL, 1984). In murine 
macrophages, phagocytosis of Trypanosoma cruzi by mouse cells was reduced 
in the presence of theophylline (Wirth & Kierszenbaum, 1982). The effect of 
theophylline on human alveolar macrophages or MDM phagocytosis has yet to 
be determined. 
Tiotropium is a muscarinic receptor antagonist that acts as an anti-cholinergic 
bronchodilator (Barnes, 1999). Macrophages express all five muscarinic 
receptor isoforms, suggesting that tiotropium is able to bind to these cells 
(Buhling et al., 2007). The effect of tiotropium on phagocytosis has yet to be 
investigated, however it has been shown to prevent production of CXCL8 by 
bronchial epithelial cells, thus reducing neutrophil chernotaxis (Profita et aL, 
2008). 
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As approximately half of all exacerbations of COPD are caused by bacterial 
infections, a mainstay for their treatment is antibiotics (Wedzicha & Donaldson, 
2003). Studies have suggested that macrolide antibiotics, such as azithromycin, 
erythromycin and clarithromycin, are able to modulate production of 
proinflammatory cytokines, thus producing anti-inflammatory effects (Khan et 
aL, 1999). They have also been shown to increase phagocytic capacity: 
Yamaryo et al, (2003) demonstrated increased uptake of apoptotic neutrophils 
by alveolar macrophages in the presence of erythromycin and clarithromycin. 
Similarly, Xu et al. (1996) found that uptake of polystyrene beads by J774 
macrophages increased after pre-treatment with various macrolides, including 
azithromycin. Most recently, Hodge et aL (2006) showed azithromycin pre- 
treatment caused a significant increase in phagocytosis of apoptotic airway 
epithelial cells by COPD alveolar macrophages. Furthermore, this increase 
returned the phagocytic capacity to that of non-smoker. 
This chapter aims to assess the effect of some of the most commonly 
prescribed agents on phagocytosis of bacteria in MDM isolated from non- 
smoker, smoker and COPD subjects. Therefore, MDM (as described in Chapter 
3) will be incubated with steroids, formoterol, tiotropium, theophylline and 
azithromycin and phagocytosis of H. influenzae and S. pneumoniae will be 
quantified. 
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5.2. Methods 
5.2.1. Subject selection 
Healthy non-smoking, smoking and COPD subjects were recruited as described 
in section 2.2.1. 
5.2.2. Isolation and culturing of MDM 
Monocytes were isolated from whole blood as described in section 2.2.3.1. The 
isolated cells were then cultured for 12 d at 370C in complete media 
supplemented with 2ng/ml GM-CSF in 96-well culture plates. 
5.2.3. Effect of pharmacological agents on phagocytosis 
MDM were cultured from whole blood obtained from non-smoker, smoker and 
COPID subjects as described in section 2.2.3. Cells were then incubated at 
370C with complete medium supplemented with either dexamethasone, 
budesonide, formoterol, tiotropium or theophylline for I h, or azithromycin for 24 
h. Media was then aspirated and replaced with the pharmacological agent as 
before in the presence of 100pl 1mg/ml fluorescently labelled heat inactivated 
H. influenzae or S. pneumoniae for a further 1 h. 
Following incubation, bacteria that had not been engulfed were removed by 
aspiration of media and washing by addition then aspiration of 100pl D-PBS. 
100PI trypan blue (2% r/v)) was then added for 1 min in order to quench 
autofluorescence. Measurement of phagocytosis was determined using a 
fluorescence plate reader (excitation A 480nm and emission A 520nm). Control 
values of background fluorescence (cells without beads or bacteria) were 
averaged and subtracted from the fluorescence values of the treated cells. In 
order to calculate the volume of bacteria that had been ingested, fluorescence 
values were compared to those of known concentrations of bacteria (Fig. 3.2). 
5.2.4. Statistics 
Comparisons between treatments were carried out using Wilcoxon signed rank 
tests, comparing medians of samples to controls. EC50 values were obtained by 
log transforming concentration values, then calculating a non-linear fit curve for 
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each subject's data. Values were compared using a Kruskal-Wallis (ANOVA) 
test followed by Dunn's post correctional test. Ap value of <0.05 was 
considered significant. All analyses were performed using GraphPad Prism 
software. 
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5.3. Results 
5.3.1. Subject demographics 
The characteristics of non-smoker, smoker and COPD subjects used In this 
study are shown in Table 5.1. COPD patients were significantly older than both 
non-smoker and smoker subjects. There was no difference in smoking history 
between COPID and smoker subjects, but both had a significantly greater 
number of pack years than non-smoker. COPID patients had a significantly 
reduced FEVI, FEVI % predicted, FVC and FEVI: FVC ratio than non-smoker 
and smoker subjects. There was no difference in lung function parameters 
between the control groups. 
Non-smokers 
Smokers (n=12) COPD (n=22) 
(n=15) 
Age (years) 50 ±3 53 ±3 67 ± 2*+ 
Sex (M: F) 10: 5 7: 5 13: 9 
Smoking history 
O. O±O. O+ 23.0 6.2 50.0 ± 2.7* 
(pack years) 
FEV, (1) 3.1 ± 0.2 2.9 0.3 1.3 0.1 *+ 
FEV, % 
105.7 ± 3.0 93.1 3.1 46.7 4.1 *+ 
predicted 
FVC (1) 4.3 0.3 3.6 0.3 2.4 0.2*+ 
FEV,: FVC 0.8 0.03 0.8 0.03 0.5 0.03*+ 
.a ble 5.1. Study participant demographics 
Data are presented as mean ± SEM. I pack year represent 20 cigarettes per day for 1 year. 
represents p<0.001 vs. non smokers, + represents p<0.001 vs. smokers. 
6.3.2. Effect of steroids on phagocytosis of bacteria 
Approximately 90% of the COPD patients used in this study were currently 
being prescribed corticosteroids. In order to establish whether these drugs are 
involved in the reduced phagocytic response of COPID macrophages, their 
effect on bactedal uptake in vitro was investigated. MDM were incubated with 
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increasing concentrations of either dexamethasone, which Is a steroid 
commonly used in laboratory-based investigations, or budesonide, an active 
ingredient in two of the commonly prescribed COPD treatments, Symbicort and 
Pulmicort, and phagocytosis of H. influenzae and S. pneumonlae was 
measured. Whilst dexamethasone and budesonide are both corticosteroids, the 
latter has a nine-fold higher relative binding affinity than the former, suggesting 
that they may elicit different magnitudes of response (Issar et aL. 2006). 
Phagocytosis of H. influenzae by MDM isolated from non-smoker, smoker and 
COPID subjects was significantly increased by treatment with IpM 
dexamethasone, and in cells from smoker subjects by all concentrations used 
(Fig. 5.1A). The ECso values for the phagocytic responses of MDM in the 
presence of dexamethasone were not significantly different (non-smokers: 
0.04±0.03pM, smokers: 0.37±0.33pM, COPD: 0.08±0.06pM). Therefore, cells 
from all groups are equally sensitive to the effects of dexamethasone treatment. 
Cells from COPID subjects phagocytosed significantly more S. pneumonlae in 
the presence of 0.01 and O. 1pM dexamethasone compared with untreated cells, 
yet there was no difference in uptake by non-smoker and smoker MDM (Fig. 
5.1 B). The EC50value for the response of COPD MDM to dexamethasone was 
0.41±0.35pM, which is not significantly different to the values for uptake of H. 
influenzae by these cells, suggesting that there is no difference between the 
effects of this compound on uptake of each bacterium. 
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ethasone on. phagocytosis of bacteria. 
MDM isolated from non-smoking (m), smoking (n) and COPD (a) subjects were incubated with 
dexamethasone at concentrations indicated for 1 h. Media was then aspirated and 
dexamethasone was added as before with 1mg/ml heat inactivated, fluorescently labelled, H. 
influenzae (panel A) or S. pneumoniae (panel B) for 1h. Ingestion of bacteria was quantified 
using a fluorescence plate reader. Data are presented as mean±SEM of percentage uptake 
compared to bacteria only controls, non-smoking n=6, smoking n=6, COPD n=5. * represents 
p<0.05 compared to controls. 
Treatment with 1 pM budesonide resulted in a significant increase in 
phagocytosis of H. influenzae by MDM isolated from non-smoker, smoker and 
COPID subjects (Fig. 5.2A). The EC50 values for the responses of MDM to 
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uptake of H. influenzae in the presence of budesonide were not significantly 
different (non-smokers: 0.71i0.66pM, smokers: 0.40A. 30pM, COPD: 
0.07±0.04pM) Therefore cells from all groups are equally sensitive to 
budesonide. Only COPD subject cells demonstrated a significant increase In 
uptake of S. pneumoniae following treatment with 1 pM budesonide (Fig. 5.213). 
The EC5o value for this response (0.03±0.02pM) was not significantly different 
to that of H. influenzae, suggesting that in the presence of budesonide the 
response of these cells to both bacteria is similar. 
These data suggest that glucocortocids improve phagocytosis, and therefore 
are not responsible for the reduced uptake of bacteria by COPID MDM 
demonstrated in Chapter 4. 
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igure 5.2. Effect of budesonide on pha-qocytosis of bacteria. 
MDM isolated from non-smoking (m), smoking (m) and COPID (w) subjects were incubated with 
budesonide at concentrations indicated for 1 h. Media was then aspirated and budesonide was 
added as before with 1 mg/ml heat inactivated, fluorescently labelled, H. influenzae (panel A) or 
S. pneumoniae (panel B) for 1h. Ingestion of bacteria was quantified using a fluorescence plate 
reader. Data are presented as mean±SEM of percentage uptake compared to bacteria only 
controls, non-smoking n=6, smoking n=6, COPD n=5. * represents p<0.05 compared to 
controls. 
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5.3.3. Effect of formoterol on phagocytosis of bacteria 
78% of the COPD patients used in this study were currently treated with P2- 
agonists (either Serevent, Ventolin or Oxis, whose active Ingredients are 
salmeterol, salbutamol and formoterol respectively). Therefore, in order to 
investigate whether P2-agonists affect the phagocytic behaviour of 
macrophages, MDM were incubated with Increasing concentrations of 
formoterol and phagocytosis of H. influenzae and S. pneumonlae was 
measured. 
Treatment with 1pM formoterol significantly increased the phagocytosis of H. 
influenzae by MDM isolated from non-smoker and smoker subjects. 
Additionally, O. 1pM formoterol increased uptake of H. influenzae and S. 
pneumoniae by non-smoker MDM. No significant effect was demonstrated with 
COPD cells. The ECw values for A influenzae phagocytic responses in the 
presence of formoterol were not significantly different (non-smokers: 
0.04±0.02pM, smokers: 0.04±0.02pM), which suggests that these cells are 
equally sensitive to treatment with this compound. EC50 values for the S. 
pneumoniae response cannot be calculated as no concentration dependent 
effect of formoterol on phagocytosis exists. 
These data suggest that it is unlikely that reduced phagocytosis by COPD MDM 
is due to systemic effectsOf P2-agonists. 
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Figure 5.3. Effect of formoterol on phaqocvtosis of bacteria. 
MDM isolated from non-smoking (m), smoking (n) and COPD (w) subjects were incubated with 
formoterol at concentrations indicated for 1 h. Media was then aspirated and formoterol was 
added as before with 1 mg/ml heat inactivated, fluorescently labelled, H. influenzae (panel A) or 
S. pneumoniae (panel B) for 1h. Ingestion of bacteria was quantified using a fluorescence plate 
reader. Data are presented as mean±SEM of percentage difference compared to bacteria only 
controls, non-smoking n=6, smoking n=6, COPD n=6. 
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5.3.4. Effect of theophylline on phagocytosis of bacteria 
Theophylline or its derivative, aminophylline, are widely prescribed to COPD 
patients for their bronchodilatory functions. In order to Investigate whether 
theophylline alters macrophage phagocytosis, MDM from non-smoker, smoker 
and COPD subjects were incubated with increasing concentrations of 
theophylline, and phagocytosis of H. influenzae and S. pneumoniae was 
measured. 
There was no significant difference in uptake of either bacteria by MDM from all 
three disease groups at any concentration of theophylline tested (0.01-lopM) 
(Fig. 5.4). This suggests that treatment with theophylline is unlikely to Interfere 
with the phagocytic reponses of macrophages. 
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Figure 5 4. Effect of theophylline on phaqocytosis of bacteria 
MDM isolated from non-smoking (n), smoking (m) and COPID (n) subjects were incubated with 
theophylline at concentrations indicated for 1 h. Media was then aspirated and theophylline was 
added as before with 1 mg/ml heat inactivated, fluorescently labelled, H. influenzae (panel A) or 
S. prieurrioniae (panel B) for 1 h. Ingestion of bacteria was quantified using a fluorescence plate 
reader. Data are presented as mean±SEM of percentage uptake compared to bacteria only 
controls, non-smoking n=6, smoking n=5, COPD n=6. 
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5.3.5. Effect of tiotroplum on phagocytosis of bacteria 
Of the patients used for this study, 34% had been prescribed the long acting 
muscarinic receptor antagonist, tiotropium. In order to Investigate whether this 
may have altered the phagocytic behaviour of IVIDIVI, cells from non-smoker, 
smoker and COPD subjects were incubated with increasing concentrations of 
tiotropium and phagocytosis of H. influenzae and S. pneumonlae was 
measured. 
However, there was no significant difference in uptake of either of the bacteria 
by MDM from all three disease groups at any concentration of tiotropium tested 
(0.001-1pM) (Fig. 5.5). Therefore, it is unlikely that treatment with tiotropium is 
responsible for the reduced phagocytic capacity identified in COPD MDM. 
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Fiqure 5.5 Effect of tiotropium on phagocytosis of bacteria 
MDM isolated from non-smoking (m), smoking (n) and COPD W subjects were incubated with 
tiotropium at concentrations indicated for 1 h. Media was then aspirated and tiotropium was 
added as before with 1 mg/ml heat inactivated, fluorescently labelled. H. influenzae (panel A) or 
S. pneumoniae (panel B) for 1 h. Ingestion of bacteria was quantified using a fluorescence plate 
reader. Data are presented as meantSEM of percentage uptake compared to bacteria only 
controls, non-smoking n=6, smoking n=5, COPD n=6. 
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5.3.6. Effect of azithromycin on phagocytosis of bacteria 
Macrolide antibiotics are prescribed to COPD patients during exacerbations, 
and have previously been shown to improve phagocytosis of apoptotic airway 
epithelial cells by alveolar macrophages isolated from COPID patients (Hodge et 
aL, 2006a). In order to investigate whether macrolides, augment the phagocyfic 
behaviour of macrophages, MDM were incubated with increasing 
concentrations of azithromycin, and phagocytosis of H. influenzae and S. 
pneumoniae was measured. 
MDM from all three groups phagocytosed significantly more H. influenzae in the 
presence of 1pM azithromycin. The EC5o values for the H. influenzae 
phagocytic responses of MDM in the presence of azithromycin were not 
significantly different (non-smokers: 0.41±0.4OpM, smokers: 0.15±0.07pM, 
COPD: 0.23±0.22pM). Therefore cells from these groups are equally sensitive 
to the effects of azithromycin. An increased phagocytic response towards S. 
pneumoniae by non-smoker and smoker MDM was also demonstrated in the 
presence of 1pM azithromycin. The EC50 values for this response were not 
significantly different (non-smokers: 0.07±0.02pM, smokers: 0.12±0.02pM). 
These values were similar to those for uptake of H. influenzae suggesting that 
there is no difference in sensitivity to azithromycin. 
These data suggest that reduced phagocytosis by COPD MDM is not due to 
systemic effects of azithromycin treatment. 
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Fiqur ý 5.6. Effect of azithromycin on phagocytosis of bacteria. 
MDM isolated from non-smoking (m), smoking (a) and COPD (a) subjects were incubated with 
azithromycin at concentrations indicated for 1 h. Media was then aspirated and azithromycin 
was added as before with 1mg/mI heat inactivated, fluorescently labelled, H. influenzae (panel 
A) or S. prieumoniae (panel B) for 1h. Ingestion of bacteria was quantified using a fluorescence 
plate reader. Data are presented as mean±SEM of percentage uptake compared to bacteria 
only controls, non-smoking n=6, smoking n=5, COPD n=6. * represents p<0.05. 
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5.4. Discussion 
The data presented in Chapter 4 suggested that COPID macrophages have a 
reduced ability to phagocytose bacteria. However, all the COPID patients 
included in this study had been prescribed pharmacological therapies to 
improve their disease symptoms and these may have an effect on 
phagocytosis. To examine this hypothesis, the role of commonly prescribed 
therapies on uptake of bacteria by MDM was investigated. Treatment with 
glucocorticoids (either dexamethasone or budesonide) resulted In at least a 
two-fold improvement in phagocytosis by COPID MDM. The explanation for this 
is unclear, but Giles et aL (2001) suggest that steroids induce a reduction In 
tyrosine phosphorylation of the signalling molecules, paxillin and pyk2. This In 
turns would lead to increased Rac activity, causin an upregulation of 
phagocytosis. This study examined uptake of apoptosing neutrophils, but it is 
not known whether this mechanism is applicable to phagocytosis of bacteria. 
Another possible explanation for the increased bacterial clearance is that cell 
surface receptors that are involved in phagocytosis are upregulated by steroids. 
It has been suggested previously that increased uptake of apoptotic eosinophils 
by airway epithelial cells in the presence of dexamethasone is associated with 
increased expression of the apoptotic cell receptor, annexin I (Wang et aL, 
2007). Expression of scavenger receptor MARCO mRNA was also upregulated 
following treatment with dexamethasone, together with cell surface expression 
of mannose receptor and CD163 (Gratchev et aL, 2005). Both of these findings 
were associated with an increased uptake of both polystyrene beads and E. 
coli. These data strongly suggest that increased expression of receptors may be 
responsible for the improved clearance of H. influenzae and S. pneumoniae 
demonstrated here. 
Given that the majority of COPD patients used in this study are prescribed 
corticosteroids and that their MDM demonstrate a reduced phagocytic 
response, it seems counterintuitive that increased bacterial clearance in vitro 
should result from steroid treatment. Data obtained from all three disease 
groups displayed large error bars, which would be even greater if the data was 
presented as standard deviations instead of the standard error, as were used 
here. This suggests that the variability between subjects within each disease 
group is high, therefore increasing the number of subjects in each group would 
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be of benefit to test the validity of this data further. Additionally, the 
concentrations of steroids needed to elicit the increase in phagocytic response 
(I pM) are significantly higher than those administered to patients (W), and are 
therefore not a viable pharmacological target for improvement of phagocytosis. 
Furthermore, alveolar macrophages isolated from COPID patients demonstrate 
a reduced sensitivity to dexamethasone treatment when compared to non- 
smoker and smoker cells, which may not be reflected by the MDM model used 
in this study (Culpitt et aL, 2003). Combined, these observations indicate that 
steroid treatment is unlikely to increase phagocytosis by macrophages In a 
clinical setting. 
The P2-agonist, formoterol, increased bacterial phagocytosis by non-smoker 
MDM (and by smoker MIDM in the case of H. influenzae), despite the fact that 
this compound induces an increase in cyclic adenosine monophosphate (cAMP) 
levels (Johnson, 1998), which has been shown to reduce phagocytosis 
(Makranz et aL, 2006). However, it is possible that activation of pathways 
independent of the classically recognised, anti-phagocytic, cAMP signalling 
cascade might be responsible for this observation. For example, cAMP 
activates the tyrosine kinase, Src, and thus the MAP kinase pathway (Daaka et 
aL, 1997), both of which are involved in phagocytosis (Suzuki et aL, 2000). 
By contrast, other studies have shown either no effect or a reduction in 
phagocytic capacity following incubation with P2-agonists (Henricks et aL, 1988; 
Zetterlund et al., 1998). Given the contradiction with previous findings and the 
relative modesty of the increase (when compared to that in the presence of 
steroids) it is likely that this provides little clinical benefit to patients. Similarly to 
glucocorticoids, the concentrations Of P2 agonists that elicited an increase in 
phagocytosis are higher than those administered to patients. Therefore it is 
unlikely that formoterol enhances phagocytosis in COPD patients. 
Other bronchodilators, tiotropium and theophylline, had no effect on 
phagocytosis of bacteria, suggesting that signalling pathways affected by these 
drugs do not play a role in phagocytosis of bacteria. This is despite the fact that 
theophylline is known to elevate cAMP levels via its PDE4 inhibiting action 
(Barnes, 1995) and as previously discussed, this in turn leads to decreased 
phagocytosis. This discrepancy may be due to a reduced expression of PDE4 
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following differentiation of monocytes to macrophages, as has been reported 
previously, thus ablating the potential for theophylline to increase cAMP release 
(Gantner et aL, 1997). 
Improved phagocytic responses of MDM in the presence of azithromycin may 
be due to upregulated expression of surface receptors. Phosphatidylserine 
levels and phagocytosis of apoptotic neutrophils were increased on alveolar 
macrophages following incubation with erythromycin (Yamaryo et aL, 2003). 
Additionally, azithromycin caused an upregulation of mannose receptor on the 
surface of the alveolar macrophages that demonstrated an increased clearance 
of apoptosing airway epithelial cells (Hodge et aL, 2008). As the COPD patients 
used in this study were not currently being prescribed azithromycin, these data 
suggest that this may provide a new treatment for reduction of exacerbations. 
In conclusion, none of the commonly prescribed therapeutic agents investigated 
herein reduced phagocytosis of bacteria by MDM. This suggests that the 
defective uptake identified in COPD cells (Chapter 4) is not due to prescribed 
treatments. Some of the agents investigated increased bacterial clearance, 
which may indicate that, in the absence of pharmacological intervention, 
phagocytosis by COPD macrophages may be reduced further. 
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6.1. Introduction 
Sphingosine-1 -phosphate (S1P) is a lipid mediator that Is derived from 
sphingolipids present in all mammalian cell membranes. S1P is produced from 
ceramide, which is formed in the endoplasmic reticulurn by combination of 
serine and palmitoyl-CoA. This is then converted to sphingosine by 
ceramidases (Le et al., 2004) and sphingosine kinases (SPHK) 1 and 2 then 
convert the sphingosine to S1 P (Liu et al., 2000). SPHK 1 is primarily located In 
the cytosol whereas SPHK 2 is a nuclear protein (Igarashi et al., 2003). The 
relative concentrations of ceramide and S1P are tightly regulated by SPHK and 
ceramidases as they have greatly differing effects: whereas ceramide inhibits 
cell division and promotes apoptosis, S1P is pro-survival and anti-apoptotic 
(Pyne & Pyne, 2000). S1P acts both intra- and extracellularly. Within the cell of 
origin S1P acts as a second messenger, for example, S1P binding leads to 
mobilisation of calcium stores from the endoplasmic reticulurn (Ghosh et aL, 
1994). Additionally, DNA synthesis and proliferation of fibroblasts are both 
induced by S1 P (Van Brocklyn et aL, 1998; Zhang et aL, 1991). 
Extracellularly, S1P binds to five G-protein coupled receptors, termed SIPI-5 
(formerly EDG1,5,3,6,8 respectively) (Spiegel & Milstien, 2000). S1P1/2/3 are 
widely expressed, but S1P4/5 are restricted to immune cells and the nervous 
systems respectively. Ligation of different receptors leads to coupling of specific 
G proteins; whilst SlPI couples to Gi, S1P2 and S1P3 couple to Gi, Gq and G13 
(Windh et aL, 1999), which leads to downstream signalling effects. For example, 
binding of S1 P to S1 P1 activates MAPK or P13K pathways, leading to migration, 
mitogenesis and actin assembly (Kluk & Hla, 2002; Takuwa, 2002). 
In macrophages, SIP appears to have an anti-inflammatory role: Hughes et aL 
(2008) demonstrated that pre-treatment of macrophages with SIP resulted in a 
reduction of LPS induced cytokine release. Furthermore, LPS causes an 
increase in expression of SPHK 1 (Hammad et a/., 2008). This in turn causes 
polarisation of macrophages from a proinflammatory MI phenotype to the 
antinflammatory M2 phenotype, hence, SIP may play a role in regulation of the 
inflammatory phenotype (Weigert et al., 2006; Weigert & Brune, 2008). 
Antimicrobial activity of macrophages has also been shown to be increased in 
the presence of SIP: intracellular killing of mycobacterium by human MDM and 
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the monocytic cell line TH P1 was increased following treatment with S1P (Garg 
et aL, 2004). The mechanism for this increased killing is thought to be an up- 
regulation of phagosome acidification in the presence of SIP. 
In phagocytosis, SPHK 1 activity is increased during uptake of S. aureus, 
Mycobactetium tuberculosis and latex beads, suggesting a role for SIP In 
particle engulfment (Malik et al., 2003). It has also been suggested that SIP is 
associated with phagosome maturation, since SPHK 1 translocates to the 
phagosome. Further evidence has come from the observation that M. 
tuberculosis avoids intracellular killing by inhibition of SPHK 1 (Thompson et al., 
2005). SPHK I is also activated following Fc signalling in the monocyte cell line 
U937, which leads to calcium release and subsequent vesicular transport 
(Melendez et al., 1998). 
Whether or not SlP contributes to airways disease pathogenesis has yet to be 
fully elucidated. Various reports suggest that it may have a significant role. For 
example, SPHK 2 is involved in the muscarinic receptor-dependent control of 
airway constriction (Pfaff et aL, 2005). SlP has also been shown to stimulate 
airway smooth muscle cell proliferation and cytokine release (Ammit et aL, 
2001). This study also reported an increase in S1P following allergen challenge 
in asthmatic subjects. SlP is associated with airway remodelling since it 
stimulates smooth muscle actin expression (Urata et aL, 2005). In addition, lung 
fibroblast chernotaxis towards fibronectin was enhanced in the presence of 
Slp, suggesting that it may play a role in cell recruitment to sites of 
inflammation (Hashimoto et aL, 2008). Inhibition of S113 production using an 
SPHK inhibitor reduces eosinophil infiltration and peroxidise activity in an 
ovalburnin mouse model of asthma (Nishiuma et aL, 2008), which is attributed 
to reduced chernotaxis. Conversely, SlP treatment also caused a disruption of 
airway epithelial cell tight junctions, leading to oedema (Gon et aL, 2005). 
Taken together these data suggest SlP may have a role in lung disease and 
may also regulate macrophage functions including phagocytosis. Therefore, the 
aim of this chapter is to assess whether S1P signalling is altered in COPD and 
whether this affects bacterial clearance. 
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6.2. Methods 
6.2.1. Subject selection 
Healthy non-smoking, smoking and COPD subjects were recruited as described 
in section 2.2.1. 
6.2.2. Isolation and culturing of IVIDIVI 
Monocytes were isolated from whole blood as described in section 2.2.3.1. The 
isolated cells were then cultured for 12 d at 370C in complete media 
supplemented with 2ng/ml GM-CSF in 96-well culture plates. 
6.2.3. Detection of SIP in MDM supernatants 
MDM from non-smoker, smoker and COPD subjects were isolated as described 
in section 2.2.3. Supernatants were then removed and stored at -200C. 
Concentrations of SIP were detected in supernatants using a SIP enzyme 
linked immunosorbance assay (ELISA) (Echelon Biosciences, Utah, USA) as 
instructed by the manufacturer. 
A 96-well microtiter plate was blocked with blocking solution for 1h at RT. The 
plate was then washed 4 times by addition then removal of 300pl PBS. SlP 
solutions of known concentrations were produced by combining S1P standard 
solution (1OOpM) and delipidised serum, then carrying out serial dilutions to 
provide the lower concentrations necessary for compiling a standard curve. 
Supernatant samples were then diluted 1: 10 in delipidised serum. Samples and 
standards were then combined with S1P antibody prior to transfer to the 
microtiter plate in triplicate. The plate was then incubated at 270C for 1 h. 
Following incubation, the plate was washed with PBS as before, then 100pl of 
an HRP labelled streptavidin solution was added to each well. The plate was 
then incubated at 27T for 1h and washed again with PBS. A solution of 
tetramethyl benzadrine (TMB) substrate was added to the plate (100pl for 4 
min). The reaction was stopped by addition of 50pl 1N sulphuric acid and the 
absorbance of the wells at 450nm was measured using a spectrophotometer. 
188 
6.2.4. Effect of pharmacological agents on phagocytosis 
MDM were cultured from whole blood obtained from non-smoking, smoking and 
COPID subjects. Cells were then incubated In complete medium supplemented 
with SPHKI, CAY10444, JTE-013, FTY720 or a DMSO vehicle control for 1h at 
370C. Media was then aspirated and replaced. Solutions of either H. influenzae 
or S. pneumoniae were then added to wells to a final concentration of 1mg1ml. 
Cells were incubated for 1h prior to quantification of phagocytosis. 
6.2.5. Phagocytosis assays 
Following incubation, unphagocytosed bacteria were removed by aspiration of 
media, and washing by addition then aspiration of 100pl D-PBS. 100pl trypan 
blue (2% (vlv)) was then added for I min in order to quench autofluorescence. A 
measurement of phagocytosis was determined using a fluorescence plate 
reader (excitation A 480nm and emission A 520nm). Control values of 
background fluorescence (cells without beads or bacteria) were averaged and 
subtracted from the fluorescence values of the treated cells. 
In order to calculate the volume of bacteria that had been ingested, 
fluorescence values were compared to those of known concentrations of 
bacteria (Fig. 3-2). 
6.2.6. Western blotting 
MDM were cultured from whole blood obtained from non-smoker, smoker and 
COPD subjects as described in section 6.2.2. then lysed by the addition of 
50pVwell RIPA lysis buffer containing protease and phosphatase inhibitors. 
Measurement of protein levels was carried out using a BioRad protein assay as 
described in section 2.2.13.1.30pg of protein was then mixed with sample 
buffer to a final volume of 30pl. Samples were denatured by heated at 900C for 
1 min. 
4-12% gradient Bis-Tris polyacrylamide gels were used for separation of 
proteins according to size. I Opl of a molecular weight marker or 30pl of each 
sample was added to wells, the gel tank was connected to a power source and 
proteins were resolved at 1 OOV, 1 OOmA for 2 h. Proteins were then transferred 
189 
from the gel to a nitrocellulose membrane using a transfer tank attached to a 
power source at 200mA, 200V for 1 h. 
To prevent non-specific binding of antibodies, the nitrocellulose membrane was 
blocked by incubation in 12ml 4% (w/v) BSA dissolved in TBS-Tween 20. for 1h 
at RT. This was then replaced with BSA/TBS-Tween 20 containing an antibody 
raised against the protein of interest and incubated for 16 h at 40C. The 
membrane was washed repeatedly to remove unbound antibody, then 
transferred to a solution of BSA/TBS-Tween 20 containing an appropriate HRP 
conjugated secondary antibody and incubated for 1h at RT. 
This antibody was then visualised by incubating the membrane with ECL 
detection solutions for 2 min at RT. The intensity of the protein present was 
detected by developing Hyperfilm after exposure to the membrane. Bands were 
analysed using UVP GelDoc-IT imaging system and Labworks software. 
6.2.7. Statistics 
Comparisons between disease groups were carried out using Kruskall-Wallis 
(ANOVA) tests followed by Dunn's post correctional tests. Comparisons 
between treatments were carried out using Wilcoxon signed rank tests, 
comparing medians of samples to controls. EC50 values were obtained by log 
transforming concentration values, then calculating a non-linear fit curve for 
each subject's data. Ap value of <0.05 was considered significant. All analyses 
were performed using GraphPad Prism software. 
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6.3. Results 
6.3.1. Subject demographics 
The characteristics of non-smoker, smoker and COPD subjects used In this 
study are shown in Table 6.1. COPD patients were significantly older than both 
non-smoker and smoker subjects. There was no difference In smoking history 
between COPD and smoker subjects, but both had a significantly greater 
number of pack years than non-smokers. COPD patients had a significantly 
reduced FEW FEVI % predicted, FVC and FEVI: FVC ratio than non-smoker 
and smoker subjects. There was no difference in lung function parameters 
between the control groups. 
Non-smokers 
Smokers (n=14) COPD (n=24) 
(n=16) 
Age (years) 53 ±3 52 ±2 67 ± 2** 
Sex (M: F) 9: 7 9: 5 13: 11 
Smoking history 
0.0±0.0+ 25.0 ± 5.8 50.0 ± 2.9* 
(pack years) 
FEVi (1) 3.1 ± 0.2 2.6 ± 0.3 1.3 ± 0.1*+ 
FEVi % 
99.0 ± 2.8 89.5 ± 3.0 47.0 ± 4.1 *+ 
predicted 
FVC (1) 4.3 ± 0.2 3.4 ± 0.3 2.5 ± 0.2*+ 
FEWFVC 0.8 ± 0.03 0.8 ± 0.03 0.5 ± 0.03*+ 
Table 6.1. Study varticipa t demographics 
Data are presented as mean i SEM. 1 pack year represent 20 cigarettes per day for 1 year. 
represents p<0.001 vs. non smokers, + represents p<0.001 vs. smokers. 
6.3.2. SIP production by MDM 
SJP is an ubiquitously expressed signalling molecule with a vadety of different 
downstream effects, therefore, the ability of MDM to produce SIP was 
investigated. Supernatants were removed from cultured MDM following 
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differentiation for 12 d (and media changing on days 4 and 8). The amount of 
S1 P in each sample was quantified using a S1 P ELISA kit. 
There was significantly more SlP present in the supernatants of COPD patient 
cells than in non-smoker supernatants (0.036±0.003pM vs. 0.010±0.001 pM, 
p<0.005) (Fig. 6.1). Although increased, there was no significant difference in 
production by smoker (0.021 ±0.001 pM) when compared to non-smoker MDM. 
*** 
0.03 
0.02 
cn 
0.01 
0. 
COPD 
tions in MDM supernatants. 
Supernatants were removed from 12 day old MDM isolated from non-smoker, smoker and 
COPD subjects and SlP levels were measured by ELISA. Data presented are mean±SEM. 
non-smoker n=6, S n=6, COPD n=6. *** indicates p<0.005. 
6.3.3. Effect of inhibition of sphingosine kinase 
In order to assess whether the increased SlP concentrations are associated 
with the reduced bacterial phagocytosis by MDM from COPD patients, 
production of SlP was reduced using an inhibitor of sphingosine kinase 1 
(SPHKI), as SPHK 1 is the most highly expressed isoform in the lung (Fukuda 
et al., 2003). 
Treatment with 1 and 1OpM SPHKI resulted in a significant increase in 
phagocytosis of H. influenzae by MDM from non-smokers, smokers and COPID 
patients (Fig. 6.2A). The EC50 values for this response were not significantly 
different (non-smokers: 0.09±0.06pM, smokers: 0.47±0.27pM, COPD: 
0.35±0.1 1 pM). Therefore cells from all three groups are similarly sensitive to the 
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effects of SPHKI. Phagocytosis of S. pneumontae was only significantly 
improved by SPHKI in COPD MDM (Fig. 6.21B). This response did not 
demonstrate a concentration dependent relationship, therefore EC50 values 
cannot be calculated. These data suggest that modulation of SlP levels may 
alter phagocytic responses in macrophages. 
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Figur ý 6.2. Effect of SPHKI on phagocytosis of bacteria. 
MDM isolated from non-smoker (n), smoker (m) and COPD (a) subjects were incubated with 
SPHIKI at concentrations indicated for 1 h, Media was then aspirated and SPHKI was added as 
before with 1mg1mI fluorescently labelled, H. influenzae (panel A) or S. pneumontae (panel B) 
for 1h. Ingestion of bacteria was quantified using a fluorescence plate reader. Data are 
presented as mean±SEM of percentage uptake compared to bacteria only controls, non- 
smoking n=6, smoking n=6, COPD n=5. * represents p<0.05. 
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6.3.4. Effect of an SIP analogue 
In order to confirm that augmentation of phagocytic capacity is due to changes 
in SIP concentrations, an SIP analogue, FTY720, was used to stimulate 
signalling via the SIP cascade. This compound is structurally similar to 
sphingosine, and is phosphorylated by sphingosine kinase. It then binds to S1P 
receptors (SlPl/3/4/5 only) and elicits the same downstream signalling 
responses as SIP. It is known to have immunosuppressive effects and can 
prevent the egress of lymphocytes from the thymus and secondary lymphoid 
organs (Chiba et aL, 2006). FTY720 also reduces airway hyperresponsiveness 
and inflammation in models of asthma (Sawicka et aL, 2003). As treatment with 
SPHKI increased phagocytosis, it was hypothesised that FTY720 may reduce 
uptake of bacteria. Therefore, in order to ensure that macrophages had a large 
phagocytic capacity prior to treatment, non-smoker MDM were used. 
MDM from non-smokers were treated with FTY720 and phagocytosis of H. 
influenzae and S. pneumoniae was quantified. Treatment with 0.1,1 and IlOpM 
FTY720 significantly decreased MDM phagocytosis, of H. influenzae (Fig. 6.3A). 
Engulfment of S. pneumoniae was decreased in the presence of 0.01,10 and 
100pM FTY720 (Fig. 6.313). As a concentration dependent relationship between 
FTY720 and phagocytosis of either bacterium was not demonstrated by this 
data, the EC5o values cannot be calculated. 
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Fiqure 6.3. Effect of FTY720 on phagocytosis of bacteria. 
MDM isolated from non-smoker subjects were incubated with FTY720 at concentrations 
indicated for 1 h. Media was then aspirated and FTY720 was added as before with 1 mg/ml heat 
inactivated, fluorescently labelled, H. influenzae (panel A) or S. pneurrioniae (panel B) for 1h. 
ingestion of bacteria was quantified using a fluorescence plate reader. Data are presented as 
mean±SEM of percentage uptake compared to bacteria only controls, non-smoking n=6, 
smoking n=6, COPD n=5. * represents p<O 05. 
6.3.5. Effect of Sl P receptor antagonism 
The data presented thus far has demonstrated that macrophages isolated from 
COPD patients produce more SlP than control cells. Furthermore, decreasing 
the production of SlP results in an Increase in phagocytosis and an agonist of 
the S1P receptors induces a decrease in phagocytosis. Therefore, an 
association exists between S1 P signalling and regulation of particle uptake. The 
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nature of this association is not clear, thus the involvement of the SIP receptors 
in the process of bacterial engulfment was investigated. The two most highly 
expressed SIP receptors on macrophages are S1P2 and S1P3 (Duong et a/., 
2004). In order to assess whether either of these receptors are important In the 
regulation of phagocytosis, MDM from non-smokers, smokers and COPD 
subjects were treated with the receptor antagonists JTE-013 and CAY10444, 
which have selectivities for S1132 and S1P3 respectively, and phagocytosis of 
H. influenzae and S. pneumoniae was quantified. 
Treatment with 0.1 and 1 pM JTE-01 3 significantly increased phagocytosis of H. 
influenzae by MDM from non-smokers, smokers and COPID patients (Fig. 6.4A). 
The ECso values for this response were not significantly different (non-smokers: 
o. 17±0.14pM, smokers: 0.15±0.14pM, COPID: 0.31±0.24pM). Therefore, cells 
from all three groups are equally sensitive to the effects of JTE-013. Uptake of 
S. pneumoniae was also increased following incubation with 1pM JTE-013 by 
non-smoker MDM and with 0.001,0.1 and 1pM by COPID MDM (Fig. 6.413). The 
EC5o values for this data were not significantly different (non-smokers: 
0.009±0.004pM, COPID: 0.071±0.02pM). The EC50 values were similar to those 
obtained using H. influenzae, suggesting that the uptake of Gram positive and 
Gram negative bacteria is equally affected by antagonism of these receptors. 
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Fiqure 6.4. Effect of JTE-01 3 on phaqOCvtosis of bacteria. 
MDM isolated from non-smoker (m), smoker (a) and COPD (a) subjects were incubated with 
JTE-013 at concentrations indicated for 1 h. Media was then aspirated and JTE-013 was added 
as before with 1mg/ml heat inactivated, fluorescently labelled, H. influenzae (panel A) or S. 
pneumoniae (panel B) for 1h. Ingestion of bacteria was quantified using a fluorescence plate 
reader. Data are presented as mean±SEM of percentage uptake compared to bacteria only 
controls, non-smoking n=6, smoking n=6, COPD n=5. * represents p<0.05. 
Incubation with the S1P3 receptor antagonist, CAY10444, significantly 
increased uptake of H. influenzae by non-smoker (at 1OOpM) and COPID MIDIVI 
(at 10 and 1OOpM) (Fig. 6.5A). However, there was no significant difference in 
phagocytosis of S. pneumoniae by any disease group at any of the 
concentrations used (Fig. 6.513). 
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MDM isolated from non-smoker (m), smoker (m) and COPD (0) Subjects were incubated with 
CAY10444 at concentrations indicated for 1 h. Media was then aspirated and CAY10444 was 
added as before with 1 mg/mI heat inactivated, fluorescently labelled, H intluenzae (panel A) or 
S. pneumoniae (panel B) for 1h. Ingestion of bacteria was quantified using a fluorescence plate 
reader. Data are presented as meantSEM of percentage uptake compared to bacteria only 
controls, non-smoking n=6, smoking n=6, COPD n=7. * represents p<0.05. 
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6.3.6. Expression of Sl P receptors by MDM 
To investigate whether differences in the effects of S1P receptor antagonists in 
COPID cells could be due to different levels of receptor expression, western 
blots were perforned and expression of S1P2 and S1P3 in MDM from non- 
smoker, smokers and COPD subjects was quantified. 
There was no significant difference in expression of SlP2 between MDM from 
non-smoker, smokers and COPD MDM (Fig. 6.6). 
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MDM were isolated from non-smoking, smoking and COPID Subjects. proteins were isolated and 
resolved by SDS-PAGE prior to transfer to nitrocellulose before immunoblotting for S1 P2 (panel 
A). Densitometry was performed on the bands and data are presented as meantSEM relative to 
actin expression. Non-smoking (m) n=6, smoking (m) n=6 and COPID (n) n=6 (panel B) 
There was also no significant difference in expression of S1P3 by MDM from 
any group (Fig. 6.7) 
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Figure 6.7. Expression of S1 P3 by MDM- 
MDM were isolated from non-smoking, smoking and COPD subjects, proteins were isolated and 
resolved by SDS-PAGE prior to transfer to nitrocellulose before immunoblotting for S1 P3 (panel 
A). Densitometry was performed on the bands and data are presented as mean±SEM relative to 
actin expression. Non-smoking (s) n=6, smoking (m) n=6 and COPD (n) n=6 (panel B) 
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6.4. Discussion 
SIP is a potent signalling molecule, with the ability to act both Intra and 
extracellularly, conferring a wide range of downstream effects. The finding that 
SIP production is significantly increased by MDM from COPD subjects may be 
of importance to macrophage responses in this disease. For example, SIP 
upregulates expression of CXCL8 and IL-6 (Ammit et al., 2001; Cummings et 
al., 2002), and correspondingly, increased concentrations of these inflammatory 
cytokines have been identified in the airways of COPD patients and are 
implicated in the associated chronic pulmonary inflammation (Sethi et al., 2006). 
The cause of this upregulated release of Sip in COPD may be increased 
production by SPHK. In COPD patients this may be due to hypoxic conditions, 
which increase expression of SPHK mRNA and protein (Schwalm et al., 2008). 
induction of hypoxia by maternal inhalation of carbon monoxide in rats also 
results in an increased concentration of two Sip precursors, sphinganine and 
sphingosine, in the blood of offspring (Carratu et al., 2000). However, MDM are 
not cultured in hypoxic conditions, therefore another possible explanation for 
increased Sip in COPD MDM supernatants is that the release of intracellular 
Sip to the extracellular space is upregulated. In platelets Sip increases 
intracellularly due to high SPHK activity and low expression of the 
dephosphorylating enzyme Sip phosphatise, but is then released upon 
stimulation (Kobayashi et al., 2006). The activity and expression of the relevant 
enzymes in COPD patient macrophages has yet to be investigated. 
Data presented in this chapter using SPHKI and FTY720 suggests that Sip is 
involved in control of phagocytosis. However, given the high variability between 
samples, it is questionable whether the compounds directly reduce 
phagocytosis, or if this is an effect of the augmentation of other cell signalling 
pathways. Furthermore, the effect of FTY720 was not concentration-dependent, 
suggesting that little if any relationship exists between phagocytosis and 
treatment with these compounds, and that a statistical association may be 
misleading. The responses of MDM towards H. influenzae in the presence of 
SPHKI demonstrate large standard error bars, further suggesting that there may 
be too much donor-to-donor variation to draw solid conclusions from this data 
and this could be resolved with increasing the sample size. 
201 
However, this finding does concur with previous data obtained on the effects of 
SIP precursors on phagocytosis: Hinkovska-Galcheva et a/. (2003) 
demonstrated that inhibiting ceramide synthesis (a requirement for SIP 
production) increases neutrophil phagocytosis. Additionally, sphingosine, which 
is an intermediate between ceramide and SIP, reduces Fc receptor-mediated 
phagocytosis of red blood cells by neutrophils (Raeder et al., 1999). The 
mechanism by which SIP exerts this response is unknown but may involve 
receptor signalling following recognition of bacteria. For example, TLR2 
activation has been shown to be reduced by S1P in human monocytes (Duenas 
et aL, 2008). Alternatively, SIP may inactivate signalling pathways associated 
with phagocytosis that lead to either an increased threshold required to trigger 
uptake or a slower response time. For example, the small GTPase, Rac, is 
negatively regulated by SIP signalling through SlP2 and is involved in actin 
polymerisation during phagocytic cup formation (Hall, 2005; Takuwa, 2002). 
SIP also triggers pseudopodia retraction, which would also prevent phagocytic 
cup formation (Koh et aL, 2007). These potential causes of the SIP mediated 
down-regulation of phagocytosis are depicted in Fig. 6.8. 
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Fiqure 6.8. Potential mechanisms by which Sl P reduces phagocytosis by COPQ MDM 
SiP may inhibit phagocytosis via modulation of TLR activation (1), inhibition of the signal 
transduction pathways that are activated following bacterial recognition (2) or the retraction of 
pseudopodia which are necessary for engulfment (3). 
SiP has been shown to augment autophagy, a cell defence mechanism 
whereby cells degrade cYtosolic components, either to remove pathogens or to 
obtain amino acids and other essential compounds during periods of nutrient 
deprivation (Lavieu et al., 2006). This process is increased following 
transfection with SPHK, suggesting that SlIP production triggers 
autophagosome formation. As many of the lysosome trafficking components 
involved in autophagy are also involved in phagocytosis (Sanjuan et al., 2007), 
this data suggests a regulatory role for S1 P in particle clearance. 
Data presented here demonstrates a greater SlIP-mediated increase in 
phagocytosis of H. influenzae compared to uptake of S. pneumoniae. Therefore 
it is possible that S1 P has a differential effect on phagocytosis of Gram positive 
and negative bacteria. There is currently no published data pertaining to the 
importance of SlP signalling in bacterial clearance by macrophages, therefore 
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further investigation of the regulatory mechanisms involved would be required to 
establish whether species specific differences occur. 
There were differential effects of antagonism of receptors S1P2 and S1P3 on 
phagocytosis of H. influenzae and S. pneumoniae. Whilst preventing binding of 
S1P to S1P2 resulted in an increase in phagocytosis of H. influenzae by MDM 
from all groups and S. pneumoniae by non-smoker and COPD cells, the S1P3 
antagonist only increased uptake of H. influenzae by COPD MDM. The different 
roles of the the SlP receptors may explain this finding. For example, whilst 
SlP3 acts as a chemoattractant receptor, S1P2 is a chemorepellant (Takuwa, 
2002). Furthermore, Rac is activated by S1P3 but inhibited by S1P2 (Okamoto 
et aL, 2000; Paik et aL, 2001). Therefore, it is plausible that the S1P receptors 
may play different roles in the process of phagocytosis. Additionally, S1P3 is 
expressed at lower levels than S1P2 on macrophages, which may explain why 
JTEO 13 elicited a greater response than CAY1 0444 (Duong et a/., 2004). 
In conclusion, SlP expression is increased by COPD macrophages when 
compared to controls. S1P appears to play a role in the reduced phagocytosis 
identified in these cells, as attenuation of S1P signalling augments the 
phagocytic response and may provide a novel mechanism for improving uptake 
of bacteria by these cells. 
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Chapter 7 
Gene Expression Analysis of 
6 
MDM Phaqocytosis 
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I. Introduction 
Data presented thus far has demonstrated fundamental differences in the ability 
of macrophages from COPD patients to phagocytose bacteria. However, the 
mechanism of this defect has not yet been fully elucidated. Potential causes 
that have been identified include: 
o Reduced -expression 
of scavenqer receptors 
Previous studies examining reduced phagocytosis of apoptotic cells by COPID 
alveolar macrophages indicated that azithromycin improved cell clearance. 
Moreover, this was associated with upregulated expression of the mannose 
receptor. Expression of CD36 (thrombospondin receptor), CD91 (LDL receptor 
related protein), CD44 (hyaluron receptor) and CD71 (transferrin receptor) on 
alveolar macrophages from current smokers (both with and without COPD) was 
also decreased when compared to non-smoking controls (Hodge et aL, 2007a). 
Other receptors that may be involved include the scavenger receptor MARCO, 
whose expression is decreased in response to cigarette smoke on the 
monocytic cell line (THP1) derived macrophages (Baqir et a/., 2008), or TLR2, 
which is downregulated on alveolar macrophages isolated from COPD subjects 
when compared to controls (Droemann et aL, 2005). CD163 which is increased 
in skeletal muscle of COPID patients (Montes de, Oca et aL, 2005) and 
scavenger receptor A, which recognises both Gram positive and Gram negative 
bacteria may also be involved (Pluddemann et aL, 2006). 
Aberrant expression of proteins involved in microtubule rearrangement 
(ChaDter 4) 
Proteins involved in regulation of microtubules include the motor protein 
dynamin 2, shown to be important in the phagocytosis of opsonised red blood 
cells by a murine macrophage cell line (RAW264.7) (Eng et al., 2007; Gold et 
al., 1999). HOOK3, a microtubule binding protein involved in signalling via 
scavenger receptor A may have a role in phagocytosis of unopsonised particles 
(Sano et al., 2007). Additionally alterations in the expression of genes encoding 
the tubulin deacetylasing enzymes, HDAC6 and SIRT2 may be involved in 
reduced clearance of bacteria by COPD MDM. 
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e Proteins associated with SlP siqnalling (Chapter 6) 
Expression of the SPHK enzymes, which are responsible for phosphorylation of 
sphingosine, may be altered in COPD, as may that of ceramidase or S1 P lyase. 
Similarly altered expression of the 81 P receptors and S1 P kinases 1 and 2 may 
be important in the regulation of phagocytosis by COPD MDM. 
The involvement of these potential causes in the reduction of phagocytosis in 
COPI) will be investigated by comparison of specific gene expression by MDM 
isolated from non-smokers, smokers and COPD subjects. This will be achieved 
using Illumina microarray analysis, which allows for the comparison of 
approximately 48,000 genes in parallel. Other microarray systems have 
previously been employed for investigating gene expression in macrophages 
either at baseline, or following stimulation. A comparison of alveolar 
macrophages, MDM and monocytes demonstrated significant differences in 
gene expression by each cell type in the absence of stimulation (Li et al., 2007). 
21% of the genes examined were differentially expressed by alveolar 
macrophages and monocytes. Despite their apparently similar phenotype, 
alveolar macrophages and MDM demonstrated significant differential 
expression of 2229 out of the 13583 total genes (16.4%). Investigations into the 
gene expression response of macrophages to various stimuli have also been 
performed. Recognition of bacteria by macrophages triggers various signalling 
pathways, which elicit downstream effects. One such effect is phagocytosis, 
others include cytokine release and production of reactive oxygen species. 
Each of these responses may require gene expression and subsequent 
transcription and translation to produce the necessary proteins. For example, 
following recognition of Gram negative bacterial surface molecule LPS by TLR- 
4, genes encoding proinflammatory mediators, cytokines, and chemokines (such 
as TNFa, IL-1P, IL-6, CXCL10, CCL3,45 and cycloxygenase-2) are expressed 
(Bjorkbacka et al., 2005). 
Little is known about genome-wide expression by macrophages during 
phagocytosis, as many studies have involved microorganisms that have 
evolved mechanisms to evade engulfmentrintracellular killing by phagocytes. 
However, Matsusaki et al. (2007) performed microarray analysis of cytokine 
release by macrophage-like U937 cells following phagocytosis of polyethylene 
particles. They found that eight cytokine-related genes were upregulated; these 
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included the chemokines CXCL8, CXCL2 and CCL4 and the chemokine 
receptor CXCR4 (Matsusaki et al., 2007). 
Similarly, studies have been performed to identify genes that are associated 
with COPID. For example, expression profiles of lung tissue isolated from non- 
smokers and COPID patients demonstrated 3222 upregulated genes when 
compared to the controls, and 203 of these were associated with lung function 
measurements (Wang et al., 2008). This study identified PLAU (urokinanse 
plasminogen activator), the PLAU receptor (PLAUR) and thrombospondin as 
being upregulated in COPID. Another study compared gene expression in lung 
tissue from COPID patients and smokers without airway obstruction, and this 
demonstrated differential expression of 327 genes in COPID subjects compared 
to smokers, including an upregulation of inflammation associated genes 
(TGFP1, ILAR), transcription factors and a down regulation in multiple genes 
expressing extracellular matrix proteins (Ning et al., 2004). However, as these 
studies involved analysis of tissue samples it is unknown which cells are 
responsible for these differences. 
The aim of this chapter is to investigate the expression of genes by MDM 
isolated from non-smoking, smoking and COPD subjects in the presence or 
absence of H. influenzae, to establish whether defective expression is involved 
in the reduced phagocytosis identified by COPD macrophages. 
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7.2. Methods 
7.2.1. Subject selection 
Healthy non-smoking, smoking and COPD subjects were recruited as described 
in section 2.2.1. 
7.2.2. Isolation and culturing of IVIDIVI 
Monocytes were isolated from whole blood as described in section 2.2.3.1. The 
isolated cells were then cultured for 12 d at 371C in complete media 
supplemented with 2ng/ml GM-CSF. 
7.2.3. RNA isolation 
MDM were cultured in 6-well plates then incubated with or without heat killed H. 
influenzae for 1 h. Total RNA was isolated from using the Qiagen RNeasyO 
miniprep RNA extraction kit as indicated by the manufacturer (see section 
2.2.14.1). The quality of the RNA samples was quantified using the RNA 6000 
Nano AssayTm kit with the Agilent 2100 BioanalyserTm and the Nanodropo ND- 
1000 UV-Vis spectrophotometer. 
7.2.4. Illumina gene expression profiling 
The gene expression profile of MDM incubated in the presence and absence of 
H. influenzae was analysed using the Illumina Whole Genome Expression 
Analysis microarray system. This allows for the quantification of -48,000 using 
relatively small volumes of cRNA (Schena et aL, 1995). Illumina arrays 
incorporate randomly arranged microspheres onto a silicon chip, with each 
sphere being bound to approximately 70,000 copies of a specific 
oligonucleotide probe (Kuhn et aL, 2004; Michael et aL, 1998). Each of these 
probes also incorporates an identifier sequence that allows for the mapping of 
the array to determine the location of each bead. When fluorescently labelled 
cRNA is hybridised onto the chip it binds to its corresponding probe. The 
fluorescence of the array can then be measured and the number of copies of 
the genes bound to the probe can be quantified. The fluorescence values are 
then compared to a map of the known location of the bead/oligonucleotide to 
give specific expression values for each gene. In addition to the genes of 
209 
interest, control probes are also included in the array. Probes with mismatching 
sequences or house keeping genes detect non-specific binding and RNA 
concentrations respectively, and hybridisation and labelling controls guard 
against discrepancy in the processing of the chips. Finally, background 
fluorescence values are recorded and deducted from probe values. 
RNA was isolated from MDM (as described in section 7.2.3) then converted to 
labelled cRNA for hybridisation onto the gene expression chips using the 
Illuminao Totalprep RNA amplification kit as indicated by the manufacturer. 
Initially, this involved synthesis of first strand cDNA from total RNA. Second 
strand synthesis was then performed, followed by cDNA purification using a 
spin filter column. Labelled cRNA was then transcribed from the cDNA. cRNA 
was purified using a filter column, then washed to remove unincorporated 
NTPs, salts, enzymes and inorganic phosphates. The biotinylated cRNA was 
then eluted from the filter columns in nuclease free water. cRNA concentration 
and quality were tested using the RNA 6000 Nano AssayTm kit and the 
NanodropO ND-1000 UV-Vis spectrophotometer The required yield for 
continuation of the procedure is between 20-50pg/sample. The expected cRNA 
profile is a distribution of sizes from 250-5500 nucleotides (nt) with most of the 
cRNA at 1000-1500 nt. 
cRNA was then hybridised onto an expression chip using humidity control and 
hybridisation buffers and incubation in a hybridisation oven for 16 h. Following 
this the chips were washed repeatedly, blocked by incubation with a blocking 
buffer at RT for 10 min and then transferred to blocking buffer containing 
Streptavidin-CY3 for a further 10 min. Following further washing the chips were 
analysed on the BeadArray Reader. 
7.2.5. Taqman Real Time PCR 
The expression of the genes encoding 10 targets of interest (identified from 
microarray data) was quantified using real time polymerase chain reaction (RT- 
PCR) analysis. RNA was isolated from MDM following incubation in the 
presence or absence of H. influenzae (as described in section 7.2.3). Reverse 
transcription of the RNA to produce cDNA was carried out using the High 
Capacity cDNA Reverse Transcription kit (Applied Biosystems, California, USA) 
as advised by the manufacturer. Total RNA was combined with reverse 
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transcription buffer, RNAse inhibitor, dNTPs, reverse transcriptase and random 
primers then loaded into a thermal cycler for 10 min at 250C, 120 min at 370C 
and 5 sec at 8511C. Following this cDNA concentrations were measured using a 
Nanodropo ND-1000 UV-Vis spectrophotometer as described in section 
(2.2.14.2) 
The PCR reaction was carried out using TaqManO gene expression assays. Ing 
cDNA of each sample was suspended in RNAse-free water and transferred to a 
96-well reaction plate and combined with TaqMano Universal PCR Master Mix, 
the TaqMano probe for the gene of interest (probe sequences displayed in 
Appendix 1), or the endogenous control, HPRT. The reaction plate was the 
loaded into the RT-PCR machine for analysis. 
7.2.6. Statistics 
Data obtained by Illumina microarrays was background normalised (against the 
values for housekeeping gene probes) using Illumina BeadStudio software to 
reduce variation between probes. Quality control data was analysed to ensure 
that fluorescence values of control probes for non-specific RNA binding, 
hybridisation and labelling errors and binding strigency were within acceptable 
limits. 
Statistical analysis of differential gene expression was performed by Dr Bernard 
North, Imperial College Statistical Advisory Service. Analyses using quantile 
normalisation to account for variations between arrays was carried out using R 
software (Gentleman et aL, 2004). Differential gene expression analysis was 
then carried to compare expression of genes by MDM from non-smokers, 
smokers and COPD subjects in the presence and absence of H. influenzae 
from. Baseline (no bacteria) values for non-smokers, smokers and COPID 
subjects were also compared. 
Microarray analysis allows for the unbiased assessment of thousands of genes 
simultaneously, using small amounts of RNA, however, the vast number of 
genes can result in multiple false positive results. Therefore the significance 
value must be reduced to reflect the number of genes being examined. A 
Bonferroni correction involves dividing the significance value by the number of 
genes (48701 in this case of Illumina microarrays) and then using this to 
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calculate ap value. Therefore, this correction was applied to all p values to 
provide an adjusted value, for which p<0.05 was considered significant. 
For analysis of Taqman data, plots of the normalised reporter dye fluorescence 
(RN) VS- cycle number were generated by SDS software (Applied Biosystems, 
California, USA). A threshold RN value for each gene was selected, and the 
cycle number at which the expression reached this threshold was recorded. 
Each gene was normalised to the expression of the endogenous control and 
comparisons of expression in the presence and absence of bacteria were 
carried out. Values were then compared using a paired West. 
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7.3. Results 
7.3.1. Subject demographics 
The characteristics of non-smoking, smoking and COPD subjects used in this 
study are shown in Table 7.1. There was no significant difference in the ages of 
the subjects, nor in smoking history between COPID and smoker subjects, but 
both had a significantly greater number of pack years than non-smokers. COPID 
patients had a significantly reduced FEVI, FEV, % predicted and FEVI: FVC 
ratio than non-smoking. There was no difference in lung function parameters 
between the control groups. 
Non-smokers 
Smokers (n=5) COPD (n=5) 
(n=5) 
Age (years) 54±4 54±3 65±5 
Sex (M: F) 3: 2 3: 2 4: 1 
Smoking history 
O. O±O. O+ 28.7±5.3 54.0±10.1* 
(pack years) 
FEV1 (1) 2.9±0.16 2.9±0.39 1.3±0.20+* 
FEVi % 100.5±8.4 97.1±2.7 49.5±6.6* 
predicted 
FVC (1) 3.5±0.26 3.9±0.49 2.7±0.32 
FEVi: FVC 0.87±0.08 0.75±0.02 0.50±0.03* 
Tabl 3,7.1. Study participant demographics 
Data are presented as mean ± SEM. 1 pack year represent 20 cigarettes per day for I year. 
represents p<0.001 vs. non smokers. 
7.3.2. Comparison of baseline MDM gene expression 
PhagocYtic capacity is significantly reduced in MDM from COPID subjects, which 
may reflect differences in the expression of proteins involved in the regulation or 
mechanics of this process. In order to assess whether gene expression by 
COPID MDM differs from that non-smokers or smokers, the baseline expression 
values from each disease group were compared. A list of the 100 most 
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differentially expressed genes by each of the groups is presented in Appendix 
2. The 10 most differentially expressed gene between non-smokers and 
smokers are presented in Table 7.2. 
7.3.2.1. Comparison of gene expression by non-smoker and smoker MDM 
Once the p values were adjusted to account for potential false positive results, 
there was no significant difference in expression of any of the genes between 
non-smokers and smokers. The expression values for the genes that previous 
findings suggested may be potentially important in defective phagocytosis by 
COPID MDM (as described in section 7.1) are displayed in Table 7.3. There was 
no significant difference in expression of any of these genes. 
Gene ID 
Log fold 
change 
Average 
Expression 
P Value 
Adjusted P 
value 
Z133 -1.547 9.093 0.000138 0.999730 
ZP3 -1.270 7.527 0.000151 0.999730 
HS. 565901 -0.205 6.143 0.000296 0.999730 
HS. 574845 -0.231 5.831 0.000364 0.999730 
FLJ39061 -0.194 5.816 0.000598 0.999730 
HS-112899 0.164 5.628 0.000875 0.999730 
HS. 529547 -0.157 5.532 0.000976 0.999730 
LOC650836 0.217 5.655 0.000997 0.999730 
CRB3 0.274 5.772 0.001075 0.999730 
HS. 4131-93 0.204 5.548 0.001151 0.999730 
Tab , 7.2. The 10 most differentially expressed genes between non-smoker- and smoker 
lutLQcts. 
RNA was extracted from MDM isolated from non-smoking and smoking individuals, and 
converted to fluorescently labelled CRNA for hybridisation onto Illumina genechips. The 
fluorescence of each of the probes on the chip was then quantified and data normalised. A 
differential expression analysis between the two groups was then carried out using R software. 
Log fold change indicates difference in expression between the two groups and adjusted p 
value refers to a Bonferroni adjusted p value. The 10 most differentially expressed genes are 
presented, non-smokers n=5, smokers n=5. 
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7.3.2.2. Comparison of gene expression by non-smoker and COPD MDM 
In order to assess whether COPID is associated with an altered mRNA profile at 
baseline, the gene expression by MDM isolated from COPD subjects was 
compared to that of non-smoking controls. The only gene that was differentially 
expressed significantly was SERPINA1 (Table 7.4). COPD subjects MDM 
express significantly less of this gene than non-smoking subject cells. There 
was no significant difference in expression of the genes predicted to be involved 
in the phagocytosis process between non-smoker and COPID isolated MDM 
(Table 7-5). 
Gene ID 
Log 
fold 
change 
Average 
Expression 
P Value 
Adjusted P 
value 
SERPINA1 -2.026 12.506 0.00000006 0.003045 
RGS20 1.030 6.562 0.00000956 0.125773 
SLC7A7 -0.591 12.945 0.0000105 0.125773 
SMAD7 -0.787 8.333 0.00001116 0.125773 
HS. 571422 0.552 6.387 0.00001385 0.125773 
FLJ38482 0.496 8.758 0.00001562 0.125773 
IKIP 0.649 8.275 0.00002377 0.125773 
CLEM -1.114 8.203 0.00002577 0.125773 
CCDC132 0.458 9.346 0.00003466 0.125773 
TLR8 -1.855 10.543 0.00003693 0.125773 
Tabi - 7.4. The 10 most differentially expressed genes between COPQ and - non-smoker 
jub je_cts. 
RNA was extracted from MDM isolated from non-smoking and smoking individuals, and 
converted to fluorescently labelled cRNA for hybridisation onto Illumina genechips. The 
fluorescence of each of the probes on the chip was then quantified and data normalised. A 
differential expression analysis between the two groups was then carded out using R software. 
The 10 most differentially expressed genes are presented, non-smokers n=5, smokers n=5 
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7.3.2.3. Comparison of gene expression by COPD and smoker MDM 
Although little difference between non-smokers and COPID subjects was found, 
smokers without COPID may be a more appropriate control. However, when 
compared to smokers, COPID MDM demonstrated a decreased expression of 
SERPINA1 (Table 7.6). Additionally, SLC7A7, which codes for an amino acid 
transporter protein, whose mutation is associated with the multi organ disorder 
lysinuric protein intolerance, was also increased in COPID subjects, when 
compared to smokers (Torrents et aL, 1999). There was no sianificant 
difference in expression of any of the genes that had been proposed to be 
involved in defective phagocytosis (Table 7.7). 
Gene ID 
Log fold 
change 
Average 
Expression 
P Value 
Adjusted 
P value 
SERPINA1 1.944 12.506 0.000000 0.005083 
Sl-C7A7 0.713 12.945 0.000001 0.030783 
RGS20 -1.133 6.562 0.000003 0.051044 
HS. 571422 -0.615 6.387 0.000004 0.051044 
ETFA -0.450 11.967 0.000006 0.052380 
RAPGEF3 -1.128 9.972 0.000007 0.052380 
RAB61P1 1.249 10.177 0.000009 0.052380 
RHEB -0.380 12.373 0.000011 0.052380 
APPBP1 -0.468 10.791 0.000012 0.052380 
FLJ38482 -0.509 8.758 0.000012 0.052380 
Table 7.6. The 10 most differentially expressed genes between COPD and smoker subiects. 
RNA was extracted from MDM isolated from non-smoking and smoking individuals, and 
converted to fluorescently labelled cRNA for hybridisation onto Illumina genechips. The 
fluorescence of each of the probes on the chip was then quantified and data normalised. A 
differential expression analysis between the two groups was then carried out using R software. 
The 10 most differentially expressed genes are presented, non-smokers n=5, smokers n=5. 
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7.3.3. Effect of bacteria on MDM gene expression - microarray data 
At baseline, the only gene that is differentially expressed by COPID MDM 
compared to both control groups is SERPINA1. SERPINAII encodes C11- 
antitrypsin, however, its role in phagocytosis is unclear. None of the proteins 
that had previously been suggested to be involved in the reduced phagocytosis 
in COPID cells were differentially expressed. However, despite similarities at 
baseline, there may be discrepancies in the manner to which COPD patients 
MDM respond to bacteria. To investigate which genes are expressed in 
response to bacteria, a genome-wide gene expression analysis was carried out 
using MDM from non-smoker, smoker and COPID subjects following incubation 
for Ih in the presence or absence of H. influenzae. An incubation time of 1h 
was selected as this same period was used for phagocytosis assay (Chapter 3). 
Differential expression analyses were carried out to compare RNA from cells 
from each subject group in the presence and absence of bacteria. No genes 
were differentially expressed by non-smoker cells incubated with bacteria, 
however, 9 genes were significantly up or downregulated in smoker MDM in the 
presence of H. influenzae. COPD MDM expressed altered levels of 162 genes 
in the presence of bacteria (Table 7.8). This striking difference in gene 
expression by MDM suggests that COPD causes an exaggerated response to 
bacteria, compared to that of control cells. 
The 10 genes with the greatest differential expression between MDM in the 
presence and absence of bacteria are presented in Tables 7.9-7.11. In both 
smoker and COPD cells the majority of the genes that were differentially 
expressed in the presence of bacteria were upregulated (9 out of 9 genes and 
142 out of 162 genes respectively). A list of the 100 most differentially 
expressed genes by each disease group is presented in Appendix 3. 
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Non-smokers Smoker COPD 
Number of genes 0 9 142 
upregulated by bacteria 
Number of genes 0 0 20 
downregulated by bacteria I 
Tabl ý 7.8. Differential expression of MDMqenes in the presence of H. inlfuenzae 
MDM isolated from non-smoking individuals were incubated for 1h in the presence or absence 
of Jmg1ml heat killed H. influenzae. Total RNA was then extracted from the MDM then 
converted to fluorescently labelled cRNA for hybridisation onto Illumina genechips. The 
fluorescence of each of the probes on the chip was then quantified and data was normalised. A 
differential expression analysis between the two treatment groups was then carried out using R 
software. The number of genes up-regulated or down-regulated are presented, non-smoker 
n=5, smoker n=5, COPID n=5. 
There were no differentially expressed genes by non-smoker MDM as a result 
of incubation with H. influenzae (Table 7.9). 
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Gene ID 
Log fold 
change 
Average 
Expression 
P Value 
Adjusted P 
value 
CCL1 0.873186 9.952735 0.00000596 0.11839996 
PTP4A2 0.556711 9.581236 0.00000783 0.11839996 
HS. 439642 0.778906 6.328938 0.00000922 0.11839996 
HES1 0.479511 6.233637 0.00001085 0.11839996 
LOC653610 0.541869 7.871417 0.00001311 0.11839996 
SNORD13 1.614088 8.380169 0.00001532 0.11839996 
HS. 550293 0.64509 7.003101 0.00001702 0.11839996 
SCARNA9 1.326054 9.301726 0.00002326 0.14159975 
HS-126187 0.74734 6.24774 0.00002666 0.14426357 
HS. 580797 0.694454 9.885829 0.00ýý2: 
L 
0.14705492 
iene expression by non-smoker MDM between incubation in the 
H. influenzae- 
MDM isolated from non-smoking individuals was incubated for Ih in the presence or absence 
of 1 mg1ml heat killed H. influenzae. Total RNA was then extracted from the MDM and converted 
to fluorescently labelled cRNA for hybridisation onto Illumina genechips. The fluorescence of 
each of the probes on the chip was then quantified and data was normalised. A differential 
expression analysis between the two treatment groups was then carried out using R software. 
The 10 most differentially expressed genes are presented, n=5. 
Smoker MDM demonstrated upregulated expression of TRIB1 (Tribbles protein 
1), PDGFB (plate let-d e rived growth factor-P polypeptide), KLF6 (Kruppel-like 
factor 6), ARI-513 (ADP-ribosylation factor-like 513), BTG2 (B cell translocation 
gene 2), OTUD1 (OUT domain), PLEKHF2 (pleckstrin homology domain 
containing, family F), DUSP1 (dual specificity phosphatase 1) and THBD 
(thrombomodulin) following incubation with H. influenzae (Table 7.10). 
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Gene ID 
Log fold 
change 
Average 
Expression 
P Value 
Adjusted P 
value 
TRIB1 2.002448 11.07953 0.00000009 0.00450965 
PDGFB 0.893143 6.750249 0.00000202 0.04076287 
KLF6 1.200623 13.33368 0.00000251 0.04076287 
ARI-513 1.533969 7.806689 0.00000355 0.04326615 
BTG2 2.175127 10.47734 0.00000514 0.04653096 
OTUD1 1.147349 9.828594 0.00000607 0.04653096 
PLEKHF2 0.946972 9.545206 0.00000833 0.04653096 
DUSP1 3.547624 12.15939 0.00000846 0.04653096 
THBD 0.97195 6.64882 0.0000086 0.04653096 
F-UýC642035 2.051108 7.101435 0.00001088 0.05269534 
Tablq 7.10. Differential gene expression by smoker MDM between incubation in the Dresence 
and 3bsence of H. influenzae, 
MDM isolated from smoking individuals was incubated for Ih in the presence or absence of 
1 mg1ml heat killed H. int7uenzae. Total RNA was then extracted from the MDM and converted to 
fluorescently labelled cRNA for hybridisation onto Illumina genechips. The fluorescence of each 
of the probes on the chip was then quantified and data was normalised. A differential 
expression analysis between the two treatment groups was then carried out using R software. 
The 10 most differentially expressed genes are presented, n=5. 
Expression of TNF, GADD45B (growth arrest and DNA-damage-inducible 
protein P), CCL3L1 (chemokine (C-C motif) ligand 3-like 1), IER3 (immediate 
eary response gene 3), CCL20, IL-1p, EGRJ (early growth response gene 1), 
CXCL2, EB12 (Epstein-Barr virus induced gene 2) and BTG2 (B cell 
translocation gene 2) by COPID MDM was significantly increased in the 
presence of bacteria (Table 7.11). A further 152 other genes were differentially 
expressed and the 100 highest significance values are presented in Appendix 3. 
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Gene ID 
Log fold 
change 
Average 
Expression 
P Value 
Adjusted P 
value 
TNF 6.770866 10.01442 0 0.00000001 
GADD45B 2.224333 9.514022 0 0.00000002 
CCI-31-1 3.216471 9.449922 0 0.00000002 
IER3 5.368556 10.73044 0 0.0000001 
CCL20 5.716999 9.280939 0 0.00000013 
11-113 5.872856 9.98761 0 0.00000039 
EGR1 2.682857 8.513008 0 0.00000041 
CXCI-2 4.643175 9.586881 0 0.00000101 
EB12 3.07647 10.78128 0 0.00000185 
BTG2 1.865865 10.16796 0 0.00000238 
ene expression by COPQ MDM between incubation in the presence 
and ab_sence of H. influenzae. 
M DM isolated from COPID subjects was incubated for 1h in the presence or absence of 1 mg/ml 
heat killed H. influenzae. Total RNA was extracted from the MDM and converted to fluorescently 
labelled cRNA for hybridisation onto Illumina genechips. The fluorescence of each of the probes 
on the chip was then quantified and data was normalised. A differential expression analysis 
between the two treatment groups was then carried out using R software. The 10 most 
differentially expressed genes are presented, n=5. 
7.3.4. Effect of bacteria on MDM gene expression - Taqman data 
Concerns have been raised previously as to the reliability of microarrays 
(Canales et aL, 2006). Therefore, studies have been carried out to compare the 
reproducibility of the assays, and report varying success (Marshall, 2004; Qin et 
aL, 2006). To combat these issues, a second method of analysing gene 
expression was employed in order to confirm the microarray findings. The 
expression of 10 gene targets identified from the 100 most differentially 
expressed genes by COPD MDM were quantified using RT-PCR (presented in 
Appendix 3). These genes were selected for their relevance to the process of 
bacterial phagocytosis or COPD pathogenesis (Table 7.12). 
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Gene Alternative name Function 
CCL20 MIP3a * Increased in the airways of COPD patients, 
* Mitogenic properties 
CXCL1 GROa 
9 Neutrophil chemoattractant 
* MAPK phosphatase 
Dual specificity * Increased expression by macrophages in 
DUSP1 
phosphatase 1 response to LPS or dexamethasone 
9 Can modulate cytokine production 
Early growth 9 Modulates TNF production 
EGR1 
response gene 1 0 Involved in airway responsiveness 
-- Has a role in regulation of apoptosis 
1 
Immediately early 
: 
1E R3 
response gene 3 
Transcribed rapidly in response to 
inflammatory stimuli 
* Increased in sputum from COPD patients 
11-113 Interleukin 1P 
Causes leukocytosis 
Increased in sputum from COPD patients 
11-6 Interleukin 6 Increased during exacerbations 
Increased in BAL fluid of COPD patients 
GXCI-8 Interleukin 8 Neutrophil chemoattractant 
Increased in sputum from COPD patients Tumour necrosis 
TNF Induces epithelial cells to release cytokines factor a 
Induces release of matrix metalloproteinases 
Regulates MAPK signalling 
Controls smooth muscle cell proliferation and 
TRIB1 Tribbles protein 1 
chemotaxis 
Modulates TLR signalling 
L--ý 
lable 7 12 Genes of interest and relevance to COPQ atu=-L-Lý' 
The expression of each of these by MDM from non-smokers, smokers and 
COPD subjects, as quantified by microarray, is presented in Table 7.10-12. 
Expression of these genes by non-smoker MDM was unaltered by incubation 
with bacteria (Table 7.13). 
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Gene 
ID 
Log fold 
change 
Average 
Expression 
P Value 
Adjusted P 
value 
CCL20 4.3026722 11.29425 0.00054875 0.47722675 
CXCL1 2.6981296 11.66525 0.00173869 0.69980603 
DUSPI 2.4252365 12.47329 0.00077585 0.5451827 
EGR1 2.3481595 9.666539 0.0008343 0.5451827 
IER3 3.6410399 12.21901 0.00046674 0.43963544 
11-113 3.6537944 11.62184 0.00098492 0.59979284 
11-6 3.1481593 11.16071 0.00270215 0.81737632 
CXCLB 2.212062 12.67937 0.00389844 0.86355252 
TNF 3.964767 12.1962 0.00143922 0.65195682 
TRIBI 1.1695215 11.07003 0.00489676 0.89086742 
Tables 7.13. Differential expression of genes of interest (as identified in Table 7.121 by non. 
d by microarray. 
MDM isolated from non-smoker subjects were incubated for Ih in the presence or absence of 
I mg1ml heat killed H. influenzae. Total RNA was then extracted from the MDM and converted to 
fluorescently labelled cRNA for hybridisation onto Illumina genechips. The fluorescence Of each 
of the probes on the chip was then quantified and data was normalised. A differential 
expression analysis between the two treatment groups was then carried out using R software. 
t4=5. 
Expression of TRIM and DUSPI was significantly upregulated in smoker MDM 
in the presence of bacteria (Table 7.14). 
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Gone ID 
Log fold 
change 
Average 
Expression 
P Value 
Adjusted P 
value 
CCL20 5.1871865 11.1981 0.00207386 0.55493976 
cXCLI 3.7060114 11.12251 0.00150864 0.485706 
DUSPI 3.5476237 12.15939 0.00000846 0.04653096 
EGR1 2.9048203 9.471539 0.00030318 0.22185159 
IER3 5.1660752 11.66852 0.00029283 0.22185159 
11-113 5.1938599 11.38262 0.00119174 0.44991438 
11-6 4.6524041 10.50061 0.0015409 0.485706 
CXCL8 3.1078696 12.31466 0.00198165 0.54218143 
TNF 5.2277904 11.55298 0.00160207 0.48996356 
r-T-R 
IB 2.0024481 11.07953 0.00000009 
I 0.00450965 
xpr Des of intere, (as; idLentified in Tables 7.14. Differential ex ression of genes terest 'g L_L Taable 7JI 2b oker J__NLýý 
, 
MDM as guantified ty microarray. 
MDM isolated from smoker subjects were incubated for 1h in the presence or absence of 
I Mg1ml heat killed H. influenzae. Total RNA was then extracted from the MDM and converted to 
fluorescently labelled cRNA for hybridisation onto Illumina genechips. The fluorescence of each 
of the probes on the chip was 
then quantified and data was normaliSed. A differential 
expression analysis 
between the two treatment groups was then carded out using R software. 
t4=5. 
Expression of all of the genes of interest was significantly increased by COPD 
MDM in the presence of H. influenzae (Table 7.15). 
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Gone ID 
Log fold 
change 
Average 
Expression 
P Value 
Adjusted P 
value 
CCL20 5.716999 9.280939 0 0.00000013 
cXCL1 3.407682 9.757039 0.00000003 0.00005755 
DUSP1 2.8190657 12.0833 0.00000003 0.00006193 
EGRI 2.6828569 8.513008 0 0.00000041 
IER3 5.3685561 10.73044 0 0.0000001 
11-113 5.872856 9.98761 0 0.00000039 
11-6 3.5685462 8.029204 0.00000004 0.00007821 
cXCL8 4.4397775 10.96978 0 0.00000911 
TNF 6.7708664 10.01442 0 0.00000001 
rTR 
1; 17 1.3182441 10.99575 1 0- 
-1 -0.0000 
-xpression of genes of interest (as identified in Table 7.12) by COPQ 
roarray. 
MDM isolated from COPID subjects were incubated for 1h in the presence or absence of 
lmglml heat killed H. influenzae. Total RNA was then extracted from the MDM and converted to 
fluorescently labelled cRNA for hybridisation onto Illumina genechips. The fluorescence of each 
of the probes on the chip was 
then quantified and data was normalised. A differential 
expression analysis between the two 
treatment groups was then carried out using R software. 
N=5. 
Having selected the genes of. interest from the microarray data of COPD MDM 
expression, RT-PCR was performed on RNA from each of the subjects, and the 
gene expression was quantified. 
out of the ten genes selected for further analysis, nine were significantly 
Upregulated by COPD MDM in the presence of bacteria. IER3 was the only 
gene whose expression did not increase, 
in contrast to the microarray data. In 
the smoker samples, IER3, TRIM and EGR1 showed no differential 
expression, whereas TNFa, IL-6. 
CXCL8, IL-10, CCL20, DUSP1 and CXCL1 
were all upregulated. This also contrasts with microarray data, where both 
TRIB1 and DUSP1 were significantly upregulated in response to recognition of 
bacteria. Non-smoker MDM RNA contained significantl .y 
more CCL20, DUSPJ 
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and EGR1 in the presence of bacteria than in the absence. The other 7 genes 
demonstrated no significant difference in expression, contrasting with the 
microarray data, which suggested that expression of none of the 10 genes 
examined by RT-PCR was altered by incubation with bacteria. 
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Figure 7.1. Real time PCR analysis of TNFg expression in the presence and absence of H. 
Lnfluenzae 
RNA was extracted from MDM isolated from non-smoking (m), smoking (a) and COPD subjects 
(m). This was then reverse transcribed to obtain cDNA, and the presence of the gene was 
quantified using TaqMan RT-PCR. Data are presented as ACT, normalised to house-keeping 
gene (HPRT1) expression. Non-smokers n=5, smokers n=5, COPD n=5. 
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R analysis of IL-6 expression in the presence and absence of H. 
influenzae 
RNA was extracted from MDM isolated from non-smoking (m), smoking (a) and COPD subjects 
(s). This was then reverse transcribed to obtain cDNA, and the presence of the gene was 
quantified using TaqMan RT-PCR. Data are presented as ACT, normalised to house-keeping 
gene (HPRT1) expression. Non-smokers n=5, smokers n=5, COPD n=5. 
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Fiqure 7.3. Real time PCR analysis of CXCL8 expression in the Presence and absence of H. 
influenzae 
RNA was extracted from MDM isolated from non-smoking (n), smoking (n) and COPD subjects 
(m). This was then reverse transcribed to obtain cDNA, and the presence of the gene was 
quantified using TaqMan RT-PCR. Data are presented as ACT, normalised to house-keeping 
gene (HPRT1) expression. Non-smokers n=5, smokers n=5, COPD n=5. 
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Fiqur ! 7.4. Real time PCR analysis of IL-1 0 expression in the presence and absence of H.. 
_influenzae 
RNA was extracted from MDM isolated from non-smoking (m), smoking (s) and COPID subjects 
(n). This was then reverse transcribed to obtain cDNA, and the presence of the gene was 
quantified using TaqMan RT-PCR. Data are presented as ACT, normalised to house-keeping 
gene (HPRT1) expression. Non-smokers n=5, smokers n=5, COPD n=5. 
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R analysis of CCL20 expression in the presence and absence of H 
_influenzae 
RNA was extracted from MDM isolated from non-smoking (m), smoking (a) and COPD subjects 
(m). This was then reverse transcribed to obtain cDNA. and the presence of the gene was 
quantified using TaqMan RT-PCR. Data are presented as ACT, normalised to house-keeping 
gene (HPRT1) expression. Non-smokers n=5, smokers n=3, COPD n=5. 
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Figure 7.6. Real time PCR analysis of DUSPI expression in the presence and absence of H 
Lnt7uenzae 
RNA was extracted from MDM isolated from non-smoking (m), smoking (m) and COPID subjects 
(s), This was then reverse transcribed to obtain cDNA, and the presence of the gene was 
quantified using TaqMan RT-PCR. Data are presented as ACT, normalised to house-keeping 
gene (HPRT1) expression. Non-smokers n=5, smokers n=3, COPID n=5. 
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R analysis of IER3 exoression in the presence and absence of H. 
. infflluenzae 
RNA was extracted from MDM isolated from non-smoking (w), smoking (m) and COPID subjects 
(s). This was then reverse transcribed to obtain cDNA, and the presence of the gene was 
quantified using TaqMan RT-PCR. Data are presented as ACT, normalised to house-keeping 
gene (HPRT1) expression. Non-smokers n=3, smokers n=3, COPD n=4. 
238 
1.4- 1.2- 
1.3- 
-0 .; i -0 -; -a *ý 0 1.2- 
CL 
1.0. 
m CL 
Ex 
t- <D 
0.9- 
1.0- 
(L 0.9- 0.8. 
0.8 0.7 
1 
Control Bacteria 
* 
0.95- 
«a 0-) 
0.90- 
CL 
x 0.85- 
0.80- 
0.751 
0. 
Control Bacteria 
Control Bacteria 
R analysis of TRIB1 expression in the presence and absence of H 
Lnt7uenzae 
RNA was extracted from MDM isolated from non-smoking (m), smoking (a) and COPID subjects 
(a). This was then reverse transcribed to obtain cDNA. and the presence of the gene was 
quantified using TaqMan RT-PCR. Data are presented as ACT, normalised to house-keeping 
gene (HPRT1) expression. Non-smokers n=5, smokers n=5, COPD n=5. 
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Figure 7.9. Real time PCR analysis of CXCL1 expression in the presence and absence of H 
influenzae 
RNA was extracted from MDM isolated from non-smoking (m), smoking (s) and COPID subjects 
(n). This was then reverse transcribed to obtain cDNA, and the presence of the gene was 
quantified using TaqMan RT-PCR. Data are presented as ACT, normalised to house-keeping 
gene (HPRT1) expression. Non-smokers n=5, smokers n=5, COPD n=5. 
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Fiqure 7.10. Real time PCR analysis of EGR1 expression in the presence and absence of H. 
_influenzae 
RNA was extracted from MDM isolated from non-smoking (w), smoking (a) and COPID subjects 
(n). This was then reverse transcribed to obtain cDNA, and the presence of the gene was 
quantified using TaqMan RT-PCR. Data are presented as ACT, normalised to house-keeping 
gene (HPRT1) expression. Non-smokers n=5, smokers n=5, COPID n=5. 
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7.4. Discussion 
As an attempt to investigate the mechanism of defective phagocytosis by COPD 
macrophages, gene expression patterns of MDM from non-smoking, smoking 
and COPD subjects were compared. In the absence of stimulation, the only 
gene that was differentially expressed by COPD MDM compared to both control 
groups was SERPINA1. This gene codes for the protease Inhibitor al- 
antitrypsin, and has previously been associated with susceptibility to COPD 
(Ericksson, 1964). The patients involved in this study did not exhibit the early 
onset emphysema that characterises severe al-antitrypsin deficiency, 
therefore, it can be assumed that the lack of this gene may be associated with 
their development of COPD only in combination with an extensive cigarette 
smoking history. In healthy subjects SERPINA1 gene is present as two Identical 
alleles, and it has been suggested that in some COPD patients one of these 
genes is mutated, such that the activity of the inhibitor is reduced (Zorzefto et 
aL, 2008). Therefore, the patients analysed by this study may have developed 
COPD as a result of this increased susceptibility. In addition to SERPINA1, 
SLC7A7 was downregulated in COPD, when compared to MDM from smokers. 
This gene, which is also expressed by human alveolar macrophages, encodes 
a transporter protein that transfers arginine into cells during nitric oxide 
synthesis (Rotoli et aL, 2007). Although this gene has not been studied In 
COPD, mutation can lead to lysinuric protein intolerance, which Is Involved in 
alveolar proteinosis (Parto et aL, 1994). The mechanism by which this gene is 
involved in this condition is not fully understood, but is likely to be due to a build 
up of lipoproteins in the alveolar space (Parto et aL, 1993). These are formed by 
the break down of surfactant, but are not sufficiently cleared due to reduced 
activity of the transporter protein (Broer, 2007). The cause of the disparate 
expression by smoker and COPD cells may be due to a polymorphism of the 
COPD gene that prevented its binding to the SLC7A7 probe. Therefore 
expression levels will appear reduced. Alternatively, expression of this gene 
may confer protection against development of the disease, hence its Increased 
expression by smoker compared to COPD MDM, and its increase in smokers 
compared to non-smokers (although this failed to reach the significance values 
assigned by the Bonferroni correction). 
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The inherent limitation associated with whole genome microarrays Is the 
inability to record the expression of gene polymorphisms. Alterations In the 
genetic code may prevent the binding of the RNA to its associated probe, and 
thus render it unrecognisable. This may be Important in the Investigation of 
defective phagocytosis, as dysfunctional genes would not be recognised. 
Translation of a mutated gene may lead to malfunctioning proteins, which then 
contribute to the defect. For example, enzyme activity is highly dependent on 
correct folding of the protein and a mutation in the genetic code that leads to an 
amino acid substitution may change its chemical properties leading to an 
altered tertiary structure. This in turn could result in a decreased/increased 
activity, and thus an altered function. Therefore, some defective genes in COPD 
that may play a role in reduced bacterial clearance may be undetected. 
The absence of more differentially expressed genes suggests that MDM from all 
groups are similar in mRNA profiles, thus, over or under-expression of a single 
molecule cannot be deemed responsible for defective bacterial clearance. One 
explanation for this finding is that the manner in which MDM respond to bacteria 
may be altered in COPD. For example, the efficiency by which sensing 
molecules, e. g. TLRs, recognise bacteria may be defective, despite an 
apparently normal expression of the receptors at baseline. To Investigate this, 
changes in gene expression following 1h incubation with H. intluenzae by MDM 
were analysed. This data demonstrated that the gene expression response by 
COPD cells is amplified when compared to control MDM. Non-smoker cells did 
not respond to the bacterial stimuli after 1h incubation, whereas smoker cells 
demonstrated a differential expression of 9 genes, which is reduced compared 
to the 162 up or down-regulated genes demonstrated in the COPID MDM profile. 
Of the genes that were upregulated in COPID MDM after incubation With 
bacteria, many were associated with inflammation, e. g. cytokines, chemokines, 
inflammatory mediators and their respective receptors. This suggests that 
following recognition of bacteria, these cells launch an exaggerated 
proinflammatory assault, which is not seen in cells from non-smoker and 
smokers without COPD. Excessive inflammation has been identified in COPD, 
and had been shown to correlate with disease severity (Hogg et aL, 2004). This 
is associated with an influx of inflammatory immune cells and a production of 
mediators, such as CXCLI, CXCL8, TNFa, IL-6 and 1L-1P (Chung & Adcock, 
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2008). Systemic inflammation is also present, for example, concentrations of 
TNFa, IL-6 and CXCL8 are increased In the serum of COPD patients compared 
to controls (Schols et a/., 1996; Yasuda et W., 1998). Therefore, the Increased 
production of genes in response to bacteria is concomitant with the persistent 
inflammation that forms part of the pathophysiology of COPD. 
The microarray findings were validated by RT-PCR analysis of 10 genes. This 
demonstrated discrepancies between the expression patterns produced by the 
two methods. This may be explained by the use of a Bonferroni correction, 
which imposes a reduced significance value In order to avoid false positive 
results. Thus, some differentially expressed genes may have been disregarded 
as they did not reach this value, yet the significance value for the TaqMan data 
was less strict, and therefore more genes were differentially expressed. 
Furthermore, the Taqman data suggested smaller magnitude of Increase In 
expression of some of the genes than identified by microarray analysis. For 
example, there was a log fold increase in TNFa expression by COPD MDM of 
6.8 in the presence of bacteria, yet in the RT-PCR data the ACT Increased from 
approximately 0.8 to 1.1, which even despite the difference In units of 
measurement is a greatly reduced change In expression. Thus it is Important to 
recognise the limitations of comparing these two methods. 
Data presented in this chapter suggests that COPD patient macrophages 
transcribe inflammatory mediator genes following recognition of bacteria, 
however, whether this results in an increased translation and secretion of the 
proteins is not explicit. Studies have shown that chronic cigarette smoke 
exposure results in a decreased LPS induced production of Inflammatory 
cytokines in bronchial epithelial cells, although this is accompanied by a 
reduced mRNA response (Laan et al., 2004). In order to investigate whether the 
increased gene transcription leads to protein synthesis, the secretion of various 
inflammatory mediators by MDM following bacteria exposure would need to be 
quantified. 
The observation that no genes were significantly altered by bacteria In non- 
smoker MDM may indicate that these cells do not mount an inflammatory 
response to pathogens. This seems unlikely given the breadth of knowledge on 
the Induction of inflammatory gene expression In response to bacterial 
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components such as LPS and peptidoglycan (Janeway et W., 2004). Instead, 
the cause of the differing responses of non-smoker, smoker and COPD MDM 
may be due the manner in which the comparison was performed. RNA was 
extracted from MDM after Ih incubation with H. influenzae, as this was the time 
point used for phagocytosis experiments. Therefore the temporal response of 
cells from different disease groups may not converge. For example, while the 
COPD MDM respond immediately, non-smoker and smoker cells require 
bacterial stimulation for longer before protein production Is Induced. In healthy 
individuals, induction of inflammatory gene expression occurs between 3-5 h 
after LPS inhalation (Prabhakar et al., 2005). Alternatively, the signal 
transduction pathways responsible for the gene expression may require 
different levels of stimulation required for activation in different diseases. In this 
case, the threshold for inflammatory gene transcription in COPD MDM may be 
significantly decreased when compared to controls, which would account for the 
increased differential expression by these cells. 
Whether or not the increased genetic response to bacteria demonstrated by 
COPD MDM is associated with defective phagocytosis is unknown. No 
differences in expression of the genes that had been previously suggested to be 
involved in this defect were revealed by the data presented here. This may be 
explained by the finding that gene transcription is Initiated approximately Is 
minutes after recognition of bacterial coat proteins (Chang ot at. 1999). 
suggesting that the increased up- or down-regulated expression of genes 
observed by COPD subjects in response to bacteria does not immediately affect 
their ability to phagocytose. The respiratory burst (the release of ROS from 
mitochondria) which accompanies phagocytosis and is critical for Intracellular 
killing has been shown to have a variety of downstream signalling effects, such 
as activation of NF-KB, which require transcription of genes (Forman & Torres, 
2002) and activation of the macrophage which results in the up-regulation of 
surface receptors and production of cytokines, and chemokines, (as described In 
section 1.2.4. ) also occurs following phagocytosis. Therefore, increased 
expression of inflammatory genes may have consequences for disease 
progression, but not the ability of macrophages to phagocytose. One potential 
link between the two observations may be that in non-smokers and smokers 
without COPD, bacteria are detected by phagocytosis receptors then engulfed 
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in an efficient manner. Therefore, they do not elicit a subsequent inflammatory 
response via activation of other surface receptors. However, in COPD, 
phagocytosis is defective which results in bacteria being bound to the surface of 
the cell, providing extended opportunity to induce inflammatory gene 
transcription. This theory is depicted in Figure 7.11. 
Macrophage 
recognises 
bacteria 
4m 
IM. 
Bacteria are phagocytosed 
I 
Airways remain sterile 
Macrophage 
4 Receptor 
400 4 Bacteria 
Reduced phagocytosis 
I 
B2cteri2l colonisation 
I TNFa 
IL-6 * 
IL-1 ß 
4w 
ow 
40b 
4ow 
Chronic inflammation Inflammatory gene production in response to 
bacterial recognition 
chanism for increased inflammatory qene expression by COPQ MDM 
compared to non-smokers and smokers. 
Macrophages in the airways of non-smokers and smokers without COPID phagocytose invading 
bacteria, thus maintaining sterility. However, in COPID this process is defective, which results in 
increased bacterial colonisation and production of inflammatory mediators by macrophages. 
In conclusion, in the absence of bacterial stimuli, gene expression by COPID 
patients is similar to that of control cells, suggesting that over or under 
expression of a single signalling component is not responsible for defective 
phagocytosis. However, in response to bacteria, these cells increase mRNA 
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COPD Non-smokers/smokers 
expression significantly more than controls, suggesting an Increased 
Inflammatory response that may be due to continuous sensing of bacteria that 
have not been cleared from the extracellular space. This then perpetuates the 
chronic inflammation of the lung which characterises COPD. 
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Chapter 8 
General Discussion 
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8.1 Discussion 
The hypothesis of this thesis stated that MDM isolated from COPD patients are 
less phagocytic than those isolated from subjects without COPD. The data 
presented herein confirms this hypothesis, in respect to clearance of bacteria, 
as phagocytosis of E coli, S. pneumoniae and H. influenzao was reduced by 
MDM from COPD subjects. However, no difference in uptake of polystyrene 
beads was observed. Therefore, COPD macrophages are capable of 
engulfment, but demonstrate a defect in the mechanism required for recognition 
or uptake of pathogens. This suggests that macrophages from COPD patients 
are inherently different to those from non-smokers and smokers without airflow 
obstruction, and contribute to the pathogenesis of the disease. 
The findings presented in this thesis suggest that defective macrophage 
function is not a consequence of direct exposure to cigarette smoke, as the 
MDM were not derived in the lung. The aberrant phagocytic response may, 
therefore, either be a result of a genetic predisposition or due to systemic 
effects of chronic tobacco smoke exposure. If genetic factors alone were 
involved, it is likely that a proportion of the control population would also 
demonstrate the defect. Similarly, systemic effects of smoking cannot be 
entirely responsible for reduced phagocytosis as MDM Isolated from the 
smoking group were capable of clearing bacteria to a similar extent to that of 
non-smoker cells. Therefore, the findings in this thesis suggest a combination of 
genetic predisposition and systemic effects are involved in establishing the 
defective phagocytosis phenotype identified in COPD subjects. 
Whilst defects in the innate immune response to pulmonary pathogens may 
explain the chronic colonisation of bacteria in the airways, an association 
between COPD and infections of other organs has not been demonstrated. For 
example, in a meta-analysis of COPD co-morbidities, there was no association 
between COPD and skin or urinary tract infections, sepsis or diarrhoeal disease 
(Benfield et al., 2008). This suggests that defective macrophage phagocytosis is 
exclusive to the lung. It is possible that pulmonary macrophages behave 
differently to other macrophages around the body, however, the data presented 
in this thesis suggests otherwise; as the MDM (although similar to alveolar 
macrophages as a result of the GM-CSF derivation process) were not matured 
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in the lung, and circulating monocytes are the precursors for all types of 
macrophages. Therefore, the reduced macrophage phagocytosis may occur 
only in response to specific pathogens, such as those which commonly colonise 
the lungs of COPD patients. Since cigarette smoke-induces alterations to other 
defence mechanisms, such as mucus hypersecretion, this would allow bacteria 
to enter the lung, and subsequently colonise. These organisms may then 
downregulate the ability of COPD macrophages to phagocytose, either directly 
or by the release of mediators, thus further prolonging the Infection. However, 
as phagocytosis by non-smoker and smoker IVIDIVI was greater than that of 
COPD MDM, an H. influenzae or S. pneumonlao-induced down-regulation of 
macrophage function alone cannot be the cause of the bacterial colonisation of 
the lungs. This adds further credence to the suggestion that systemic effects of 
cigarette smoke and/or genetic predisposition have an Influence on the 
development of COPD. 
The cellular mechanism for the reduced MDM phagocytosis identified here has 
not yet been fully elucidated. However, defective microtubule rearrangement 
might account for this observation. The process of cytoskeletal rearrangement 
involves the accumulation of post-translational modifications. One such 
modification is acetylation, and this is also associated with microtubule stability. 
These data demonstrate a reduction in acetylated microtubules In COPD MDM. 
A possible explanation for this finding is altered activity of deacetylating 
enzymes. Whilst the cellular expression of HDAC6 and SIM was not 
significantly different in MDM isolated from COPD patients, the ability of these 
enzymes to remove acetyl modifications from microtubules may be Increased 
due to the disease. Alternatively. the acetyltransferase that is responsible for 
acetylating tubulin may be reduced, or its activity may be decreased. It is not yet 
possible to examine either of these as the enzyme involved is currently 
unknown. The presence of other post-translational modifications, such as 
glycosylation and tyrosinsation may also be involved in defective microtubule 
rearrangement, and therefore warrants further investigation. 
Another potential cause of reduced phagocytosis In COPD is Increased S113 
signalling. This is indicated by Increased SIP production by COPD MDM and 
altered phagocytosis in response to manipulation of the pathway. It would be of 
interest to examine an association between altered SIP signalling and defective 
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microtubule rearrangement. The effect of the SIP kinase Inhibitor on 
microtubule acetylation, and conversely the effect of nocodazole or colchicine 
on SIP production would illuminate this mechanism. A prospective relationship 
between these two mechanisms is suggested by the finding that phorbol 12- 
myristate 13-acetate (PMA) induces a decrease In tyrosination of microtubules 
leading to changes in mouse fibroblast morphology, which are reversed by 
treatment with sphingosine (Aplin et aL, 1992). Additionally, SIP Induced 
retraction of pseudopodia by mouse fibroblasts is associated with reorientation 
of the microtubule network (Koh et aL, 2007). However, gene expression 
studies in Chapter 7 did not highlight any differences in these pathways, but this 
may be due to the sensitivity of the assays and would require more detailed 
genetic anaysis. 
Macrophages are not the only phagocytes responsible for bacterial clearance 
within the airways. Whilst the increased numbers of macrophages found In the 
lungs of COPID patients is suggestive of their importance in defence against 
pathogens, other cells are also capable of engulfment. Neutrophils phagocytose 
S. aureus and E coli to a similar extent to macrophages (Nagl et d' 2002). 
Similarly, neutrophil numbers are also increased in the lungs of COPID patients 
(Lacoste et al., 1993), and are important in innate Immune defences. Since 
phagocytosis by COPID macrophages is reduced, it is possible that uptake by 
neutrophils is also decreased. Both cell types rely on substantial cytoskeletal 
rearrangement in order to carry out the process of phagocytosis, and as the 
data presented in this thesis indicates a defect in the action of microtubules In 
COPD, it would be of interest to discover whether this is altered In neutrophils. 
If defective microtubule rearrangement were to exist in COPD neutrophils, it 
may indicate a global defect that affects responses other than phagocytosis. For 
example, chernotaxis also requires the microtubule network, as it is Involved in 
polarising cells, directing them towards a stimulus (Watanabe et aL, 2005). 
Additionally, the chernotactic response of neutrophils from COPD patients is 
increased when compared to controls, which may contribute to the Increased 
presence of these cells in the airways of COPD patients (Bumett et aL, 1987). It 
is plausible therefore, that defective microtubule rearrangement induced by 
chronic exposure to cigarette smoke or a pre-existing susceptibility to the 
development of COPD, may account for increased chernotaxis of neutrophils 
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from patients with the disease. Another function which Is modulated by 
microtubules is autophagy, as demonstrated by findings that HDAC6 mediated 
acetylation of tubulin is essential for autophagic degradation of endogenous 
proteins (Aplin et aL, 1992; Iwata et aL, 2005). This process Is Increased In cells 
isolated from lung tissue samples from COPID patients, when compared to non- 
smoking controls, again suggesting a role for dysregulated microtubule 
rearrangement in the development of COPD (Chen et aL, 2008). 
In addition to the reduced bacterial clearance and Increased exacerbation 
frequency that may result from defective macrophage phagocytosis, there may 
be more widespread consequences to COPD patients. The increased Induction 
of inflammatory genes by COPD MDM following recognition of bacteria, as 
identified by microarray analysis, is suggestive of Inherent differences In the 
manner in which these cells respond to pathogens. This may be the cause of 
the inflammation present in the lungs of COPID patients, as reduced 
phagocytosis results in an extended exposure of COPD macrophages to 
bacteria, thus increasing the opportunity for stimulation. The existing 
inflammation is then further perpetuated, and the vicious cycle of inflammation 
continues as follows: the initial stimulus (bacteria) causes cells in the airways to 
produce antimicrobial peptides, inflammatory mediators and chemoattractant 
proteins. These damage epithelial cells, leading to wound repair mechanisms 
which involve further production of chemokines and cytokines. This also causes 
the infiltration of inflammatory cells, such as lymphocytes and macrophages, 
and consequently the production of yet more inflammatory mediators. Thus the 
inflammation in the lungs of these patients propagates, leading to many of the 
symptoms associated with COPD. For example, chronic bronchitis as a result of 
mucus hypersecretion will occur due to goblet cell hyperplasla. Similarly, MMP 
production by macrophages and neutrophils will be increased. leading to the 
degradation of the extracellular matrix which is associated with the development 
of emphysema. 
An important consideration for analysis of the data presented in this thesis is the 
use of GM-CSF as the macrophage-deriving cytokine. As described In section 
1.2.6., other cytokines are capable of stimulating monocytes to mature Into 
macrophages, although each is known to produce different phenotypes of 
MDM. One explanation for the reduced phagocytic capacity identified here is 
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that COPD MDM respond differently to GM-CSF than cells from non-disease 
controls. There is no difference in the expression of GM-CSF receptors In lung 
biopsies from COPD subjects when compared to non-smoking and smoking 
control subjects (Saha et aL, 2009), but little is known about whether the signal 
transduction pathways activated by ligation of the receptors Is altered by 
disease state. Information on the phagocytic capacity of macrophages derived 
by other stimuli may help elucidate this feature. However, given the wealth of 
data suggesting that GM-CSF derived macrophages closely resemble alveolar 
macrophages care must be taken to ensure that the model used Is still relevant 
to the lung, which raises another potential limitation to the data presented here: 
the use of MDM rather than alveolar cells. As discussed previously, 
bronchoscopic retrieval of lavaged alveolar macrophages Is potentially Injurious 
and the yields are highly variable. Therefore, an MDM model Is an attractive 
method for overcoming these challenges. It would be of Interest to Investigate 
whether, in addition to a genetic susceptibility, the presence of cigarette smoke 
affects the phagocytic behaviour of the macrophages. To address this, 
comparisons of phagocytosis by macrophages, and of differential gene 
expression analysis, should be repeated using alveolar macrophages. 
Another limitation of the work presented here is that correlations between 
phagocytic capacity and pathophysiological features of COPD. COPID Is a 
heterogeneous disease that can manifest itself differently from one patient to 
the next. For example, the degree of emphysema or bronchiolitis varies greatly, 
and can only be determined during a post-mortern examination. Similarly, the 
exacerbation frequency, severity and presence of pulmonary pathogens at the 
time of sampling were not taken into consideration when comparing 
phagocytosis of MDM. Therefore, the effect of a defect in bacterial clearance on 
the long term progression of the disease cannot be established. Additionally, 
the role of reduced phagocytosis on the Inflammatory process was not cleady 
demonstrated. Whilst microarray data suggests that exposure to bacteria results 
in an increased production on inflammatory proteins in COPID MDM. as only the 
rnRNA was quantified it is not possible to state that this is responsible for the 
inflammation identified in the lungs of COPD patients. Instead expression of the 
protein would need to be quantified over longer time periods than those used for 
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phagocytosis assays, and compared to that of non-smoking and smoking 
controls. 
In order to establish the cause of defective phagocytosis, a number of additional 
experiments would be required. Little is known about how COPD macrophages 
respond to bacteria at the signalling level, and this may be of great Interest to 
the advancement of the work presented here. Many signalling molecules, 
including Syk, Rac and Cdc42, are known to be activated downstream following 
ligation of scavenger receptors (Aderem & Underhill, 1999). However, what 
effect COPID may have on the action of these proteins Is not known, yet this 
may be of importance in the regulation of phagocytosis. Many of the signalling 
cascade inhibitors, such as the S1 P kinase antagonist, taxol and TSA may have 
wide ranging effects on the behaviour of the MDM, which are not associated 
m6th the process of phagocytosis. These processes may have indirectly caused 
the reduced bacterial clearance, perhaps by inducing a state of cell 
senescence, or apoptosis. Therefore, more specific targeting of the phagocytic 
control pathways, for example using small interfering RNA (siRNA), is required 
for elucidation of the mechanism of defective phagocytosis. 
Increasing phagocytosis may be a novel treatment target in COPD, given its 
proposed link with bacterial colonisation, exacerbations and Inflammation. 
Increasing the uptake and removal of pathogens would reduce the presence of 
bacteria in the lung and may diminish inflammation. Possible mechanisms for 
increasing phagocytosis by alveolar macrophages Include augmentation of 
microtubule stability. In data presented in this thesis, both taxol and TSA 
increased the uptake of H. influenzae by COPD MDM. Both of these 
compounds are readily available, Taxol has previously been used to treat 
specific forms of cancer and TSA has been widely investigated in in vitro and in 
vivo models of disease (Monneret, 2005; Wiemik et aL, 1987). However, 
concerns about the toxicity of these compounds have been raised (Nuijen et at., 
2001). Therefore, novel microtubule stabilising drugs, that are less toxic, such 
as the newly characterised epothilones, may be a suitable treatment for 
reducing the frequency of pulmonary infections In COPD patients (Cortes & 
Baselga, 2007). 
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Alternatively, the S1 P signalling cascade may provide targets for the restoration 
of macrophage phagocytic function. When treated with an SlP kinase Inhibitor, 
or an SIP receptor antagonist, MDM from COPD patients phagocytosed more 
bacteria. This suggests that modulating the action of SIP may provide a means 
for reducing bacterial colonisation. SIP is implicated In a number of other 
diseases, including multiple sclerosis and various cancers, and treatments that 
alter its functions are currently undergoing clinical trials. The best characterised 
treatment is FTY720, an SlP analogue, which reduces the relapse rate In 
patients with multiple sclerosis (Kappos et aL, 2006). A mechanism by which 
S1P signalling is inhibited and, therefore, phagocytosis Is increased may 
provide a similar improvement in disease pathogenesis for COPD. 
Reducing the frequency of exacerbations would provide significant 
improvements to the lives of COPD patients. These episodes of Infection are 
associated with worsening of symptoms and in some cases, admission to 
hospital, which a study recently demonstrated leads to 38% mortality within the 
following 180 days (Wildman et aL, 2008). Additionally, treatment of 
exacerbations requires a significant amount of resources. It is estimated that the 
NHS spends over E250 million per year on inpatient treatment of COPD patients 
(Pearce, 2006). Furthermore, the usual treatment regimen for COPID 
exacerbations, oral antibiotics, is often ineffective due to widespread antibiotic- 
resistance that has arisen due to inappropriate prescription of the drugs, thus 
reducing the available treatments and extending the duration of many Infections 
(Nseir et aL, 2006). Therefore, a novel means of reducing exacerbations would 
provide extensive benefits. 
Whilst increasing phagocytosis by alveolar macrophages may reduce 
symptoms and provide relief from frequent exacerbations, it Will not prevent the 
development of COPD or reverse its effects. However, the defects Identified In 
this thesis are present in macrophage precursors, suggesting that a 
susceptibility to the disease may exist in COPD patients, prior to their chronic 
cigarette smoke or particulate inhalation. This would explain why approximately 
80% of smokers do not develop the disease. If either reduced microtubule 
stability or altered SIP production could be identified prior to the onset of airflow 
obstruction, it may provide a means for determining which Individuals are at a 
high risk of developing the condition later In life. For example, if defective 
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microtubule rearrangement, as indicated by reduced tubulin acetylation, was 
found to be a biomarker for susceptibility to COPD, screening of smokers 
between the ages of 20-30 years may identify those who are likely to develop 
the disease. 
Over 100 years ago, Sir Almoth Wright identified the role of phagocytes In 
defence against microbial infection. He proposed that stimulating macrophage 
functions provides a mechanism for reducing colonisation (Wright & Douglas, 
1903). The data presented here supports his hypothesis, as increasing the 
clearance of bacteria from the lungs of COPD patients could have wide- 
reaching benefits, both to their respiratory symptoms and quality of life. 
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8.2. Future work 
* Whilst MDM appear to be a good model of alveolar macrophage function, It 
would be beneficial to confirm that reduced uptake of H. influonzao and S. 
pneumoniae also occurs in COPD alveolar macrophages. Similarly, the 
expression of acetylated tubulin and production of SlP would be 
investigated in these cells. 
e The relationship between MDM phagocytosis and exacerbations would be 
examined by comparing the responses of cells isolated from patients during 
an exacerbation to that at baseline. Furthermore, the theory that COPD 
patients can be divided into frequent and Infrequent exacerbators, as 
suggested by Donaldson et aL (2002), would be used to assess the role of 
phagocytosis in determining exacerbation frequency. 
The effect of reduced phagocytosis on airway inflammation could be 
examined using an animal model of COPD. Markers of inflammation would 
be quantified in the lungs of the model organism, and the Influx of 
inflammatory cells following the onset of bacterial infection could be 
examined. Systemic effects of pulmonary bactedal Infections could also be 
investigated, by quantifying the concentrations of serum biomarkers. 
9 To investigate whether either of the proposed mechanisms for the reduced 
phagocytosis (defective microtubule acetylation or altered S1P signalling) 
have other effects on COPD patients, their roles In other macrophage 
functions, such as intracellular killing of bacteria and cytokine production, 
would be examined. Phagocytosis by neutrophils would also be Investigated, 
to assess whether the process of engulfment is deficient in all phagocytes. 
9 The mechanism by which microtubule acetylation is decreased in COPD 
MDM would be investigated. Initially the activity of HDAC6 and SIM would 
be compared in MDM from non-smokers, smokers and COPD subjects. 
Other proteins that are involved in microtubule rearrangement, such as 
dynein would also be examined, as would the presence of other post- 
translational modifications, such as tyrosination and glycosylation. 
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o The cause of the upregulated production of SlP by MDM isolated from 
COPD patients merits further investigation. Possible causes Include altered 
SPHK or S1 P lyase activity. The presence of S1 P in sputum and BAL would 
also be examined to assess whether the defect is also present In the 
airways of these patients. 
9 The role of SlP in phagocytosis is relatively poorly understood. Therefore, 
examination of the roles of the different S1P receptors may provide potential 
mechanisms for increasing engulfment. A potential link between S1P and 
microtubule rearrangement would also be investigated by augmentation of 
one (by treatment with either nocodazole, colchicine or SPHKI) and 
quantification of the other (e. g. microtubule acetylation or Sl P production). 
9 Further examination of the increased inflammatory response by COPD 
subjects would elucidate the cause of the differences between these and 
cells from control subjects. Incubating the MDM for different times and with 
different concentrations of bacteria would demonstrate whether the Induction 
of inflammatory gene transcription occurs earlier in COPD cells or if they are 
more sensitive to the effects of bacteria. 
Throughout the investigations carried out in this thesis, there have been 
various differences in the responses of cells depending on the bacterial 
stimuli used. Therefore, MDM phagocytosis of other bacteria (both Gram 
positive and Gram negative) would be carried out. 
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Appendix 1 
TaqMan probes sequences used in Chapter 7: 
Gene Sequence 
CCL20 ctcctcagtaaaaaagtcaagaacatgtaaaaactgtggcttttctggaatggaattggacatagcccaa 
gaacagaaagaaccttgctggggttg 
CXCLI gtgacaaatccaactgaccagaagggaggaggaageteactggtggctgttcctgaaggaggccctg 
cc 
gtgcagttftgccaaggagtgctaaagaacttagatgtr-agtgcataaagaeatactccaaaedttccac 
CXCL8 
cccaaafttatcaaagaactgagagtgattgagagtggac 
DUSP1 tcatagactcoatcaagaatgctggaggaagggtgtttgtcractgccaggcaggcatttcccgg 
EGRI agtcttttcctgacatctetctgaacaacgagaaggtgctggtggagaccagttaccccagccaaa=c 
tc 
IER3 ctgctcaccatcgtcttctgccagatcctgatggctgaagagggtgtgcoggegeccctgectecagagg 
acgcccctaacgccgeatccctggc 
IL-1p Agtggtgttctccatgtcctttgtacaaggagaagaaagtaatgacaaaatacctgtggccttgggr-ctca 
aggaaaagaatctgtacctgtcc 
I L-6 cttgcctggtgaaaatr-atcactggtcttttggagtttgaggtatacctagagtaectcragaacagatttga 
gagtagtgaggaacaagccaga 
TNFa gcaaaccctcaagctgaggggcagctceagtggctgaaccgccgggccaatgccctcctggccaatg 
gcgtggagctgag 
TRIM ftcccattaaar-actacr-aggae2aaatcaggccttacatccagctgccategr-acagr-aacattactg 
gcaftgtgg 
HPRT aaggaccccaegaagtgttggatataagccagactttgftggatftgaaattccagar-aagtttgttgtagg 
atatgcccftgactataatgaatacftcagggatttgaateatgtttgtgtcatt 
Table Al. 1. Tagman- RT-PCR pmbe sequences, 
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Appendix 2 
The 100 most differentially expressed genes by MDM at baseline. 
Non-smokers vs. smokers: 
Gene Log fold 
change 
Average 
expression P value 
Adjusted P 
value 
ZP3 -1.547 9.093 0.0001376 0.9997300 
ZP3 -1.270 7.527 0.0001508 0.9997300 
HS. 565901 -0.205 6.143 0.0002964 0.9997300 
HS. 574845 -0.231 5.831 0.0003639 0.9997300 
FLJ39061 -0.194 5.816 0.0005977 0.9997300 
HS. 112899 0.164 5.628 0.0008751 0.9997300 
HS. 529547 -0.157 5.532 0.0009755 0.9997300 
LOC650836 0.217 5.655 0.0009973 0.9997300 
CRB3 0.274 5.772 0.0010748 0.9997300 
HS. 413193 0.204 5.548 0.0011506 0.9997300 
HS. 541125 -0.208 5.660 0.0012196 0.9997300 
KISS1R -0.236 5.910 0.0012515 0.9997300 
PWWP2 -0.162 5.798 0.0012724 0.9997300 
HS. 537188 0.238 5.891 0.0014824 0.9997300 
CDC42BPA 0.415 6.854 0.0015714 0.9997300 
IFNA10 -0.163 5.690 0.0017138 0.9997300 
HS. 540730 0.172 5.783 0.0018034 0.9997300 
HS. 130203 -0.160 5.702 0.0018250 0.9997300 
RNF14 -0.151 5.790 0.0018385 0.9997300 
LOC145837 -0.141 5.706 0.0019699 0.9997300 
TRIM6 0.751 6.888 0.0019734 0.9997300 
DLX4 -0.156 5.644 0.0019914 0.9997300 
HS. 540592 0.192 5.632 0.0021185 0.9997300 
HS. 564546 -0.182 5.641 0.0022175 0.9997300 
HS. 121070 0.145 6.526 0.0022423 0.9997300 
HS. 541161 -0.188 5.867 0.0023768 0.9997300 
HS. 560749 0.247 5.747 0.0025498 0.9997300 
HS. 304253 0.146 5.785 0.0025569 0.9997300 
HS. 563669 0.204 5.535 0.0025588 0.9997300 
HS. 539976 0.204 5.597 0.0028472 0.9997300 
300 
LOC644276 -0.209 5.718 0.0029184 0.9997300 
ETFA -0.229 11.967 0.0029277 0.0997300 
HS. 54471 9 0.149 5.638 0.0029363 0.9997300 
ACTUA -0.184 5.693 0.0030011 0.9997300 
LOC649060 0.161 5.778 0.0030171 0.9997300 
HS. 543826 0.146 5.638 0.0030524 0.9997300 
HS. 159975 0.164 5.721 0.0030611 0.9997300 
HS. 541015 0.154 5.689 0.0032598 0.9997300 
HS. 582329 -0.154 5.981 0.0034120 0.9997300 
HS. 579968 0.141 5.704 0.0034898 0.9997300 
SKP2 -0.241 6.642 0.0034975 0.9997300 
HYDIN -0.247 6.359 0.0035763 0.9997300 
Hs. 433029 0.193 5.592 0.0036197 0.9997300 
RYRI 0.638 7.499 0.0036388 0.9997300 
MGC40489 -0.232 6.584 0.0036773 0.9997300 
NDUFA12L 0.518 9.064 0.0036926 0.9997300 
HS. 563926 0.146 5.858 0.0037241 0.999'7300 
HS. 444692 -0.144 5.743 0.0037401 0.9997300 
LOC652647 0.179 6.018 0.0038076 0.9997300 
HS. 560714 0.148 5.654 0.0038333 0.9997300 
HS. 544199 0.177 5.538 0.0038938 0.9997300 
HS-148889 0.209 5.597 0.0039438 0.9997300 
HS. 581415 0.187 5.566 0.0039541 0.9997300 
MGC39545 -0.193 6.041 0.0039720 0.9997300 
C90RF153 -0.167 5.714 0.0040583 0.9997300 
FAM9OA2P 0.162 5.521 0.0041692 0.9997300 
LOC389102 0.143 5.699 0.0042902 0.9997300 
HS. 149004 -0.186 5.502 0.0043638 0.9997300 
TRPC6 -0.209 5.798 0.0045455 0-99973DO 
HS. 573478 0.142 5.814 0.0045806 0.9997300 
LOC653589 0.210 5.708 0.0045887 0.9997300 
HS. 540258 -0.146 5.549 0.0045912 0.9997300 
HS. 580847 -0.157 5.491 0.0046291 0.9997300 
C120RF12 0.159 5.819 0.0047597 0.9997300 
GOT1 0.254 10.539 0.0048349 0.9997300 
HS. 534711 -0.144 5.690 0.0048715 0.9997300 
HS. 540542 0.188 5.589 0.0048978 0.9997300 
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LOC643747 -0.158 5.810 0.0049458 0.9997300 
HS. 563367 0.249 5.494 0.0049474 0.9997300 
SMYD5 0.201 6.252 0.0050096 0.9997300 
HS. 559956 -0.153 5.729 0.0050365 0.9997300 
GPATC4 0.139 5.908 0.0050699 0.9997300 
ABCD4 0.158 5.739 0.0050971 0.9997300 
HS. 542884 0.182 5.599 0.0051225 0.9997300 
HS. 576048 -0.130 5.686 0.0051927 0.9997300 
TMEM10 0.159 5.578 0.0052301 0.0997300 
HS. 571900 -0.143 5.638 0.0053643 0.9997300 
LOC646038 -0.339 6.609 0.0054097 0.9997300 
CCR2 0.157 5.617 0.0054186 0.9997300 
LOC653050 0.147 5.668 0.0055030 0.9997300 
HS. 209381 -0.403 7.498 0.0055085 0.9997300 
CHRNA4 0.132 5.783 0.0055328 0.9997300 
HS. 580665 0.199 5.832 0.0055412 0.9997300 
PIK3CG 0.581 10.432 0.0055875 0.9997300 
LOC645218 0.166 5.787 0.0056076 0.9997300 
HS. 284450 -0.178 5.606 0.0056126 0.9997300 
HS. 282828 0.178 5.975 0.0056584 0.9997300 
ORM1 1.304 6.624 0.0057061 0.9997300 
HS. 365071 -0.204 5.800 0.0057315 0.9997300 
LOC401589 0.117 5.768 0.0057599 0.9997300 
PAK3 0.172 5.914 0.0057813 0.9997300 
LOC645362 -0.291 6.242 0.0058132 0.9997300 
HS. 541590 -0.148 5.811 0.0059366 0.9997300 
HS. 580187 0.164 5.739 0.0059648 0.9997300 
LOC441632 -0.147 5.629 0.0059999 0.9997300 
HS. 564554 0.121 5.621 0.0060235 0.9997300 
HS. 538966 -0.153 5.594 0.0061216 0.9997300 
LOC645123 0.172 5.721 0.0061542 0.9997300 
HS. 562914 0.230 5.610 0.0062125 0.9997300 
HS. 382374 -0.149 5.718 0.0062902 0.9997300 
Table A2.1. Whole gene expression analysis compadson of non-smoker vs, smoker MDM. 
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Non-smokers vs. COPD: 
Gene Log fold 
change 
Average 
expression 
P value 
Adjusted P 
value 
SERPINA1 -2.026 12.506 0.0000001 0.0030452 
RGS20 1.030 6.562 0.0000096 0.1257731 
SLC7A7 -0.591 12.945 0.0000105 0.1257731 
SMAD7 -0.787 8.333 0.0000112 0.1257731 
HS. 571422 0.552 6.387 0.0000139 0.1257731 
FLJ38482 0.496 8.758 0.0000156 0.1257731 
IKIP 0.649 8.275 0.0000238 0.1257731 
CLECIA -1.114 8.203 0.0000258 0.1257731 
CCDC132 0.458 9.346 0.0000347 0.1257731 
TLR8 -1.855 10.543 0.0000369 0.1257731 
NOD2 -1.477 7.321 0.0000372 0.1257731 
PGM5 -1.842 9.259 0.0000376 0.1257731 
ACVR1B -1.074 9.695 0.0000396 0.1257731 
BRSK2 0.284 5.947 0.0000400 0.1257731 
HEBP1 0.702 11.367 0.0000415 0.1257731 
133GNT8 0.794 6.937 0.0000442 0.1257731 
IMMP21- 0.567 7.702 0.0000464 0.1257731 
VEGFB 0.558 12.831 0.0000465 0.1257731 
MF12 1.109 7.069 0.0000529 0. i-2-83333 
C30RF54 1.374 7.063 0.0000558 0.1283333 
C170RF76 0.479 7.259 0.0000575 0.1283333 
SLC4A8 0.694 7.106 0.0000620 0.1283333 
CHST10 0.446 6.305 0.0000640 0.1283333 
FCN1 -2.129 10.122 0.0000655 0.1283333 
PGM5 -1.762 9.017 0.0000695 0.1283333 
ALDH2 -1.660 11.175 0.0000695 0.1283333 
RAPGEF3 0.903 9.972 0.0000714 0.1283333 
STOM -1.086 12.873 0.0000738 0.1283333 
RAB61P1 -1.004 10.177 0.0000898 0.1476842 
NDP -3.852 8.725 0.0000937 0.1476842 
APPBP1 0.382 10.791 0.0000940 0.1476842 
BTLA -0.600 6.696 0.0000981 0.1492329 
FBX05 -0.582 7.500 0.0001048 0.1546724 
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GIMAP8 -1.968 9.803 0.0001105 0.1583098 
RTNI -1.098 10.191 0.0001160 0.1613544 
DUSP13 1.389 7.808 0.0001213 0.1640304 
S1 OOA8 -2.662 11.475 0.0001284 0.1689724 
KIA-Al 706 0.988 7.898 0.0001340 0.1716923 
CCR2 -0.613 6.383 0.0001663 0.2034348 
ST6GALl -1.064 12.092 0.0001671 0.2034348 
SyTi 1 -0.952 7.803 0.0001741 0.2039245 
STM 1 -1.104 11.539 0.0001759 0.2039245 
PLEKHG3 -1.758 7.306 0.0001866 0.2076546 
OXT 1.071 6.872 0.0001899 0.2076546 
ABCC5 0.859 8.383 0.0001979 0.2076546 
CTSC -0.560 6.528 0.0001990 0.2076546 
ATP6VlD 0.810 12.773 0.0002004 0.2076546 
STX2 0.987 9.691 0.0002178 0.2209726 
AQP8 1.255 7.187 0.0002332 0.2318121 
CPB2 0.473 6.225 0.0002491 0.2405618 
CFB -2.444 8.608 0.0002519 0.2405618 
CATSPER2 0.577 6.885 0.0002744 0.2565215 
ADAMDEC1 -3.278 9.513 0.0002826 0.2565215 
C20ORF82 1.195 6.408 0.0002935 0.2565215 
SERPINB6 0.558 12.755 0.0003033 0.2565215 
FBXL2 0.450 6.268 0.0003035 0.2565215 
LM04 -1.217 10.551 0.0003044 0.2565215 
SCCPDH 0.546 9.033 0.0003139 0.2565215 
RHEB 0.272 12.373 0.0003155 0.2565215 
ITGBlBP3 1.956 7.251 0.0003209 0.2565215 
LOC197322 0.390 6.329 0.0003293 0.2565215 
REPS2 0.875 7.158 0.0003298 0.2565215 
ATP51 0.529 6.253 0.0003322 0.2565215 
ITGBlBP3 1.239 6.365 0.0003371 0.2565215 
FAM20A -1.280 7.448 0.0003592 0.2596617 
HSPA4L 0.285 6.184 0.0003602 0.2596617 
DUSP13 0.380 5.988 0.0003606 0.2596617 
HS. 541125 -0.241 5.660 0.0003626 0.2596617 
N4BP1 -0.226 6.062 0.0003716 0.2622993 
HS. 535360 0.636 7.080 0.0003772 0.2624576 
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ATP8B2 -0.906 6.755 0.0003867 0.2652204 
MGC33556 -1.612 7.438 0.0003986 0.2672734 
BCL3 -1.263 7.318 0.0004089 0.2672734 
SPINT2 -1.141 10.231 0.0004111 0.2672734 
LOC647166 0.206 5.697 0.0004140 0.2672734 
TNFAIP6 -2.838 10.734 0.0004171 0.2672734 
DARS2 0.485 9.540 0.0004302 0.2702924 
SNAG1 -0.200 5.962 0.0004329 0.2702924 
PWWP2 -0.184 5.798 0.0004394 0.2708750 
TMEM99 0.864 8.486 0.0004487 0.2731286 
NHS 1 -0.516 6.051 aOO04727 0.2823668 
BPHL 0.536 8.608 0.0004754 0.2823668 
LOC283340 0.954 8.970 0.0005079 0.2936969 
BCKDHB 0.363 7.476 0.0005098 0.2936969 
TSPAN17 0.715 12.615 0.0005166 0.2936969 
RAB34 -0.634 8.795 0.0005186 0.2936969 
ITK -1.824 7.459 0.0005441 0.3027817 
SEC22C 0.456 9.330 0.0005512 0.3027817 
TNFSFIO -3.005 9.087 0.0005533 0.3027817 
PRR3 -0.305 6.700 0.0005691 0.3079378 
ABCA3 0.341 6.530 0.0005782 0.3089638 
PLXNA2 0.814 6.641 0.0005888 0.3089638 
RTN4R 1.208 8.958 0.0005900 0.3089638 
FABP3 0.743 6.798 0.0005992 0.3104352 
CDH23 0.883 6.882 0.0006280 0.3219267 
FARP1 1.573 8.034 0.0006372 0.3231728 
MANEAL 0.671 6.910 0.0006498 0.3231728 
HSPA6 -1.934 8.514 0.0006541 0.3231728 
FBX038 1.097 10.126 0.0006570 0.3231728 
HS-122453 1.122 7.372 0.0006897 0.3320068 
Table A2.2. Whole gene expression analysis compadson of non-smoker VS. COPD MDM. 
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Smokers vs. COPD: 
Gene Log fold change 
Average 
expression P value 
Adjusted P 
value 
SERPINA1 1.944 12.506 0.0000001 0.00508311 
SLC7A7 0.713 12.945 0.00000126 0.0307833 
RGS20 -1.133 6.562 0.00000332 0.05ID4428 
HS. 571422 -0.615 6.387 0.00000419 0.05ID4428 
ETFA -0.450 11.967 0.00000571 0.05237955 
RAPGEF3 -1.128 9.972 0.00000693 0.05237955 
RAB61P1 1.249 10.177 0.00000937 0.05237955 
RHEB -0.380 12.373 0.00001147 0.05237955 
APPBP1 -0.468 10.791 0.00001169 0.05237955 
FLJ38482 -0.509 8.758 0.00001188 0.05237955 
BPHL -0.779 8.608 0.00001243 0.05237955 
TLR8 2.050 10.543 0.00001291 0.05237955 
STOM 1.273 12.873 0.0000143 0.05357279 
AQP8 -1.602 7.187 0.00002093 O. D6314432 
LILRB1 1.846 8.118 0.00002129 0.06314432 
REPS2 -1.155 7.158 0.00002193 0.06314432 
ACVRIB 1.137 9.695 0.00002204 0.06314432 
IMMP21- -0.598 7.702 0.0000271 0.07204641 
BCKDHB -0.490 7.476 0.00002957 0.07204641 
NOD2 1.510 7.321 0.00002959 0.07204641 
AKR7A2 -0.715 12.637 0.00003408 0.07903212 
SLC35F3 -1.053 7.509 0.00003683 0.08153048 
ALDH2 1.759 11.175 0.00003871 0.08195606 
LOC283340 -1.233 8.970 O-OOOD4557 0.09248D47 
SLC4A8 -0.704 7.106 0.00005418 0.10080942 
CFDP1 -0.591 9.195 0.00005513 0.10080942 
C11ORF45 -1.340 10.234 0.00005589 0.10080942 
ST6GAI-1 1.176 12.092 0.00006339 0.1102565 
S100AB 2.824 11.475 0.00007242 0.11939143 
FLYWCH1 -0.484 6.552 0.00007509 0.11939143 
MGST1 -0.874 12.654 0.00007601 0.11939143 
FBX05 0.600 7.500 0.00007845 0.11939143 
IKIP -0.561 8.275 0.00010369 0.15012242 
PGM5 1 1.661 9.259 0.00010538 1 0.1501 ýý 
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EIF4A3 -0.439 11.676 0.00010853 0.15012242 
ALPL -1.791 7.501 0.00011097 0.15012242 
SP140 1.701 7.942 0.0001196 0.1560642 
TACC2 -1.713 8.745 0.00012177 0.1560642 
VEGFB -0.498 12.831 0.00014211 0.17393674 
CLECIA 0.938 8.203 0.00014286 0.17393674 
SL - 5A4 -0.988 7.763 0.00014812 0.1759451 
HK1 0.706 11.897 0.00015938 0.18481211 
MGC33556 1.773 7.438 0.00016802 0.18749779 
PHACTR2 0.595 10.969 0.00017032 0.18749770 
ITGBIBP3 -2.082 7.251 0.00018157 0.18749779 
CAPN3 -1.950 8.257 0.00018257 0.18749779 
STxll 1.098 11.539 0.00018438 0.18749779 
RAB34 0.710 8.795 0.00018605 0.18749779 
SKP2 -0.345 6.642 0.00018865 0.18749779 
MGLL -1.231 7.095 0.00019848 0.18823925 
MANEAL -0.767 6.910 0.0001995 0.18823925 
C30RF54 -1.203 7.063 0.00020099 0.18823925 
EDG2 1.107 9.380 0.00021063 0.18978564 
SEC22C -0.508 9.330 0.0002114 0.18978564 
C20ORF82 -1.233 6.408 0.00021971 0.18978564 
MNAT1 -0.484 8.241 0.00022201 0.18978564 
OXT -1.053 6.872 0.00022271 0.18978564 
NPL -0.681 12.671 0.00022602 0.18978564 
MTHFDlL 0.605 8.196 0.00023857 0.19505399 
HS. 560714 0.209 5.654 0.00024031 0.19505399 
MF12 -0.942 7.069 0.00025278 0.19674485 
AVPll -0.461 11.462 0.00026589 0.19674485 
NRSN2 0.443 6.413 0.00027063 0.19674485 
HEBP1 -0.578 11.367 0.00027111 0.19674485 
FABP5 -1.138 10.935 0.00027333 0.19674485 
ITGBlBP3 -1.267 6.365 0.00027681 0.19674485 
PGM5 1.521 9.017 0.0002791 0.19674485 
WDR33 -0.270 7.518 0.0002822 0.19674485 
HSPA4L -0.293 6.184 0.00028547 0.19674485 
TSPAN17 -0.765 12.615 0.00028705 0.19674485 
GIMAP8 1.77 4 9.803 0.00029086 0.19674485 
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PLEKHG3 1.674 7.306 0.00029087 0.19674485 
SYTII 0.896 7.803 0.00030131 0.19871168 
PLXNA2 -0.878 6.641 0.00030194 0.19871168 
UNC84B 0.786 9.712 0.00030869 0.20044605 
ABCC5 -0.815 8.383 0.00031907 0.20277226 
ATP51 -0.531 6.253 0.0003206 0.20277226 
LOC730051 -0.695 6.858 0.00032596 0.20351887 
CFB 2.358 8.608 0.00034677 0.21337051 
DUSP13 -1.238 7.808 0.0003505 0.21337051 
CCR2 0.564 6.383 0.0003554 0.21368024 
LOC651834 0.199 5.643 0.00036604 0.21739683 
HBA2 -0.717 6.404 0.00037413 0.21952371 
LOC644150 -1.388 6.528 0.00039301 0.22785425 
GK 1.544 9.649 0.00040505 0.23083827 
HS. 122453 -1.193 7.372 0.00041004 0.23083827 
LOC643747 -0.218 5.810 0.0004161 0.23083827 
HS. 538713 -0.255 5.796 0.00042033 0.23083827 
GBA3 -0.223 5.655 0.00042391 0.23083827 
SERPINB6 -0.536 12.755 0.00043174 0.23083827 
CTDSP2 0.801 11.114 0.00043601 0.23083827 
FLJ39061 -0.201 5.816 0.00043607 0.23083827 
GLMN -0.634 8.652 0.00048191 0.25235853 
TNFAIP6 2.771 10.734 0.00051235 0.26309335 
FNDC5 -0.476 5.977 0.00051998 0.26309335 
FAM20A 1.225 7.448 0.00052688 0.26309335 
RHBDFI -0.907 10.970 0.0005275 0.26309335 
ST8SIA4 0.868 7.141 0.00052942 0.26309335 
JAK2 1.172 8.703 0.00053793 0.2646246 
STX2 -0.890 I-- 
9.691 
I- 
0.00054556 0.26569541 
Table A2.3. Whole qene expression analvsis comoadson of smoker vs, COPD MDM. 
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Appendix 3 
The 100 most differentially expressed genes In the absence and presence of bacteria 
by MDM. Non-smokers: 
Gene Log fold change 
Average 
expression P value 
Adjustod P 
value 
CCU 0.873 9.953 0.00000596 0.11839996 
PTP4A2 0.557 9.581 0.00000783 0.11839996 
HS. 439642 0.779 6.329 0.00000922 0.11839996 
HES1 0.480 6.234 0.00001085 0.11839996 
LOC65361 0 0.542 7.871 0.00001311 0.11839990 
SNORD13 1.614 8.380 0.00001532 0.11839996 
HS. 550293 0.645 7.003 0.00001702 0.11839996 
SCARNA9 1.326 9.302 0.00002326 0.14159975 
HS. 126187 0.747 6.248 0.00002666 0.14426357 
HS. 580797 0.694 9.886 0.0000302 0.14705492 
LOC647389 0.664 8.948 0.00004125 0.18261059 
TMEM88 0.668 6.649 0.00005565 0.21261778 
HS. 163752 0.683 9.613 0.00006318 0.21261778 
ATG10 0.400 8.242 0.00006424 0.21261778 
HS. 193767 0.564 6.849 0.00006859 0.21261778 
PDE6H 1.318 7.202 0.00006985 0.21261778 
HS. 544637 0.527 9.141 0.00007458 0.21364275 
HS. 562219 0.787 6.528 0.00010212 0.26372416 
HOXA5 0.594 7.216 0.00010289 0.26372416 
STMN3 -0.666 7.461 0.00011202 0.27277956 
HS. 543887 0.567 6.215 0.00012176 0.28027582 
CXCL9 0.556 10.233 0.00012661 0.28027582 
LOC85389 0.366 6.392 0.00015549 0.31644953 
KLF6 0.900 6.900 0.00015595 0.31644953 
BTG2 1.460 10.796 0.00017055 0.33224097 
CD300LB -0.307 6.827 0.00017955 0.33537467 
RN7SK 0.405 6.180 0.0001933 0.33537467 
LOC647346 -0.379 10.543 0.00019799 0.33537467 
LOC731003 0.315 6.091 0.00020263 0,33537467 
RBMS1 0.357 7.679 0.00021773 0.33537467 
HS. 562875 0.448 7.324 0.00022061 0.33537467 
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HS. 571616 0.725 6.396 0.00022663 0.33537467 
HS. 543824 0.446 5.805 0.00022725 0.33537407 
YRDC 0.383 9.619 0.00026194 0.37510379 
HS . 278948 0.959 6.340 0.00028139 0.39154326 
CTSC -0.334 6.643 0.00029594 0.3980073 
GADD45G 0.718 10.017 0.00030238 0.3980073 
GADD45B 1.516 10.172 0.00032177 0.4113145 
NCBP2 -0.316 10.504 0.00032938 0.4113145 
HS. 575034 0.476 8.031 0.00033979 0.41370394 
SLC5A8 0.363 7.246 0.00035127 0.41725334 
sloop 0.514 7.252 0.00036378 0.42182287 
Pimi 0.692 13.070 0.00038123 0.42770942 
HS. 541829 0.556 6.930 0.00038747 0.42770942 
MAP3K5 0.318 10.614 0.00039521 0.42770942 
RPGRIPl 0.275 6.586 0.00041695 0.43963544 
ABCC3 -0.508 10.879 0.00042833 0.43963544 
TEX261 -0.280 10.815 0.0004492 0.43963544 
HS. 560357 0.666 8.460 0.00045606 0.43963544 
NFYA -0.267 6.848 0.00046344 0.43963544 
IER3 3.641 12.219 0.00046674 0.43963544 
HS. 563486 0.415 6.080 0.00046942 0.43963544 
ARPC4 -0.285 11.564 0.00051794 0.4759291 
PPP2R5C 0.277 7.094 0.00053064 0.47722675 
RPL1 5 -0.319 11.721 0.00054049 0.47722675 
CCL20 4.303 11.294 0.00054875 0.47722675 
HS. 542993 0.495 8.565 0.00056973 0.48677622 
KCNJ2 0.970 9.194 0.00060255 0.50594199 
HS. 573356 0.287 6.225 0.00062811 0.51846504 
FAMIOOB 0.528 10.978 0.00064459 0.52320171 
TRKI 0.362 6.565 0.00066015 0.52705002 
PRDM8 0.968 7.222 0.00069292 0.54428973 
LOC643882 0.309 6.966 0.00073196 0.5451827 
IQWDI -0.405 11.283 0.00075036 0.5451827 
LOC642333 0.443 9.968 0.0007516 0.5451827 
C150RF44 -0.324 7.734 0.00075365 0.5451827 
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DUSPI 2.425 12.473 0.00077585 0.5451827 
LOC399900 0.367 6.214 0.00077619 0.5451827 
GALNT3 0.295 7.063 0.00079754 0.5451827 
Cl ORF63 -0.438 7.739 0.00079784 0.5451827 
LOC441087 0.400 13.024 0.00080218 0.5451827 
BCL2AI 0.731 10.792 0.00081579 0.5451827 
ACCN2 -0.334 6.889 0.00082017 0.5451827 
EGRI 2.348 9.667 0.0008343 0.5451827 
LMOD3 0.499 8.897 0.00083959 0.5451827 
HS. 25892 0.670 8.803 0.00086013 0.55117626 
IFNAI 0.234 5.682 0.00088415 0.55920547 
PLDN -0.262 9.525 0.00091456 0.57102744 
ILIB 3.654 11.622 0.00098492 0.59979284 
C70RF38 0.551 11.005 0.00100794 0.59979284 
ADAM28 -0.279 6.580 0.00101787 0.59979284 
MRPS27 -0.264 9.252 0.00103909 0.59979284 
CHANA 0.244 7.835 0.00104081 0.59979284 
YTHDF3 -0.240 9.585 0.00104332 0.59979284 
CCULI 2.482 11.572 0.00104684 0.59979284 
ZFP36 2.324 11.556 0.00106156 0.6011525 
LEPREL2 -0.311 6.536 0.00107651 0.60261311 
copi 0.357 7.473 0.00109071 0.60362032 
HS. 562122 0.379 8.221 0.00112505 0.61562905 
HS. 571946 0.347 6.941 0.0011743 0.63544091 
NFKBIZ 2.719 11.810 0.00120827 0.63618956 
HS. 184721 1.032 7.553 0.00122776 0.63618956 
C20ORF123 0.461 10.678 0.00122962 0.63618956 
HIST2H2AC 0.348 10.998 0.00123178 0.63618956 
Cl ORN 19 -0.367 9.443 0.00125503 0.63618956 
LOC727820 0.247 7.475 0.00126437 0.63618956 
PGK1 -0.251 12.791 0.00127497 0.63618956 
HS. 571206 0.261 7.069 0.00128019 0.63618956 
LOC85390 0.423 6.556 0.00129873 0.63888165 
Table All, Whole gene expression analgis of non-smoker MDM In the Dresence and. -Bbse= 
of bacteda. 
Smokers: 
Gene Log fold 
change 
Average 
expression 
P value 
Adjustad P 
valuo 
TRIBI 2.002 11.080 0.00000009 0.00450965 
PDGFB 0.893 6.750 0.00000202 0.04076287 
KLF6 1.201 13.334 0.00000251 0.04076287 
ARI-513 1.534 7.807 0.00000355 0.04326615 
BTG2 2.175 10.477 0.00000514 0.04653096 
OTUDI 1.147 9.829 0.00000607 0.04653090 
PLEKHF2 0.947 9.545 0.00000833 0.04653096 
DUSPI 3.548 12.159 0.00000846 0.04653096 
THBD 0.972 6.649 0.0000086 0.04653096 
LOC642035 2.051 7.101 0.00001088 0.05269534 
NFE21-2 0.764 11.868 0.00001296 0.05269534 
TA-NFKBH 1.614 7.649 0.00001339 0.05269534 
GPR175 0.531 9.092 0.00001504 0.05269534 
KLF6 1.586 11.933 0.00001515 0.05269534 
ZNF689 -0.757 8.801 0.00001651 0.05359023 
PHLDAI 2.093 9.364 0.00001761 0.05359909 
RASGEFI B 0.972 8.107 0.00002085 0.05733556 
ARRDC3 1.021 8.348 0.00002119 0.05733556 
IER2 0.867 7.188 0.00002339 0.05993459 
RHOB 1.494 8.627 0.00002461 0.05993459 
SESM 0.663 9.920 0.00002661 0.06170714 
RAP2C 0.502 10.291 0.00003507 0.07516175 
OSR2 1.692 7.110 0.00003603 0.07516175 
HBEGF 1.214 8.927 0.00003964 0.07516175 
OLR1 0.628 11.886 0.0000402 0.07516175 
SLC2A3 0.562 11.875 0.00004309 0.07516175 
GADD45B 2.355 10.079 0.00004409 0.07516175 
BHLHB2 1.178 13.286 0.00004413 0.07516175 
PPP1R15B 0.719 7.390 0.00004627 0.07516175 
RPUSD2 -0.629 8.919 0.0000463 0.07516175 
PLAU 1.366 11.552 0.00004998 0.07803224 
PTGER4 1.353 12.247 0.00005127 0.07803224 
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KLF6 0.886 6.654 0.00006072 0.0896112 
RGSI 1.773 12.303 0.00006390 0.09113009 
DUSP2 2.454 10.369 0.00006549 0.09113099 
HSPAIA 1.360 12.237 0.00006807 0.0912551 
BRF2 -0.597 7.478 0.00006933 0.0912551 
I ZNF217 1 0.721 1 9.454 1 0.00008483 1 0.10823825 
LOC401317 1.550 6.886 0.00008668 0.10823825 
ZFP36 3.252 11.413 0.00009183 0.11180231 
HS. 184721 1.248 7.530 0.00011914 0.14151802 
LOC132241 -0.686 6.713 0.00012471) 0.14470030 
MYC 0.964 9.023 0.00014113 0.1598380 
TNFSF9 3.476 9.404 0.00014562 0.16118038 
FBX05 -0.473 7.469 0.00015094 0.16176486 
SNX16 0.358 9.090 0.00015279 0.16176486 
VAMP1 -0.694 7.581 0.00017319 0.17945342 
HESI 0.609 6.283 0.0001815 0.1801119 
HS. 143408 -0.950 6.787 0.00018448 0.1801119 
MAD2LIBP -0.383 8.908 0.00018492 0.1801119 
HS. 319477 0.832 7.177 0.00019896 0.18692312 
ZNF342 -0.684 6.978 0.00019959 0.18692312 
CPEB3 0.416 8.217 0.0002062 0.18720165 
PTGS2 4.585 9.539 0.00020829 0.18720165 
PLK3 0.881 8.611 0.00021141 0.18720165 
RND3 0.925 7.780 0.00023273 0.19812004 
PPPIR15A 1.687 13.107 0.00023456 0.19812004 
EIFIB 0.652 11.895 0.00023862 0.19812004 
EB12 3.980 10.881 0.00024002 O. l98i2OO4 
NFIL3 1.713 9.983 0.00024809 0.20136864 
GEM 2.189 9.140 0.00025441 0.20311858 
CD44 1.328 7.672 0.00027593 0.21674518 
SLC25A3 -0.314 12.901 0.00028608 0.22115084 
IER3 5.166 11.669 0.00029283 0.22185159 
OTUDI 1.173 10-065 0.00029887 0.22185159 
EGRI 2.905 9.472 0.00030318 0.22185159 
313 
RAB12 0.387 6.489 0.00030521 0.22185159 
RAPGEF1 0.432 6.245 0.00032138 0.23016847 
DUSP6 0.730 7.522 0.00033597 0.23713010 
MAP3K8 2.339 10.717 0.00036998 0.25453992 
JUN 1.598 8.293 0.00037308 0.25453092 
LOC643930 1.644 6.746 0.00037631 0.2.5453992 
CDKNIB -0.582 8.264 0.0003929 0.26211574 
SPRYI 0.553 8.001 0.00039847 0.26224294 
GPRI09B 1.860 7.428 0.00041209 0.26669424 
PDE6H 1.568 6.903 0.00041619 0.26669424 
NFKBIZ 3.670 11.692 0.00043823 0.27717116 
ARRDC2 -0.968 7.147 0.00046257 0.28881752 
TCHH 1.816 7.824 0.00048793 0.30017118 
HS. 562219 0.775 6.341 0.00049308 0.30017118 
IFRDI 0.573 9.463 0.00051946 0.31071457 
CXCL2 4.812 10.752 0.00052882 0.31071457 
LOC441268 0.323 7.139 0.00053042 0.31071457 
CEBPD 0.882 10.550 0.00053592 0.31071457 
IRF8 1.055 12.089 0.00054912 0.31461845 
PTGER2 0.356 8.295 0.00055667 0.31523723 
CLCFI 2.857 8.685 0.00057243 0.32043467 
LOC338758 2.801 9.433 0.00059651 0.33012256 
ZNF671 -0.489 7.700 0.00060445 0.33075527 
PRDM8 0.643 6.553 0.00061156 0.33093038 
DUSP5 1.598 11.600 0.00063801 0.34144701 
ZFP36LI 0.873 10.949 0.00067368 0.35026479 
CISH 0.435 7.662 0.00068085 0.35026479 
RASL1 1A 0.983 6.601 0.00068241 0.35026479 
PIMI 0.839 13.065 0.0006834 0.35026479 
CD69 0.541 7.240 0.00069045 0.35026479 
HS. 126187 0.807 6.093 0.00070209 0.35250222 
SENP5 0.478 8.040 0.00071568 0.35420479 
TAGAP 0.894 7.543 0.00072003 0.35420479 
Table A3.2. Whole-gene exoressiort analysis of smoker-MDM in the Dresence and obsence-d 
bacteHa, 
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COPD: 
Gone Log fold 
channo 
Average 
expression 
P value Adjusted P value 
TNF 6.771 10.014 0 0.00000001 
GADD45B 2.224 9.514 0 0.00000002 
CCI-31.1 3.216 9.450 0 0.00000002 
IER3 5.369 10.730 0 0.0000001 
CCL20 5.717 9.281 0 0.00000013 
11.113 5.873 9.988 0 0.00000039 
EGRI 2.683 8.513 0 0.00000041 
CXCL2 4.643 9.587 0 0.00000101 
E812 3.076 10.781 0 0.00000185 
BTG2 1.866 10.168 0 0.00000238 
LOC399888 -1.100 7.031 0 0.00000567 
ZFP36 2.950 10.467 0 0.00000567 
LOC338758 2.358 9.027 0 0.00000911 
JUN 1.281 7.930 0 0.00000911 
ILB 4.440 10.970 0 0.00000911 
TRIBI 1.318 10.996 0 0.00001193 
PHLDA1 1.636 9.660 0.00000001 0.00001679 
TNFAIP3 3.921 10.208 0.00000001 0.00002118 
CCI-41-2 3.827 10.587 0.00000001 0.00003275 
GPRI09B 1.361 6.711 0.00000001 0.00003373 
CCL8 1.620 8.880 0.00000002 0.00003597 
NFKBIA 2.029 13.340 0.00000002 0.00005306 
CXCL1 3.408 9.757 0.00000003 0.00005755 
DUSPI 2.819 12.083 0.00000003 0.00006193 
11-6 3.569 8.029 0.00000004 0.00007821 
GPRI09A 1.199 6.600 0.00000005 0.00008682 
NFKBIZ 3,855 10.416 0.00000005 0.00008682 
PTGS2 4.055 8.193 0.00000006 0.00009695 
CCL3 2.993 12.003 0.00000006 0.00009695 
LOC401317 1.114 6.361 0.00000006 0.00009695 
ARRDC3 0.704 8.335 0.00000011 0.00016857 
GOS2 1.280 6.645 0.00000012 0.00017321 
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KLF6 0.902 13.048 0.00000012 0.00017320 
PPPlRl5A 1.378 12.677 0.00000012 0.00017320 
CCL3LI 2.924 11.745 0.00000015 0.00021425 
CH25H 1.568 7.792 0.00000023 0.00031231 
NR4A2 1.245 7.570 0.00000024 0.00031975 
LOC643930 1.518 6.432 0.00000027 0.00034354 
AXUD1 2.548 9.592 0.00000028 0.00034354 
ADM 2.228 10.861 0.00000037 0.00044587 
IUA 3.110 8.525 0.0000004 0.00047574 
TIPARP 1.531 11.039 0.00000046 0.00053799 
KLF6 0.688 6.657 0.00000049 0.0005501 
KLF2 1.404 8.399 0.00DO0057 0.00062873 
GADD45A 1.776 8.789 0.00000065 0.00068368 
HS. 143408 -0.756 7.035 0.00000065 0.00068368 
KCNJ2 0.748 7.730 0.00000066 0.00068368 
STMN3 -0.594 7.111 0.00000096 0.00097559 
PDE6H 1.359 6.814 0.00000104 0.00102652 
PRDMI 1.956 10.302 0.00000105 0.00102652 
KLF6 1.063 11.671 0.0000011 0.00105435 
BHLHB2 0.772 13.036 0.00000121 0.00113184 
TNFSF9 2.347 8.678 0.00000124 0.00113722 
NFKBIZ 0.969 6.235 0.00000143 0.00128761 
SNORD13 0.968 7.998 0.00000154 0.00136276 
FOS 1.630 8.450 0.00000158 0.00137186 
MAP3K8 2.433 9.590 0.00000189 0.00161635 
Msc 0.799 8.354 0.00000195 0.0016394 
OTUDI 0.803 9.128 0.00000201 0.00166015 
NLRP3 1.667 8.121 0.00000211 0.00171473 
SAMSNI 0.567 8.797 0.00000265 0.00211949 
PNRCI 0.813 6.693 0.00000303 0.00238029 
IRFI 1.640 11.212 0.00000317 0.00245136 
CCL2 1.352 9.631 0.00000352 0.00267522 
LOC132241 -0.573 6.901 0.00000373 0.00279593 
HS. 278948 0.937 6.214 0.00000456 0.00336287 
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osm 1.339 7.637 0.00000485 0.00352704 
LRRC50 1.009 6.305 0.00000507 0.00303174 
PIM3 1.545 8.924 0.00000515 0.00303174 
PMAIPI 0.913 7.167 0.00000652 0.00453092 
LOC650369 0.390 9.349 0.00000661 0.00453092 
PTGER4 1.293 11.356 0.00000693 0.00469007 
Pimi 0.793 12.369 0.00000714 0.00476654 
IER2 0.584 6.885 0.00000751 0.00489870 
HS. 406790 2.365 8.496 0.00000754 0.00489870 
SLC25A25 0.451 9.778 0.00000767 0.00491252 
PTX3 1.979 7.618 0.00000864 0.0054663 
HS. 121525 0.443 6.971 0.00000895 0.00558561 
HS. 563165 -0.454 6.635 0.00000985 0.0060705 
BIRM 2.486 9.059 0.00001047 0.00629704 
CCL5 1.746 7.820 0.00001047 0.00629704 
RGSI 1.257 12.551 0.00001157 0.00687108 
ADRB2 0.666 7.825 0.00001183 0.00694351 
xBpl 1.170 10.563 O. OOOOi2D4 0.00698156 
PIM3 1.431 8.836 0.0000139 0.00796434 
FOSB 1.161 6.880 0.00001417 0.00802431 
HS. 370423 0.476 6.530 0.00001524 0.00853226 
TCHH 1.265 7.469 0.00001575 0.00871385 
C90RF72 0.425 7.489 0.00001711 0.00936044 
CEBPD 0.435 10.244 0.0000 1 8(m 0.00975941 
CLCFI 2.029 7.601 0.00002044 0.01093829 
TLR7 0.782 7.205 0.00002098 0.01110831 
MCL1 0.622 8.649 0.00002231 0.01168461 
MED30 0.359 8.495 0.00002264 0.01173152 
HS. 126187 0.667 6.010 0.0000238 0.01208983 
CIOORFIO 0.706 8.416 0.00002405 0.01208983 
SLC2A3 0.531 10.626 0.00002408 0.01208983 
HBEGF 0.606 7.615 0.00002503 0.01244083 
Table A3.3. Whole ene enression analysis of COPD MDM in the Dresence and tmno, 91 -a 22= 
bacteda. 
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